CITATION REPORT List of articles citing



DOI: 10.1038/s41577-020-0311-8 Nature Reviews Immunology, 2020, 20, 363-374.

Source: https://exaly.com/paper-pdf/77475105/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2228	Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. 2020 , 54, 438-450		13
2227	Balancing Personal Privacy and Public Safety During COVID-19: The Case of South Korea. 2020 , 8, 1713	25-171	1333
2226	Characteristics and Outcomes of In-Hospital Cardiac Arrest Events During the COVID-19 Pandemic: A Single-Center Experience From a New York City Public Hospital. 2020 , 13, e007303		26
2225	How COVID-19 induces cytokine storm with high mortality. 2020 , 40, 37		238
2224	Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes. 2020 , 11, 574315		20
2223	Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection. 2020 , 11, 1997		19
2222	Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers. 2020 , 9,		45
2221	Effective Immune Functions of Micronutrients against SARS-CoV-2. 2020 , 12,		20
2220	Zoonotic and reverse zoonotic events of SARS-CoV-2 and their impact on global health. 2020 , 9, 2222-2	2235	25
2219	Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. 2020 , 23, 101631		39
2218	SARS-CoV-2 infection does not induce HIV viral escape in the central nervous system: A case series. 2020 , 101, 38-41		3
2217	Immunotherapeutic approaches to curtail COVID-19. 2020 , 88, 106924		29
2216	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. 2020 , 89, 107082		10
2215	The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. 2020 , 146, 105131		174
2214	Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. 2020 , 2, e0207		8
2213	Therapeutic Potential of B-1a Cells in COVID-19. 2020 , 54, 586-594		10
2212	Clinical characteristics of individuals with Down syndrome deceased with CoVID-19 in Italy-A case series. 2020 , 182, 2964-2970		6

2211	Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients. 2020 , 50, 1998-2012	62
2210	Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. 2020 , 50, 2013-2024	35
2209	Harnessing Memory NK Cell to Protect Against COVID-19. 2020 , 11, 1309	16
2208	Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. 2020 , 1, e290-e299	245
2207	The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia. 2021 , 27, 331-339	14
2206	Severe COVID-19: what have we learned with the immunopathogenesis?. 2020 , 60, 50	29
2205	Study of COVID-19 pandemic in London (UK) from urban context. 2020 , 106, 102928	29
2204	Perioperative Nonsteroidal Anti-Inflammatory Agents in the COVID-19 Orthopedic Patient. 2020 , 1-5	1
2203	Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. 2020 , 130, 215-217	18
2202	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. 2020 , 11, 2016	10
2201	Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. 2020 , 2, e764-e773	83
2200	Identification of twenty-five mutations in surface glycoprotein (Spike) of SARS-CoV-2 among Indian isolates and their impact on protein dynamics. 2020 , 21, 100891	10
2199	The role of Interleukin-4 in COVID-19 associated male infertility - A hypothesis. 2020 , 142, 103213	16
2198	Multivalent nanomedicines to treat COVID-19: A slow train coming. 2020 , 35, 100962	22
2197	Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. 2020 , 2, e754-e763	135
2196	COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. 2020 , 261, 118336	35
2195	Viral replication of SARS-CoV-2 could be self-limitative - The role of the renin-angiotensin system on COVID-19 pathophysiology. 2020 , 145, 110330	3
2194	WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies. 2020 ,	2

2193	Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): Are they similar?. 2021 , 68, 1786-1799	17
2192	Identifying pathophysiological bases of disease in COVID-19. 2020 , 5, 15	4
2191	Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. 2020 , 98, 1540-1548	185
2190	Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era. 2020 , 2, 1-6	0
2189	Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. 2020 , 116, 2197-2206	62
2188	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. 2021 , 39, 119-139	36
2187	Silent hypoxia: higher NO in red blood cells of COVID-19 patients. 2020 , 20, 269	10
2186	Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients. 2020 , 219, 108572	44
2185	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. 2020 , 262, 118541	4
2184	The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. 2020 , 6, 73	87
2183	Rabies virus-based COVID-19 vaccine CORAVAXIInduces high levels of neutralizing antibodies against SARS-CoV-2. 2020 , 5, 98	12
2182	Patient and providers' satisfaction with tele(oral)medicine during the COVID-19 pandemic. 2020 ,	4
2181	Serum Cystatin C and Coronavirus Disease 2019: A Potential Inflammatory Biomarker in Predicting Critical Illness and Mortality for Adult Patients. 2020 , 2020, 3764515	5
2180	Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. 2020 , 9, 491-502	26
2179	Role of Probiotics in Stimulating the Immune System in Viral Respiratory Tract Infections: A Narrative Review. 2020 , 12,	30
2178	Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. 2020 , 184, 104955	31
2177	Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. 2020 , 89, 107088	79
2176	Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. 2021 , 73, e2095-e2106	84

2175	Chest CT in COVID-19: What the Radiologist Needs to Know. 2020 , 40, 1848-1865	135
2174	SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. 2020 , 5, 235	122
2173	Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. 2020 , 5, 1439-1448	76
2172	Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. 2020 , 17, 2511-2530	14
2171	Reply. 2020 , 146, 922-923	
2170	A case of Covid-19 associated laryngeal synechia as a cause for failed tracheostomy decannulation. 2020 , 34, 47-49	1
2169	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. 2020 , 117, 26955-26965	138
2168	Proteomics Insights Into the Molecular Basis of SARS-CoV-2 Infection: What We Can Learn From the Human Olfactory Axis. 2020 , 11, 2101	7
2167	Fungal co-infection in COVID-19 patients: Should we be concerned?. 2020 , 37, 41-46	52
2166	Analysis of SARS-CoV-2 vertical transmission during pregnancy. 2020 , 11, 5128	169
2165	Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients. 2020 , 131, 993-999	37
2164	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. 2020 , 11, 585888	7
2163	Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome. 2020 , 54, 700-701	10
2162	Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. 2020 , 13, 463-484	5
2161	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. 2020 , 225, 152008	39
2160	High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2. 2020 , 25, 1152-1161	21
2159	Superposition of COVID-19 waves, anticipating a sustained wave, and lessons for the future. 2020 , 42, e2000178	22
2158	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2020 , 140, 86-104	14

2157 Are cystic fibrosis mutation carriers a potentially highly vulnerable group to COVID-19?. 2020, 24, 13542-135454 Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in 2156 17 Germany. 2020, 9, 8412-8422 Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells in COVID-19. 2020, 183, 1340-1353.e1€05 2155 New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in 6 2154 treating COVID-19. 2020, 889, 173615 Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?. 2020, 2153 12 889, 173629 Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a 76 nationwide observational study of 8075 participants. 2020, 56, 106144 Time of Stroke Onset in Coronavirus Disease 2019 Patients Around the Globe: A Systematic Review 8 2151 and Analysis. 2020, 29, 105325 New insights on possible vaccine development against SARS-CoV-2. 2020, 260, 118421 Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not 2149 77 Associated with Recovery in Critical COVID-19 Patients. 2020, 1, 100092 The age distribution of mortality from novel coronavirus disease (COVID-19) suggests no large 58 difference of susceptibility by age. 2020, 10, 16642 Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR 2147 116 repertoire in patients with hyperinflammation. 2020, 117, 25254-25262 560 2146 COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. **2020**, 17, 543-558 Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review 2145 110 and meta-analysis. 2020, 21, e13095 COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation. 2020, 26, 402-414 103 Preliminary detection of lung hypoperfusion in discharged Covid-19 patients during recovery. 2020, 2143 12 129, 109121 2142 Targeting TMPRSS2 in SARS-CoV-2 Infection. **2020**, 95, 1989-1999 48 2141 Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. 2020, 6, 2304-2318 25 2140 Peripheral Blood Examination Findings in SARS-CoV-2 Infection. 2020, 154, 319-329 17

2139	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721	63
2138	Methods for sequence and structural analysis of B and T cell receptor repertoires. 2020 , 18, 2000-2011	8
2137	Attenuating hyperinflammation in COVID-19: A change in paradigm?. 2020 , 60, 334-336	2
2136	Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation. 2020 , 257, 118114	39
2135	The molecular virology of coronaviruses. 2020 , 295, 12910-12934	175
2134	COVID-19 and Treg/Th17 imbalance: Potential relationship to pregnancy outcomes. 2020 , 84, e13304	37
2133	Haematological manifestations of COVID-19: From cytopenia to coagulopathy. 2020 , 105, 540-546	35
2132	Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. 2020 , 40, 1539-1554	48
2131	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. 2020 , 369,	744
2130	The spectrum of pathological findings in coronavirus disease (COVID-19) and the pathogenesis of SARS-CoV-2. 2020 , 15, 85	21
2129	Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment. 2020 , 11, 1563	19
2128	SARS-CoV-2/COVID-19: a´primer for cardiologists. 2020 , 28, 366-383	9
2127	SARS-CoV-2 (COVID-19) and cystic fibrosis. 2020 , 319, L408-L415	14
2126	Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1#Glycolysis-Dependent Axis. 2020 , 32, 437-446.e5	268
2125	A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. 2020 , 164, 66-76	25
2124	PIMS-TS and Kawasaki Disease: The Mystery Deepens. 2020 , 39, e215-e216	2
2123	Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. 2020 , 369, 1249-1255	352
2122	The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. 2020 , 129, 864-867	40

2121	Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. 2020 , 21,	11
2120	Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review. 2020 , 86, 106738	26
2119	Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people. 2020 , 11, 851-855	35
2118	GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?. 2020 , 2, e448-e449	5
2117	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. 2020 , 396, 479-488	661
2116	Could Ergothioneine Aid in the Treatment of Coronavirus Patients?. 2020 , 9,	29
2115	Profile of SARS-CoV-2. 2020 , 132, 635-644	2
2114	Serum S100B protein as a marker of severity in Covid-19 patients. 2020 , 10, 18665	31
2113	COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. 2021 , 27, 2126-2136	16
2112	Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19. 2020 , 7, 593061	1
2111	Tea Bioactive Modulate Innate Immunity: In Perception to COVID-19 Pandemic. 2020 , 11, 590716	26
2110	First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia. 2020 , 7, 596916	2
2109	Clinical Health Care during the COVID-19 Pandemic. 2020 , 9,	
2108	Trace Element Zinc, a Nature's Gift to Fight Unprecedented Global Pandemic COVID-19. 2021 , 199, 3213-3221	7
2107	High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. 2020 , 10, 19963	34
2106	Neonatal late-onset infection with SARS CoV-2. 2020 , 40, 44-49	O
2105	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. 2020 , 11, 5838	122
2104	Bioinformatics analyses of significant genes, related pathways, and candidate diagnostic biomarkers and molecular targets in SARS-CoV-2/COVID-19. 2020 , 21, 100956	8

2103	and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning	9
2102	Model. 2020 , 12, Risk for COVID-19 infection in patients with tobacco smoke-associated cancers of the upper and lower airway. 2021 , 278, 2695-2702	2
2101	Immunological basis of virus-host interaction in COVID-19. 2020 , 31 Suppl 26, 75-78	4
2100	Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses. 2020 , 8,	10
2099	Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic. 2020 , 2,	3
2098	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. 2021 , 111, 1066-1085	31
2097	Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. 2020 , 371, m4509	73
2096	COVID-19 vaccine development: What lessons can we learn from TB?. 2020 , 19, 56	4
2095	Investigation of COVID-19 comorbidities reveals genes and pathways coincident with the SARS-CoV-2 viral disease. 2020 , 10, 20848	13
2094	Perinatal Maternal-Fetal/Neonatal Transmission of COVID-19: A Guide to Safe Maternal and Neonatal Care in the Era of COVID-19 and Physical Distancing. 2020 , 21, e783-e794	7
2093	Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development. 2020 , 9,	O
2092	Coagulopatä en la infecciñ por el virus SARS-CoV-2 (COVID-19): de los mecanismos fisiopatolgicos al diagnätico y tratamiento. 2020 , 22, 44-44	2
2091	Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. 2020 , 7, 592629	27
2090	Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Protease. 2020 , 25,	23
2089	A case of newly diagnosed immune thrombocytopenia in the COVID-19 era. 2021 , 16, 2221-2225	2
2088	Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. 2021 , 9, 835-844.e4	8
2087	Lymphocyte Subset Alteration and Monocyte CD4 Expression Reduction in Patients with Severe COVID-19. 2021 , 34, 342-351	12
2086	Pre-Existing Cytokine and NLRP3 Inflammasome Activation and Increased Vascular Permeability in Diabetes: A Possible Fatal Link With Worst COVID-19 Infection Outcomes?. 2020 , 11, 557235	12

2085	Class I HLA Allele Predicted Restricted Antigenic Coverages for Spike and Nucleocapsid Proteins Are Associated With Deaths Related to COVID-19. 2020 , 11, 565730	10
2084	Plant-based vaccines and antibodies to combat COVID-19: current status and prospects. 2020 , 16, 2913-2920	16
2083	Inflammatory-Related Clinical and Metabolic Outcomes in COVID-19 Patients. 2020 , 2020, 2914275	7
2082	Serpiginous choroiditis presenting after SARS-CoV-2 infection: A new immunological trigger?. 2020 , 11206721	2 <u>0</u> 97781
2081	Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin. 2020 , 8,	11
2080	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. 2020 , 5, 283	399
2079	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. 2020 , 11, 588409	11
2078	Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. 2020 , 228, 122-128	6
2077	COVID-19 during Pregnancy and Postpartum. 2020, 1-37	8
2076	SARS-CoV-2 and interferon blockade. 2020 , 26, 103	O
2075	Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019. 2020 , 11, 589438	9
2074	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. 2020 , 11, 589474	25
2073	Peptide and peptide-based inhibitors of SARS-CoV-2 entry. 2020 , 167, 47-65	63
2072	Managing the pandemic from the radiology department's point of view. 2020 , 62, 503-514	4
2071	Rationale for Medium Cutoff Membranes in COVID-19 Patients Requiring Renal Replacement Therapy. 2020 , 144, 550-554	6
2070	Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text]. 2020 , 24, 625-632	4
2069	Postulated Adjuvant Therapeutic Strategies for COVID-19. 2020 , 10,	15
2068	Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning. 2020 , 40, 603-614	7

2067	2020 , 18, 291	5
2066	Bacterial co-infections with SARS-CoV-2. 2020 , 72, 2097-2111	82
2065	SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. 2020 , 98, 1296-1307	91
2064	Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. 2020 , 287, 198108	48
2063	Impact of the COVID-19 pandemic on clinical research. 2020 , 16, 562-564	39
2062	Increased Mortality and Major Complications in Hip Fracture Care During the COVID-19 Pandemic: A New York City Perspective. 2020 , 34, 395-402	93
2061	Screening and testing for COVID-19 before surgery. 2020 , 90, 1845-1856	23
2060	Clinical trial to test the efficacy of melatonin in COVID-19. 2020 , 69, e12683	42
2059	Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. 2020 , 26, 1261-1264	23
2058	A gendered magnifying glass on COVID-19. 2020 , 18, 14	14
2057	SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. 2020 , 12,	7
2056	The microbial coinfection in COVID-19. 2020 , 104, 7777-7785	98
2055	An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment. 2020 , 886, 173457	7
2054	Presence of Genetic Variants Among Young Men With Severe COVID-19. 2020 , 324, 663-673	375
2053	Immunological co-ordination between gut and lungs in SARS-CoV-2 infection. 2020 , 286, 198103	56
2052	Vitamin D and COVID-19: Lessons from Spaceflight Analogs. 2020 , 150, 2624-2627	6
2051	Back to Basics∄nd Translating to Success-A Call to Arms. 2020 , 48, 1245-1246	
2050	Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. 2020 , 55, 2556-2564	25

2049	Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. 2020 , 20, 1025-1031	15
2048	From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry. 2020 , 9,	44
2047	COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges. 2020 , 6,	36
2046	The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. 2020 , 11, 1582	69
2045	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169	19
2044	Approach to Nutrition in Cancer Patients in the Context of the Coronavirus Disease 2019 (COVID-19) Pandemic: Perspectives. 2021 , 73, 1293-1301	5
2043	Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. 2020 , 177, 4899-4920	35
2042	Is there an association between the level of ambient air pollution and COVID-19?. 2020 , 319, L416-L421	24
2041	Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. 2020 , 24, 454	47
2040	SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?. 2020 , 12, e12560	82
2039	COVID-19 and Diabetes: The Importance of Controlling RAGE. 2020 , 11, 526	23
2038	Establishing a Unified COVID-19 "Immunome": Integrating Coronavirus Pathogenesis and Host Immunopathology. 2020 , 11, 1642	6
2037	Coronavirus Optimization Algorithm: A Bioinspired Metaheuristic Based on the COVID-19 Propagation Model. 2020 , 8, 308-322	58
2036	The pathophysiology of 'happy' hypoxemia in COVID-19. 2020 , 21, 198	179
2035	Prevention of Severe Coronavirus Disease 2019 Outcomes by Reducing Low-Grade Inflammation in High-Risk Categories. 2020 , 11, 1762	5
2034	Regulation of Host Immune Responses against Influenza A Virus Infection by Mitogen-Activated Protein Kinases (MAPKs). 2020 , 8,	7
2033	Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV. 2020 , 30, 1-9	30
2032	Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection. 2020 , 50, e13366	14

2031	mortality. 2020 , 11, 1089-1094	30
2030	Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study. 2020 , 21, 94	61
2029	Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. 2020 , 164, 1693-1703	102
2028	Single Virus Targeting Multiple Organs: What We Know and Where We Are Heading?. 2020 , 7, 370	20
2027	Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?. 2020 , 21,	22
2026	Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. 2020 , 3, 813-834	17
2025	Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population. 2020 , 91, 104204	21
2024	Dexamethasone nanomedicines for COVID-19. 2020 , 15, 622-624	94
2023	Characteristics of pregnant patients with COVID-19 and liver injury. 2020 , 73, 989-991	9
2022	Placental barrier against COVID-19. 2020 , 99, 45-49	37
2021	Management of post-acute covid-19 in primary care. 2020 , 370, m3026	566
2020	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. 2020 , 8,	12
2019	Single-cell landscape of immunological responses in patients with COVID-19. 2020 , 21, 1107-1118	230
2018	Nutritional status of patients with COVID-19. 2020 , 100, 390-393	117
2018	Nutritional status of patients with COVID-19. 2020 , 100, 390-393 Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. 2020 , 20, 3149-3161	117 33
	Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. 2020 , 20, 3149-3161	
2017	Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. 2020 , 20, 3149-3161	33

2013	Understanding COVID-19: From Origin to Potential Therapeutics. 2020 , 17,	8
2012	Measurement of Cellular Immune Response to Viral Infection and Vaccination. 2020, 11, 575074	6
2011	A Longitudinal Study of Immune Cells in Severe COVID-19 Patients. 2020 , 11, 580250	31
2010	The upshot of Polyphenolic compounds on immunity amid COVID-19 pandemic and other emerging communicable diseases: An appraisal. 2020 , 10, 411-429	16
2009	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. <i>Nature Reviews Immunology</i> , 2020 , 20, 727-738	56
2008	The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection. 2021 , 288, 5055-5070	2
2007	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. 2020 , 10, 575404	3
2006	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. 2020 , 11, 579250	50
2005	Complementary regulation of caspase-1 and IL-1I reveals additional mechanisms of dampened inflammation in bats. 2020 , 117, 28939-28949	18
2004	Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series. 2020 , 26, 91	40
2003	Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis. 2020 , 8, 587866	6
2002	Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques. 2020 , 132, 110914	14
2001	Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment. 2020 , 14, 403-412	12
2000	Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. 2020 , 11, 583006	3
1999	Understanding Gender-Bias in Critically Ill Patients With COVID-19. 2020 , 7, 564117	3
1998	COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms. 2020 , 2, 2109-2125	12
1997	Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets. 2020 , 11, 587615	36
1996	Coronavirus disease 2019: scientific overview of the global pandemic. 2020 , 38, 100800	1

1995	Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses. 2020 , 22, 617-621	92
1994	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. 2020 , 6,	66
1993	Perspective: The Potential Effects of Naringenin in COVID-19. 2020 , 11, 570919	20
1992	Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis. 2020 , 145, 110352	7
1991	A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases. 2020 , 136, 155228	4
1990	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. 2021 , 73, e2932-e29	4@ 8
1989	A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). 2020 , 8, 37	66
1988	Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients. 2020 , 7, 501	1
1987	Mass Spectrometry Techniques in Emerging Pathogens Studies: COVID-19 Perspectives. 2020 , 31, 2013-2024	37
1986	Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. 2020 , 2, 1021-1024	86
1985	The Collision of Meta-Inflammation and SARS-CoV-2 Pandemic Infection. 2020 , 161,	13
1984	Lipidomics Issues on Human Positive ssRNA Virus Infection: An Update. 2020 , 10,	4
1983	Immunological considerations for COVID-19 vaccine strategies. <i>Nature Reviews Immunology</i> , 2020 , 20, 615-632	480
1982	The Potential Role of Immune Alteration in the Cancer-COVID19 Equation-A Prospective Longitudinal Study. 2020 , 12,	4
1981	Coronaviruses and stress: from cellular to global. 2020 , 25, 701-705	4
1980	Endovascular aortic repair in an asymptomatic COVID-19-positive patient with a symptomatic inflammatory abdominal aortic aneurysm. 2020 , 6, 531-533	4
1979	Switching Host Metabolism as an Approach to Dampen SARS-CoV-2 Infection. 2020 , 76, 297-303	19
1978	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. 2020 , 18, 359	15

Serum inflammatory factors are positively correlated with the product coronavirus disease 2019 patients. 2020 , 17, 1180-1182	ion of specific antibodies in 7
Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Po Trained Immunity, BCG and "New Old Friends". 2020 , 11, 2059	oulations in COVID-19:
1975 COVID-19: Infection or Autoimmunity. 2020 , 11, 2055	26
1974 Can Adenosine Fight COVID-19 Acute Respiratory Distress Syndrome?.	2020 , 9, 10
1973 The role of Interleukin 6 inhibitors in therapy of severe COVID-19. 202 0) , 131, 110698 46
Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG 2020 , 22, 515-524	as delivery vector system.
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoid Neurotropism Predominates in Choroid Plexus Epithelium. 2020 , 27, 93	1 F1
1970 Evolution of COVID-19 Pandemic in India. 2020 , 5, 711-718	11
1969 A Granulocytic Signature Identifies COVID-19 and Its Severity. 2020 , 22	2, 1985-1996 49
1968 Longitudinal immune profiling reveals key myeloid signatures associat	ed with COVID-19. 2020 , 5, 105
1967 COVID-19 and obesity. 2020 , 37, 149-151	3
An overview of COVID-19 with an emphasis on computational approac intervention. 2020 , 10, 435	n for its preventive
1965 Artificial intelligence in COVID-19 drug repurposing. 2020 , 2, e667-e67	6 188
1964 Are Adequate Vitamin D Levels Helpful in Fighting COVID-19? A Look a	t the Evidence. 2020 , 52, 775-783 ₂
Important Pharmacogenetic Information for Drugs Prescribed During to (COVID-19). 2020 , 13, 1023-1033	he SARS-CoV-2 Infection 6
1962 Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated	n COVID-19. 2020 , 202
1961 Cellular senescence as a potential mediator of COVID-19 severity in th	e elderly. 2020 , 19, e13237 38

1959 Case report [Prolonged SARS-CoV-2 positive PCR after resolution of symptoms. **2020**, 7, 1

SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and pub health. 2020 , 192, E973-E979	lic 35
Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. 2020 , 21, e13128	427
1956 Immune responses during COVID-19 infection. 2020 , 9, 1807836	49
A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?. 2020 , 17, 23	5, 27
1954 Implication of Aging Related Chronic Neuroinflammation on COVID-19 Pandemic. 2020 , 10,	16
1953 Atrial fibrillation in COVID-19: A review of possible mechanisms. 2020 , 34, 11347-11354	20
1952 An Antioxidant Enzyme Therapeutic for COVID-19. 2020 , 32, e2004901	34
Systems Pharmacology and Verification of ShenFuHuang Formula in Zebrafish Model Reveal Multi-Scale Treatment Strategy for Septic Syndrome in COVID-19. 2020 , 11, 584057	4
Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Recept Interaction. 2020 , 25,	cor 6
1949 The overlooked chamber in coronavirus disease 2019. 2020 , 7, 3483	3
Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from voluntary convalescent donor program. 2020 , 60, 2938-2951	a 36
SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so and the still unknown realities. 2020 , 72, 2313-2330	far, 7
Re-analysis of Single Cell Transcriptome Reveals That the NR3C1-CXCL8-Neutrophil Axis Determines the Severity of COVID-19. 2020 , 11, 2145	39
Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinica Proven Protease Inhibitor. 2020 , 10, 1448	lly 23
1944 Managing rheumatic diseases during COVID-19. 2020 , 39, 3245-3254	10
Exercise for Older Adults Improves the Quality of Life in Parkinson's Disease and Potentially Enhances the Immune Response to COVID-19. 2020 , 10,	9
1942 Challenges in heart transplantation during COVID-19: A single-center experience. 2020 , 39, 894-	-903 19

1941	[COVID-19: Questions and answers from infectiology]. 2020 , 145, 1051-1056	1
1940	A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management. 2020 , 96, 1323-1328	17
1939	No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. 2020 , 15, 2411-2427	13
1938	The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections. 2020, 13,	17
1937	Potential mechanism underlying the effect of matrine on COVID-19 patients revealed through network pharmacological approaches and molecular docking analysis. 2020 , 1-8	7
1936	Dendritic Cells and SARS-CoV-2 Infection: Still an Unclarified Connection. 2020 , 9,	29
1935	Pan-Echinocandin-Resistant Bloodstream Infection Complicating COVID-19: A Fatal Case Report. 2020 , 6,	29
1934	Can CT performed in the early disease phase predict outcome of patients with COVID 19 pneumonia? Analysis of a cohort of 64 patients from Germany. 2020 , 131, 109256	16
1933	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. 2020 , 8,	53
1932	Clinical and Prodromal Ocular Symptoms in Coronavirus Disease: A Systematic Review and Meta-Analysis. 2020 , 61, 29	31
1931	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). 2020 , 98, 1369-1383	19
1930	Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot. 2020 , 109, 1460-1468	9
1929	Immunotherapy for SARS-CoV-2: potential opportunities. 2020 , 20, 1111-1116	28
1928	A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. 2020 , 28, 1141-1152	28
1927	Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19. 2020 , 222, 1789-1793	65
1926	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. 2020 , 75, 3379-3385	66
1925	Lessons from neuronal HIF1a: Understanding its role in ventilatory acclimatization to hypoxia. 2020 , 598, 4751-4752	1
1924	Neonatal and Children's Immune System and COVID-19: Biased Immune Tolerance versus Resistance Strategy. 2020 , 205, 1990-1997	12

1923	Unraveling the Immune Response in Severe COVID-19. 2020 , 40, 958-959	3
1922	Plasmin Cascade Mediates Thrombotic Events in SARS-CoV-2 Infection via Complement and Platelet-Activating Systems. 2020 , 1, 220-227	1
1921	Macrophage activation syndrome and COVID-19. 2020 , 40, 19	58
1920	Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments. 2020 , 11, 595888	23
1919	IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients. 2020 , 9,	11
1918	SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure. 2020 , 9,	16
1917	COVID-19-related myocarditis and cholinergic anti-inflammatory pathways. 2021 , 62, 265-269	3
1916	Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension. 2020 , 11, 596684	6
1915	Post-COVID-19 Fatigue: Potential Contributing Factors. 2020 , 10,	49
1914	Morphogenetic (Mucin Expression) as Well as Potential Anti-Corona Viral Activity of the Marine Secondary Metabolite Polyphosphate on A549 Cells. 2020 , 18,	12
1913	Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. 2020 , 20, 1144	138
1912	Extracellular RNA as a Versatile DAMP and Alarm Signal That Influences Leukocyte Recruitment in Inflammation and Infection. 2020 , 8, 619221	15
1911	The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System. 2020 , 7, 602183	13
1910	Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity. 2020 , 11, 586111	14
1909	Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?. 2020 , 11, 586765	11
1908	NF-B Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. 2020, 11, 598444	66
1907	Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit. 2020 , 7, 585744	5
1906	Transformation of a Ferry Ship into a Ship Hospital for COVID-19 Patients. 2020 , 17,	4

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. 11, 6385	. 2020 ,
1904 The Microbiota/Host Immune System Interaction in the Nose to Protect from COVID-19. 20	20 , 10, 14
1903 Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction. 2020 , 25,	4
1902 Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes. 2020 , 12,	9
1901 Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology. 2020 , 20	20, 8019360 12
1900 Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. 2020 , 11, 590	6631 30
1899 Characterization of SARS-CoV-2 dynamics in the host. 2020 , 50, 457-468	18
The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. 2020 , 33, 108488	of 40
1897 Liver transplant immunosuppression during the COVID-19 pandemic. 2020 , 43, 457-463	1
Reversibility of venous dilatation and parenchymal changes density in Sars-Cov-2 pneumon toward the definition of a peculiar pattern. 2021 , 27, 353-357	ia: 5
The fetal inflammatory response syndrome: the origins of a concept, pathophysiology, diag and obstetrical implications. 2020 , 25, 101146	gnosis, 41
1894 Role of gut-lung microbiome crosstalk in COVID-19. 2020 , 1	4
A blood transcriptome-based analysis of disease progression, immune regulation, and symptocoronavirus-infected patients. 2020 , 6, 141	otoms in
Letter by Bayona et al Regarding Article, "SARS-CoV-2 and Stroke in a New York Healthcare System". 2020 , 51, e371-e372	
The Benefits of Vitamin D Supplementation for Athletes: Better Performance and Reduced COVID-19. 2020 , 12,	l Risk of
Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection Inhibition. 2020 , 11, 2098	n and 5
1889 Should We Be Worried About During the SARS-CoV2 Pandemic?. 2020 , 11, 581343	7
Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 for an elderly population. 2020 , 42, 619-634	vaccines 20

1887 Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal. 2020 , 23, 101697	11
COVID-19 disease, obesity and micronutrients: An updated narrative review of the literature. 2020 , ahead-of-print,	O
Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage. 2020 , 39, e105896	45
Prognostic factors in hospitalized patients diagnosed with SARS-CoV-2 infection, Bogot[IColombia. 2020 , 40, 116-130	5
Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility. 2020 , 35, 793-802	15
A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19. 2020 ,	5
Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation. 2020 , 25,	17
1880 Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19. 2020 , 30, 1078-1087	44
Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains. 2020 , 11, 579480	23
CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study. 2020 , 12,	13
Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions. 2020 , 25,	25
1876 Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity. 2020 , 12,	90
1875 Association of inflammatory markers with the severity of COVID-19: A meta-analysis. 2020 , 96, 467-474	225
Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature. 2020 , 86, 659-664	41
1873 COVID-19 Pandemic: Hopes from Proteomics and Multiomics Research. 2020 , 24, 457-459	10
1872 COVID-19 Clinical trials: Quality matters more than quantity. 2020 , 75, 2542-2547	12
1871 High-fluorescent lymphocytes are increased in patients with COVID-19. 2020 , 190, e76-e78	9
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. 2020 , 11, 1091	76

1869	Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. 2020 , 75, 1564-1581	496
1868	Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19. 2020 , 92, 2227-2231	41
1867	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. 2020 , 71, 2199-2206	145
1866	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094	152
1865	Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic. 2020 , 109, 154276	31
1864	COVID-19 in rheumatic disease patients on immunosuppressive agents. 2020 , 50, 680-686	36
1863	The perplexing question of trained immunity vs adaptive memory in COVID-19. 2020 , 92, 1858-1863	9
1862	SARS-CoV-2 in upper and lower airway samples of a laryngectomized patient: New insights and many lessons. 2020 , 107, 104841	10
1861	Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation. 2020 , 20, 3239-3245	46
1860	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. 2020 , 50, e13315	21
1859	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. 2020, 114, 102506	150
1858	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. 2020 , 14, 7760-7782	172
1857	Thromboembolic events and Covid-19. 2020 , 77, 100735	38
1856	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. 2020 , 11, 1512	83
1855	Clinical Pharmacology Considerations for Developing Small-Molecule Treatments for COVID-19. 2020 , 60, 1147-1154	3
1854	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. 2020 , 32, 176-187.e4	271
1853	Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. 2020 , 123, 694-697	29
1852	Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). 2020 , 52, 110-115	30

1851	the SARS-CoV-2 Pandemic?. 2020 , 11, 699	27
1850	Ocular manifestations of coronavirus disease 2019. 2020 , 258, 1959-1963	40
1849	Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. 2020 , 11, 1441	320
1848	A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19. 2020 , 12,	29
1847	Liver transplant immunosuppression during the covid-19 pandemic. 2020 , 43, 457-463	12
1846	Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. 2020 , 20, 5570-5574	159
1845	Novel insights on the pulmonary vascular consequences of COVID-19. 2020 , 319, L277-L288	69
1844	Pediatric cancer research: Surviving COVID-19. 2020 , 67, e28435	21
1843	Mental health among COVID-19 survivors: Are we overlooking the biological links?. 2020 , 53, 102217	7
1842	The laboratory's role in combating COVID-19. 2020 , 57, 400-414	26
1841	Clinical performance of different SARS-CoV-2 IgG antibody tests. 2020 , 92, 2243-2247	91
1840	Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. 2020 , 129, 104480	135
1839	A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy. 2020 , 10, 1085	7
1838	Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review. 2020 , 35, 260-273	30
1837	Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). 2020 , 27, 3196-3207	115
1836	Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2s. 2020 , 40, 1655-1670	34
1835	The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging". 2020 , 69, 825-839	125
1834	Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond. 2020 , 56,	13

1833	COVID-19 and pneumonia: a role for the uPA/uPAR system. 2020 , 25, 1528-1534	30
1832	Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. 2020 , 5, 100	50
1831	Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?. 2020 , 228, 971-975	59
1830	The neurological significance of COVID-19: Lesson learn from the pandemic. 2020 , 22, 100809	1
1829	Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19). 2020 , 1, 60-65	14
1828	Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. 2020 , 10, 277-287	37
1827	Obesity as a Potential Predictor of Disease Severity in Young COVID-19 Patients: A Retrospective Study. 2020 , 28, 1815-1825	71
1826	Anakinra in COVID-19: important considerations for clinical trials. 2020 , 2, e379-e381	34
1825	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development. 2020 , 66, 35-40	14
1824	Clinical-Forensic Autopsy Findings to Defeat COVID-19 Disease: A Literature Review. 2020 , 9,	32
1823	[Basic principles of replication and immunology of SARS-CoV-2]. 2020 , 117, 609-614	5
1822	COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. 2020 , 20, 959-964	12
1821	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. 2020 , 71, 2933-2938	100
1820	Potential neurological effects of severe COVID-19 infection. 2020 , 158, 1-5	32
1819	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. 2020 , 883, 173348	45
1818	Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature. 2020 , 16, 493-505	37
1817	COVID-19 and ethnicity: A novel pathophysiological role for inflammation. 2020 , 14, 1043-1051	32
1816	Data mining and analysis of scientific research data records on Covid-19 mortality, immunity, and vaccine development - In the first wave of the Covid-19 pandemic. 2020 , 14, 1121-1132	29

1815	Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. 2020 , 3, 374	77
1814	Covid-19 and the Renin Angiotensin System: Implications for the Older Adults. 2020 , 24, 699-704	9
1813	. 2020 , 29, 14-27	2
1812	Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. 2020 , 25, 100454	87
1811	Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. 2020 , 156, 190-199	70
1810	Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response. 2020 , 226, 38-45	32
1809	Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. 2020 , 77, 100741	100
1808	Heart transplant recipient patient with COVID-19 treated with tocilizumab. 2020 , 22, e13380	7
1807	A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19. 2020 , 30, e2119	59
1806	Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients. 2020 , 110, 154300	4
1805	Diabetes, infection risk and COVID-19. 2020 , 39, 101044	108
1804	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). 2020 , 75, 2445-2476	81
1803	COVID-19 Hyperinflammation: What about Neutrophils?. 2020 , 5,	65
1802	Quantity does not equal quality: Scientific principles cannot be sacrificed. 2020 , 86, 106711	40
1801	SARS-CoV-2 pandemic: An overview. 2020 , 77, 100736	30
1800	Immunological Implications of Physical Inactivity among Older Adults during the COVID-19 Pandemic. 2020 , 66, 431-438	41
1799	Using Mind-Body Modalities via Telemedicine during the COVID-19 Crisis: Cases in the Republic of Korea. 2020 , 17,	13
1798	Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). 2020 , 129, 104511	149

1797	The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. 2020 , 127, 571-587	254
1796	Understanding the Complex Relationship Between Androgens and SARS-CoV2. 2020 , 144, 1-3	7
1795	SARS-COV-2 and eye immunity: the lesson was learned but we are not done yet. Brainstorming on possible pathophysiology inspired by ocular models. 2020 , 40, 1879-1883	9
1794	High prevalence of COVID-19-associated diabetic ketoacidosis in UK secondary care. 2020 , 166, 108291	43
1793	Diabetes and COVID-19: Global and regional perspectives. 2020 , 166, 108303	19
1792	COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. 2020 , 34, 9843-9853	78
1791	Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review. 2020 , 21,	18
1790	Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. 2020 , 396, 535-544	1000
1789	COVID-19: a hypothesis regarding the ventilation-perfusion mismatch. 2020 , 24, 395	42
1788	COVID-19 in patients with rheumatological diseases treated with anti-TNF. 2021 , 80, e62	35
1787	Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. 2021 , 78, 1501-1522	56
1786	Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection. 2021 , 52, 143-150	3
1785	Aging in COVID-19: Vulnerability, immunity and intervention. 2021 , 65, 101205	193
1784	High-dimensional single-cell analysis reveals the immune characteristics of COVID-19. 2021 , 320, L84-L98	9
1783	Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection. 2021 , 106, e1343-e1353	114
1782	COVID-19-associated coagulopathy and disseminated intravascular coagulation. 2021 , 113, 45-57	102
1781	Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. 2021 , 27, 215-227	95
1780	Immunity after COVID-19: Protection or sensitization?. 2021 , 331, 108499	7

1779	Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. 2021 , 51, 286-292	22
1778	Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. 2021 , 82, e40-e42	27
1777	Novel coronavirus (SARS-CoV-2) infection in a patient with multivisceral transplant. 2021 , 23, e13430	1
1776	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. 2021 , 73, 36-47	34
1775	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. 2021 , 93, 1421-1427	17
1774	BCG vaccination induced protection from COVID-19. 2021 , 68, 119-124	20
1773	Selenium and viral infection: are there lessons for COVID-19?. 2021 , 125, 618-627	40
1772	Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists. 2021 , 35, 122-131	1
1771	The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities. 2021 , 125, 275-293	6
1770	Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. 2021 , 44, 223-231	65
1769	SARS-CoV-2, COVID-19, skin and immunology - What do we know so far?. 2021 , 76, 698-713	32
1768	Immunobiology and immunotherapy of COVID-19: A clinically updated overview. 2021 , 236, 2519-2543	30
1767	Severe SARS-CoV-2 disease in the context of a NF- B 2 loss-of-function pathogenic variant. 2021 , 147, 532-544.e1	13
1766	Optimising the assignment of swabs and reagent for PCR testing during a viral epidemic. 2021 , 102, 102341	7
1765	Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19. 2021 , 22, 936-945	27
1764	Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells. 2021 , 16, 419-427	23
1763	Pregnancy and COVID-19. 2021 , 101, 303-318	160
1762	Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics. 2021 , 1867, 165978	13

1761	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. 2021 , 40, 761-769		21
1760	Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. 2021 , 147, 60-71		77
1759	Roadblocks and fast tracks: How RNA binding proteins affect the viral RNA journey in the cell. 2021 , 111, 86-100		5
1758	Microvascular dysfunction in COVID-19: the MYSTIC study. 2021 , 24, 145-157		85
1757	T cell regeneration after immunological injury. <i>Nature Reviews Immunology</i> , 2021 , 21, 277-291	36.5	25
1756	Pathogenesis-directed therapy of 2019 novel coronavirus disease. 2021 , 93, 1320-1342		22
1755	Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends. 2021 , 41, 329-334		24
1754	The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. 2021 , 135, 170428		5
1753	Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 înfection. 2021 , 93, 2645-2653		8
1752	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. 2021 , 23, 101-110		11
1751	COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): A´novel disease that mimics toxic shock syndrome-the superantigen hypothesis. 2021 , 147, 57-59		37
1750	CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections. 2021 , 82, 7-11		8
1749	SARS-CoV-2 associated COVID-19 in geriatric population: A brief narrative review. 2021 , 28, 738-743		3
1748	Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. 2021 , 93, e12998		48
1747	Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update. 2021 , 147, 111887		6
1746	Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols?. 2021 , 146, 110436		9
1745	Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. 2021 , 147, 545-557.e9		160
1744	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. 2021 , 21, 1285-1294		26

1743	Neutrophils and COVID-19: The road so far. 2021 , 90, 107233	66
1742	Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. 2021 , 489, 112937	43
1741	The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. 2021 , 150, 104673	45
1740	Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. 2021 , 27, 603-610	7
1739	Reply to Vitamin D deficiency in COVID-19: mixing up cause and consequence. 2021 , 115, 154462	1
1738	Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. 2021 , 223, 933-944	57
1737	Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia. 2021 , 64, 144-151	36
1736	Severe acute respiratory syndrome coronavirus 2 infection reaches the human nervous system: How?. 2021 , 99, 750-777	20
1735	Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study. 2021 , 37, 13-19	3
1734	From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy. 2021 , 34, e14565	4
1733	Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy. 2021 , 15, 864-868	12
1732	Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic. 2021 , 69, 76-82	1
1731	Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. 2021 , 292, 198235	48
1730	The place for remdesivir in COVID-19 treatment. 2021 , 21, 20-21	52
1729	Diverse roles of long non-coding RNAs in viral diseases. 2021 , 31, e2198	3
1728	Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. 2021 , 103, 288-296	40
1727	Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. <i>Nature Reviews Immunology</i> , 2021 , 21, 49-64	56
1726	A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19. 2021 , 891, 173748	31

1725	A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development. 2021 , 10, 18-29	5
1724	Coagulopathies in novel coronavirus (SARS-CoV-2) pandemic: Emerging evidence for hematologists. 2021 , 28, 956-961	2
1723	A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. 2021 , 17, 62-72	26
1722	Immunity and coagulation and fibrinolytic processes may reduce the risk of severe illness in pregnant women with coronavirus disease 2019. 2021 , 224, 393.e1-393.e25	9
1721	Characterising and managing paediatric SARSCoV-2 infection: Learning about the virus in a global classroom. 2021 , 110, 409-422	2
1720	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. 2021 , 169, 168-189	35
1719	Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. 2021 , 159, 1884-1893	6
1718	Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19. 2021 , 66, 101978	1
1717	Next generation sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities. 2021 , 22, 616-630	59
1716	Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges. 2021 , 64, 416-425	26
1715	Extensive Arterial Thrombus Following Discharge after a Covid-19 Infection. 2021 , 72, 205-208	3
1714	The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. 2021 , 538, 80-87	10
1713	Single-step, wash-free digital immunoassay for rapid quantitative analysis of serological antibody against SARS-CoV-2 by photonic resonator absorption microscopy. 2021 , 225, 122004	18
1712	T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research. 2021 , 25, 1274-1289	13
1711	The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. 2021 , 14, 305-316	83
1710	Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. 2020 , 8, 582932	45
1709	DNA vaccines against COVID-19: Perspectives and challenges. 2021 , 267, 118919	78
1708	The SARS-CoV-2 RNA-protein interactome in infected human cells. 2021 , 6, 339-353	94

(2021-2021)

1707	Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. 2021 , 8, ofaa588	9
1706	Mathematical model for Covid-19 with protected susceptible In the post-lockdown era. 2021 , 60, 527-535	2
1705	Remdesivir: From Ebola to COVID-19. 2021 , 538, 145-150	18
1704	Can COVID-19 pandemic influence frozen shoulder outcomes?. 2021 , 55, 241	1
1703	Neurological complications in COVID-19 patients from Latin America. 2021 , 144, e29	5
1702	COVID-19 and Solid Organ Transplantation: A Review Article. 2021 , 105, 37-55	111
1701	Impact of COVID-19 in solid organ transplant recipients. 2021 , 21, 925-937	37
1700	Building a Resilient, Sustainable, and Healthier Food Supply Through Innovation and Technology. 2021 , 12, 1-28	17
1699	Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-28pecific IgG. 2021 , 27, 122-129	42
1698	ceRNA analysis of SARS-CoV-2. 2021 , 166, 271-274	1
1697	COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?. 2021 , 128, 37-45	18
1696	Coronavirus biology and replication: implications for SARS-CoV-2. 2021 , 19, 155-170	830
1695	Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. 2021 , 61, 78-93	9
1694	Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. 2021 , 159, 1019-1040	73
1693	Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. 2020 , 4, 2000172	14
1692	Recovery from COVID-19 in a Child with Chronic Granulomatous Disease and T Cell Lymphopenia. 2021 , 41, 23-25	2
1691	SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response. 2021 , 18, 613-620	66
1690	CoV-AbDab: the coronavirus antibody database. 2021 , 37, 734-735	108

1689	Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. 2021 , 100, 37-43	28
1688	Male Sex, Severe Obesity, Older Age, and Chronic Kidney Disease Are Associated With COVID-19 Severity and Mortality in New York City. 2021 , 159, 112-115	26
1687	Future perspective: biologic agents in patients with severe COVID-19. 2021 , 43, 1-7	14
1686	SARS-CoV-2 respiratory viral loads and association with clinical and biological features. 2021 , 93, 1761-1765	10
1685	Early experience with critically ill patients with COVID-19 in Montreal. 2021 , 68, 204-213	10
1684	Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). 2021 , 72, e736-e741	28
1683	Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development. 2021 , 31, e2174	4
1682	The complexity of respiratory disease associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: From immunopathogenesis to respiratory therapy. 2021 , 31, e2167	2
1681	T-cell responses and therapies against SARS-CoV-2 infection. 2021 , 162, 30-43	60
1680	Viral infection and smell loss: The case of COVID-19. 2021 , 157, 930-943	21
1679	Immunopathology of Hyperinflammation in COVID-19. 2021 , 191, 4-17	143
1678	Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. 2021 , 236, 2829-2839	58
1677	Methotrexate inhibits SARS-CoV-2 virus replication "in vitro". 2021 , 93, 1780-1785	18
1676	Nutritional status, diet and viral respiratory infections: perspectives for severe acute respiratory syndrome coronavirus 2. 2021 , 125, 851-862	34
		71
	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	
1675	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	71

1671	Mechanism and transmission routes of COVID-19. 2021 , 65-88	2
1670	Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. 2021 , 24, 101947	23
1669	Electrocardiographic modifications and cardiac involvement in COVID-19 patients: results from an Italian cohort. 2021 , 22, 190-196	1
1668	SARS-CoV-2flost cell interactions and pathways: understanding its physiology, pathology, and targeted drug therapy. 2021 , 185-210	
1667	COVID-19 pandemic as a risk factor for the reactivation of herpes viruses. 2021 , 149, e145	4
1666	Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling. 2021 , 1-16	13
1665	A Missing Link: Engagements of Dendritic Cells in the Pathogenesis of SARS-CoV-2 Infections. 2021 , 22,	7
1664	Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis. 2021 , 17, 341-356	17
1663	Inflammatory pathways and potential therapies for COVID-19: A mini review. 2021 , 19, 205873922110029	5
1662	PathExNET: A tool for extracting pathway expression networks from gene expression statistics. 2021 , 19, 4336-4344	1
1661	Therapeutic targets and potential agents for the treatment of COVID-19. 2021, 41, 1775-1797	11
1660	A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization. 2021 , 59,	10
1659	Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers. 2021 , 9,	23
1658	Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. 2021 , 63, 103153	40
1657	Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 patients.	3
1656	Temperature and Latitude Correlate with SARS-CoV-2 Epidemiological Variables but not with Genomic Change Worldwide. 2021 , 17, 1176934321989695	11
1655	Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. 2021 , 10, e1319	13
1654	Immune-Based Therapy for COVID-19. 2021 , 1318, 449-468	4

1653	Lessons from the host defences of bats, a unique viral reservoir. 2021 , 589, 363-370	70
1652	Role of the Immune Microenvironment in SARS-CoV-2 Infection. 2021 , 30, 9636897211010632	5
1651	Cardiovascular consequences of viral infections: from COVID to other viral diseases. 2021 , 117, 2610-2623	3
1650	In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex. 2021 , 3, 100094	3
1649	A pilot trial of human amniotic fluid for the treatment of COVID-19. 2021 , 14, 32	1
1648	A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19. 2021 , 18, 1866-1876	7
1647	Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury. 2020 , 11, 604944	10
1646	Integrated photothermal decontamination device for N95 respirators. 2021 , 11, 1822	5
1645	Exploring G protein-coupled receptors and yeast surface display strategies for viral detection in baker's yeast: SARS-CoV-2 as a case study. 2021 , 21,	2
1644	Evolution of cytokine production capacity in ancient and modern European populations.	
1643	[Saddle thrombus in the region of the aortic bifurcation and critical limb ischaemia of the left leg associated with SARS-CoV-2 infection]. 2021 , 26, 1-4	
1642	[Evolution of patients infected with SARS-CoV-2 according to previous metabolic status]. 2021 , 38, 1068-1074	1
1641	Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review. 2021 , 60, 4530-4537	4
1640	Clinical diagnosis of COVID-19: a prompt, feasible, and sensitive diagnostic tool for COVID-19 based on a 1,757-patient cohort (The AndroCoV Clinical Scoring for COVID-19 diagnosis).	1
1639	Association of Asthma and Rhinitis with Epigenetics of Coronavirus Related Genes. 2021 , 14, 2516865721103	9224
1638	Clinical characteristics and predictive value of lower CD4T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. 2021 , 21, 57	8
1637	Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.	1
1636	Corilagin and 1,3,6-Trigalloy-D-glucose: potential inhibitors of SARS-CoV-2 variants. 2021 , 23, 14873-14888	3

(2021-2021)

Genome-scale metabolic modeling reveals SARS-CoV-2-induced host metabolic reprogramming aridentifies metabolic antiviral targets. 2021 ,	nd 1
Dysregulated Host Response in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Critica Illness. 2021 , 8, ofab019	il 5
Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2. 2021 , 17, 155-163	5
1632 Illuminating the immunopathology of SARS-CoV-2. 2021 , 100, 33-41	6
SP-A and SP-D: Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties. 2020 , 11, 622598	24
1630 An update to "novel therapeutic approaches for treatment of COVID-19". 2021 , 99, 303-310	13
SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4. 2021 , 218,	65
In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches. 2021 , 26,	16
Obesity and COVID-19: what makes obese host so vulnerable?. 2021 , 18, 1	64
Environmental effects of stratospheric ozone depletion, UV radiation, and interactions with clima change: UNEP Environmental Effects Assessment Panel, Update 2020. 2021 , 20, 1-67	te 34
1625 Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial.	4
1624 COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. 2021 , 76, 4	12-420 81
1623 Sex Hormones and Lung Inflammation. 2021 , 1304, 259-321	10
A single-cell mathematical model of SARS-CoV-2 induced pyroptosis and the effects of anti-inflammatory intervention. 2021 , 6, 6050-6086	1
1621 Epidemiology of lung cancer. 2021 , 25, 45-52	15
1620 Possible mechanisms of cholesterol elevation aggravating COVID-19. 2021 , 18, 3533-3543	4
Structural similarity-based prediction of host factors associated with SARS-CoV-2 infection and pathogenesis. 2021 , 1-12	5
Fighting the storm: could novel anti-TNF\(\hat{\textbf{h}}\) nd anti-IL-6 cultivars tame cytokine storm in COVID-19?. 2021 , 13, 1571-1590	10

1617 The Immunology of COVID-19: Your Questions Answered. **2021**, 15, 1

1616	COVID-19-Related Laboratory Analyte Changes and the Relationship Between SARS-CoV-2 and HIV, TB, and HbA1c in South Africa. 2021 , 1321, 183-197	3
1615	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. 2021 , 11, 2608	40
1614	Indoor Air Quality Monitoring Systems and COVID-19. 2021 , 133-147	2
1613	Low-dose radiotherapy for COVID 19: A radioimmunological perspective. 2021 , 17, 295-302	2
1612	The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. 2021 , 13, e12565	5
1611	Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19. 2021 , 19, 19	4
1610	Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19. 2021 , 12, 2042098620985690	1
1609	Severe COVID-19 Lung Infection in Older People and Periodontitis. 2021 , 10,	19
1608	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. 2021 , 75, 19-47	17
1607	First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery. 2021 , 25, 1827-1838	18
1606	An Efficient Approach to Identify Economic Crisis During Covid-19 Outbreaks Utilizing Data Mining.	1
1605	COVID-19: a cross-sectional study of suspected cases admitted to a federal hospital in Rio de Janeiro, Brazil, and factors associated with hospital death. 2020 , 30, e2020750	4
1604	Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm. 2021 , 35, 231-247	10
1603	Drivers of Infectious Disease Seasonality: Potential Implications for COVID-19. 2021 , 36, 35-54	21
1602	Structural Comparison of the SARS CoV 2 Spike Protein Relative to Other Human-Infecting Coronaviruses. 2020 , 7, 594439	15
1601	MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19. 2021 , 44, e20200199	4
1600	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. 2021 , 13, 17588359211042224	3

1599	COVID-19 Pandemic: What Has Work Got to Do With It?. 2021 , 63, e245-e249	7
1598	Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19. 2021 , 16, e0245296	16
1597	Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. 2021 , 27,	44
1596	Pulmonary complications due to COVID-19 la literature review.	2
1595	Testicular Atrophy and Hypothalamic Pathology in COVID-19: Possibility of the Incidence of Male Infertility and HPG Axis Abnormalities. 2021 , 28, 2735-2742	20
1594	An immune-based biomarker signature is associated with mortality in COVID-19 patients. 2021 , 6,	109
1593	Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. 2021 , 70, 698-706	312
1592	Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19. 2020 , 11, 583777	34
1591	SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. 2021 , 6, 2	23
1590	SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage. 2021 , 41, 515-525	36
1589	Bovine colostrum: benefits for the human respiratory system and potential contributions for clinical management of COVID-19. 2021 , 32, 143-162	1
1588	Frequency-domain reconfigurable antenna for COVID-19 tracking. 2021 , 2, 100094	1
1587	Overview of the Haematological Effects of COVID-19 Infection. 2021 , 1321, 163-172	2
1586	A SCID mouse-human lung xenograft model of SARS-CoV-2 infection. 2021 , 11, 6607-6615	1
1585	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. 2021 , 19, 1661-1671	4
1584	Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19. 2021 , 6,	3
1583	Recovery of Capsaicinoids and Other Phytochemicals Involved With TRPV-1 Receptor to Re-valorize Chili Pepper Waste and Produce Nutraceuticals. 2021 , 4,	3
1582	Letter to the editor "SARS-CoV-2: What prevents this highly contagious virus from reaching the fetus?". 2021 , 104, 303	1

1581	Integrating Metamaterial Antenna Node and LiFi for Privacy Preserving Intelligent COVID-19 Hospital Patient Management. 2021 , 1-14	3
1580	[Cardiovascular diseases and COVID-19: Pathophysiology, complications and treatment]. 2021 , 46, 107-114	О
1579	Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development. 2021 , 10,	6
1578	Low-dose radiation therapy: a treatment for pneumonia resulting from COVID-19. 1-4	1
1577	Cellular Tropism of SARS-CoV-2 across Human Tissues and Age-related Expression of ACE2 and TMPRSS2 in Immune-inflammatory Stromal Cells. 2021 , 12, 718-725	2
1576	Coronavirus Infections of Animals and Humans: Biological and Epidemiological Properties of Causative Agents. 2021 , 17-36	1
1575	The Immune Response and Effectiveness of COVID-19 Therapies. 2021 , 1321, 115-126	4
1574	Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. 2020 , 11, 598402	14
1573	Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population. 2021 , 40, 2633-2642	8
1572	COVID-19 vaccine: where are we now and where should we go?. 2021 , 20, 23-44	39
1571	Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections. 2021 , 12, 53	10
1570	The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19). 2021 , 11, 6193-6213	6
1569	Impact of COVID-19 in the Mental Health in Elderly: Psychological and Biological Updates. 2021 , 58, 1905-1910	630
1568	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. 2021 , 49, 401-410	26
1567	Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients. 2021 , 5, bvaa199	19
1566	Pediatrics and COVID-19. 2021 , 1318, 197-208	1
1565	Highly Sensitive Near-Infrared Imaging of Peroxynitrite Fluxes in Inflammation Progress. 2021 , 93, 3035-3041	18
1564	SARS-CoV-2 sculpts the immune system to induce sustained virus-specific na\(\textbf{U}e-like and memory \) B-cell responses. 2021 , 10, e1339	3

1563	Ultraefficiently Calming Cytokine Storm Using TiCT MXene. 2021 , 5, 2001108	12
1562	Role of vitamin D in regulating COVID-19 severity-An immunological perspective. 2021 , 110, 809-819	4
1561	Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?. 2020 , 11, 571416	126
1560	The Balance between Two Branches of RAS Can Protect from Severe COVID-19 Course. 2021 , 15, 36-51	1
1559	Nucleocapsid and Spike Proteins of SARS-CoV-2 Drive Neutrophil Extracellular Trap Formation. 2021 , 21, e16	4
1558	Mesenchymal stem cell-derived exosome as a nano weapon to target the COVID-19 pandemic. 2021 , 45, 517-520	1
1557	Papel de los tejidos orales durante la infecciñ por SARS-CoV-2 2021 , 78, 167-175	
1556	SARS-CoV-2 receptor binding mutations and antibody mediated immunity.	3
1555	ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor. 2021 , 1-14	6
1554	Machine Learning-Based Decision Model to Distinguish Between COVID-19 and Influenza: A Retrospective, Two-Centered, Diagnostic Study. 2021 , 14, 595-604	3
1553	Impairment in selenocysteine synthesis as a candidate mechanism of inducible coagulopathy in COVID-19 patients. 2021 , 147, 110475	5
1552	Racial disparities in Coronavirus Disease 2019 (COVID-19) outcomes. 2021 , 36, 360-366	8
1551	Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics. 2021 , 9, 629635	4
1550	Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score. 2021 , 15,	5
1549	Can be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. 2021 , 7, e05990	6
1548	Atteintes pulmonaires liès ^la COVID-19. 2021 , 2, 14-24	O
1547	A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets.	4
1546	Molecular characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima, Japan. 2021 , 16, e0246383	12

1545	Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. 2021 , 11, 3461	12
1544	Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19. 2021 , 4, 1-25	35
1543	Susceptibility to COVID-19 in Pregnancy, Labor, and Postpartum Period: Immune System, Vertical Transmission, and Breastfeeding. 2021 , 2, 602572	5
1542	Macrophage Responses to Environmental Stimuli During Homeostasis and Disease. 2021 , 42, 407-435	4
1541	RNA-assisted self-assembly of monomeric antigens into virus-like particles as a recombinant vaccine platform. 2021 , 269, 120650	2
1540	Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. 2021 , 11, 110	2
1539	Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism. 2021 ,	1
1538	Targeting Lipid Rafts as a Strategy Against Coronavirus. 2020 , 8, 618296	15
1537	Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the Human-Animal Interface. 2021 , 10,	14
1536	Are women with asthma at increased risk for severe COVID-19?. 2021 , 9, 125-126	3
1535	The COVID-19 Pandemic: an Appraisal of its Impact on Human Immunodeficiency Virus Infection and Pre-Eclampsia. 2021 , 23, 9	5
1534	Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF- B : A Systematic Review. 2021 , 13,	7
1533	COVID-19: Molecular and Cellular Response. 2021 , 11, 563085	10
1532	Development and validation of an online model to predict critical COVID-19 with immune-inflammatory parameters. 2021 , 9, 19	3
1531	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. 2021 , 18, 105-118	2
1530	Human Dental Pulp Stem Cells Modulate Cytokine Production by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. 2020 , 8, 609204	5
1529	The impact of oral health status on COVID-19 severity, recovery period and C-reactive protein values. 2021 ,	8
1528	A notable key for estimating the severity of COVID-19: 25-hydroxyvitamin D status. 2021 , 46, 167-172	1

1527	Association of with COVID-19 severity: Delineating the host genetic factors in transcriptomic regulation. 2021 ,	2
1526	Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic Assessment of New IgM/IgG ELISA Kits. 2021 , 10,	12
1525	COVID-19-associated liver injury: from bedside to bench. 2021 , 56, 218-230	16
1524	Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India. 2021 , 12, 637362	2
1523	Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. 2021 , 8, 627723	9
1522	How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn. 2021 , 11,	4
1521	Administration route governs the therapeutic efficacy, biodistribution and macrophage targeting of anti-inflammatory nanoparticles in the lung. 2021 , 19, 56	6
1520	The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease Burden, With Focus on COVID-19 Consequences. 2021 , 12, 587146	28
1519	Molecular Insights into the Thrombotic and Microvascular Injury in Placental Endothelium of Women with Mild or Severe COVID-19. 2021 , 10,	14
1518	Polysaccharides obtained from natural edible sources and their role in modulating the immune system: Biologically active potential that can be exploited against COVID-19. 2021 , 108, 223-235	39
1517	The gut microbiome: a missing link in understanding the gastrointestinal manifestations of COVID-19?. 2021 , 7,	7
1516	Editorial: COVID-19 immunology and organ transplantation. 2021 , 26, 258-265	
1515	Headache during COVID-19: Lessons for all, implications for the International Classification of Headache Disorders. 2021 , 61, 385-386	4
1514	Physical phenotype of blood cells is altered in COVID-19.	5
1513	Cytokine Storm in the Novel Coronavirus Infection and Methods of its Correction. 2021, 65, 27-37	О
1512	SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids. 2021 , 22,	3
1511	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. 2021 , 18, 20200950	10
1510	Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection. 2021 , 1	8

1509	The Nexus Between Telomere Length and Lymphocyte Count in Seniors Hospitalized With COVID-19. 2021 , 76, e97-e101	5
1508	Mitochondrial Regulation of Macrophage Response Against Pathogens. 2020 , 11, 622602	4
1507	Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning. 2021 , 6, 4857-4877	6
1506	Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2. 2021 , 22,	7
1505	SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development. 2021 , 17, e1009225	74
1504	Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.	4
1503	Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. 2021 , 12, 1325	60
1502	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. 2021 , 22, 254-281	17
1501	[Mortality in sepsis and septic shock in Germany. Results of a systematic review and meta-analysis]. 2021 , 70, 673-680	2
1500	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. 2021 , 22,	5
1499	Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review). 2021 , 21, 320	
1498	Obesidade e infect por SARS-CoV-2: papel da metainflamat. 46, 1-16	
1497	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. 2021 , 15, 510	1
1496	SARS-CoV-2 genomic surveillance identifies naturally occurring truncations of ORF7a that limit immune suppression. 2021 ,	2
1495	The U-shaped association of serum iron level with disease severity in adult hospitalized patients with COVID-19.	
1494	Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19. 2021 , 12, 598925	7
1493	SARS-CoV-2 viral load in nasopharyngeal swabs in the emergency department does not predict COVID-19 severity and mortality. 2021 , 28, 306-313	19
1492	The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis. 2021 , 22,	10

1491	Coronavirus disease 2019 and cardiovascular complications: focused clinical review. 2021 , 39, 1282-1292	23
1490	Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment. 2021 , 73, 281-299	20
1489	Anti-inflammatory activity of soluble chito-oligosaccharides (CHOS) on VitD3-induced human THP-1 monocytes. 2021 , 16, e0246381	5
1488	Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection. 2021 , 14, 39	Ο
1487	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. 2021 , 12, 576448	5
1486	Morphologic Changes in Circulating Blood Cells of COVID-19 Patients. 2021 , 13, e13416	7
1485	Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. 2021 , 22, 322-335	57
1484	Dysregulated transcriptional responses to SARS-CoV-2 in the periphery. 2021 , 12, 1079	25
1483	Silence of the Lambs: The Immunological and Molecular Mechanisms of COVID-19 in Children in Comparison with Adults. 2021 , 9,	5
1482	Effect of co-infection with parasites on severity of COVID-19.	6
1481	EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection. 2021 , 26,	17
1480	Murine-Ecoronavirus-induced neuropathogenesis sheds light on CNS pathobiology of SARS-CoV2. 2021 , 27, 197-216	8
1479	Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2. 2021 , 93, 3143-3151	9
1479 1478		9
	and receptor ACE2. 2021 , 93, 3143-3151	
1478	and receptor ACE2. 2021 , 93, 3143-3151 Neopterin: A Promising Candidate Biomarker for Severe COVID-19. 2021 , 14, 245-251 Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A	3
1478	and receptor ACE2. 2021, 93, 3143-3151 Neopterin: A Promising Candidate Biomarker for Severe COVID-19. 2021, 14, 245-251 Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?. 2021, 16, 213-218 Early and Significant Reduction in C-Reactive Protein Levels After Corticosteroid Therapy Is	3

1473	Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections. 2021 , 12, 1112	18
1472	Metabolic Alterations in SARS-CoV-2 Infection and Its Implication in Kidney Dysfunction. 2021 , 12, 624698	11
1471	Possible role of purinergic signaling in COVID-19. 2021 , 476, 2891-2898	9
1470	Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients. 2021 , 12, 613070	10
1469	SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF- B pathway. 2021 ,	16
1468	SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. 2021 , 12, 1876	31
1467		
1466	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. 2021 , 10, 63-85	16
1465	Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. 2021 , 12, 650331	26
1464	Simultaneous CD8 T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs. 2021 , 9,	7
1463	Dynamic Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses. 2021 , 8, ofab122	2
1462	Insights into biological therapeutic strategies for COVID-19. 2021 , 1, 166-178	2
1461	Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis.	2
1460	LncRNAs NEAT1 and MALAT1 Differentiate Inflammation in Severe COVID-19 Patients. 2021 ,	3
1459	Stromal-immune cell crosstalk fundamentally alters the lung microenvironment following tissue insult. 2021 , 163, 239-249	3
1458	Relationship between blood eosinophil levels and COVID-19 mortality. 2021 , 14, 100521	22
1457	State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2. 2021 , 13, 14816-14843	13
1456	as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. 2021 , 9,	7

1455	Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. 2021 , 19, e3001143	62
1454	A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). 2021 ,	11
1453	Care for Patients With Neuromuscular Disorders in the COVID-19 Pandemic Era. 2021 , 12, 607790	5
1452	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.	O
1451	RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance. 2021 , 109, 1092-1103	0
1450	Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19. 2021 , 32, 310-315	13
1449	The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies. 2021 ,	
1448	Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients-A Report of 10 Cases. 2021 , 2021, 5575928	О
1447	Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-19. 2021 , 3,	1
1446	COVID-19 and human papillomavirus: Paradoxical immunity. 2021 , 20, 2001-2003	О
1445	"Mask up to keep it up": Preliminary evidence of the association between erectile dysfunction and COVID-19. 2021 , 9, 1053-1059	30
1444		
1443	Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. 2021 , 109, 829-840	21
1442	The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review. 2021 , 11, 265-271	8
1441	Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. 2021 , 12, 646701	14
1440	Predicting Severity and Intrahospital Mortality in COVID-19: The Place and Role of Oxidative Stress. 2021 , 2021, 6615787	13
1439	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. 2021 , 7,	32
1438	Ubiquitin-Modified Proteome of SARS-CoV-2-Infected Host Cells Reveals Insights into Virus-Host Interaction and Pathogenesis. 2021 , 20, 2224-2239	13

1437	Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review. 2021 , 55, 1386-1396	2
1436	COVID-19 and liver disease: mechanistic and clinical perspectives. 2021 , 18, 348-364	90
1435	HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. 2021 , 131,	39
1434	Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19. 2021 , 12, 602130	9
1433	Outcomes and Risk Factors for Cardiovascular Events in Hospitalized COVID-19 Patients. 2021 , 35, 3581-3593	7
1432	Thymidine Phosphorylase Is Increased in COVID-19 Patients in an Acuity-Dependent Manner. 2021 , 8, 653773	1
1431	SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis. 2021 , 166, 1565-1574	7
1430	Manifestaciones pulmonares de la artritis reumatoide, una revisit en tiempos de pandemia por SARS-CoV-2. 2021 ,	
1429	Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. 2021 , 82, 399-406	54
1428	IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection. 2021 , 4, 290	28
1427	Acute Coronary Syndrome and Arrhytmia Induced by SARS-CoV-2 Infection in a Patient with Non-Significant LAD Lesion. A Case Report. 2021 , 6, 43-47	
1426	The impact of ABO blood groups on clinical outcomes and susceptibility to COVID-19: A retrospective study in an unselected population. 2021 , 61, 1631-1641	6
1425	Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. 2021 ,	5
1424	The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection. 2021 , 12, 615695	7
1423	Proposed delay for safe surgery after COVID-19. 2021 , 91, 495-506	8
1422	Spontaneous Breathing and Evolving Phenotypes of Lung Damage in Patients with COVID-19: Review of Current Evidence and Forecast of a New Scenario. 2021 , 10,	19
1421	Susceptibility of the patients infected with Sars-Cov2 to oxidative stress and possible interplay with severity of the disease. 2021 , 165, 184-190	13
1420	Electrochemical sensing: A prognostic tool in the fight against COVID-19. 2021 , 136, 116198	23

1419	Nexus between COVID-19 and periodontal disease. 2021 , 49, 3000605211002695	6
1418	Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis. 2021 , 11,	9
1417	Dynamic blood single-cell immune responses in patients with COVID-19. 2021 , 6, 110	18
1416	Monitoring of SARS-CoV-2 infection in mustelids. 2021 , 19, e06459	29
1415	Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action. 2021 , 87, 3835-3850	1
1414	SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function. 2021 , 16, 478-492	29
1413	Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy. 2021 , 31, 2100088	21
1412	BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant viruses is up to 10-fold reduced.	5
1411	HIF-1, the Warburg Effect, and Macrophage/Microglia Polarization Potential Role in COVID-19 Pathogenesis. 2021 , 2021, 8841911	11
1410	COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. 2021 , 49, 677-684	11
1409	Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. 2021 , 8, 1-13	6
1408	Role of Mitochondria in Viral Infections. 2021 , 11,	13
1407	Insights on the Structural Variations of the Furin-Like Cleavage Site Found Among the December 2019-July 2020 SARS-CoV-2 Spike Glycoprotein: A Computational Study Linking Viral Evolution and Infection. 2021 , 8, 613412	3
1406	Why Does SARS-CoV-2 Infection Induce Autoantibody Production?. 2021 , 10,	1
1405	Case Report: A Severe SARS-CoV-2 Infection in a Teenager With Angelman Syndrome. 2021 , 8, 629112	
1404	In vitroscreening of herbal medicinal products for their supportive curing potential in the context of SARS-CoV-2.	1
1403	Reduced frequency of T helper 17 and T helper 1 cells and their association with critical coronavirus disease 2019. 2021 , 129, 271-279	3
1402	Targeting alveolar-specific succinate dehydrogenase A attenuates pulmonary inflammation during acute lung injury. 2021 , 35, e21468	4

1401 The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication. 2021 , 11, 5433	12
Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?. 2021 , 12, 155	5
1399 Maternal-Fetal Immune Responses in Pregnant Women Infected with SARS-CoV-2. 2021 ,	3
1398 Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly. 2021 , 10,	13
Network Meta-Analysis on the Mechanisms Underlying Alcohol Augmentation of COVID-19 Pathologies. 2021 , 45, 675-688	10
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes fro SARS-CoV-2 infection: the OnCovid Inflammatory Score. 2021 , 9,	m 11
1395 Untangling the cell immune response dynamic for severe and critical cases of SARS-CoV-2 infec	tion. 2
Negative Association Between Mediterranean Diet Adherence and COVID-19 Cases and Related Deaths in Spain and 23 OECD Countries: An Ecological Study. 2021 , 8, 591964	d 23
1393 Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. 2021 , 36, 681-688	15
SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. 2021 , 9,	20
SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis a cytokine release. 2021 ,	and 22
Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrom and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile. 2020 , 11, 598128	me 10
1389 Ketogenic Diet as a Preventive and Supportive Care for COVID-19 Patients. 2021 , 13,	8
Exploration of interethnic variation and repurposed drug efficacy in the treatment of SARS-CoV Infection (COVID-19).	/-2
1387 Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues. 2021 , 12, 597399	1
Hypoxia-induced inflammation: Profiling the first 24-hour posthypoxic plasma and central nervo system changes. 2021 , 16, e0246681	ous 1
C1q Complement/Tumor Necrosis Factor-Associated Proteins in Cardiovascular Disease and COVID-19. 2021 , 9,	2
1384 Seroconversion stages COVID19 into distinct pathophysiological states. 2021 , 10,	18

1383 Advance	es in vaccine delivery systems against viral infectious diseases. 2021 , 11, 1401-1419	7
	wide hematopoietic and immune signaling aberrations in COVID-19 revealed by deep ne and phosphoproteome analysis.	1
	ptome analysis of PBMCs reveals distinct immune response in the asymptomatic and table positive COVID-19 patients.	
13 ⁸⁰ Hospital	l mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or	2
1379 Function	nal and Structural Characterization of SARS-Cov-2 Spike Protein: An Study. 2021 , 31, 213-222	2
1378 Innate ir	nmune deficiencies in patients with COVID-19.	1
	n Dose Requirements in Adults Hospitalized With COVID-19 Infection: A Retrospective Case 2021, 8971900211000705	3
1376 Aberran	t glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets.	5
1375 SARS-Co	oV-2 engages inflammasome and pyroptosis in human primary monocytes. 2021 , 7, 43	81
	Train Your Dragon: Harnessing Gamma Delta T Cells Antiviral Functions and Trained by in a Pandemic Era. 2021 , 12, 666983	11
1373 Prevaler	nce of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients. 2021 , 1-12	3
1372 Syntheti	ic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19. 2021 , 7, 650-657	13
	Acute Respiratory Syndrome-Associated Coronavirus 2 Infection and Organ Dysfunction in Opportunities for Translational Research. 2021 , 3, e0374	12
1370 Alpha-1	antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. 2021 , 12, 1726	32
1369 COVID-1	19 vaccines: The status and perspectives in delivery points of view. 2021 , 170, 1-25	127
1368 In quest	of a new therapeutic approach in COVID-19: the endocannabinoid system. 2021 , 53, 478-490	6
	ing the antiviral type I interferon system as a first line of defense against SARS-CoV-2 enicity. 2021 , 54, 557-570.e5	84
1366 Drug rep	ourposing for COVID-19 via knowledge graph completion. 2021 , 115, 103696	28

1365	Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. 2021 , 12, 1618	46
1364	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. 2021 , 10,	6
1363	Identification, crystallization and epitope determination of public TCR shared and expanded in COVID-19 patients.	
1362	A REVIEW ON EMERGING PATHOGENESIS OF COVID-19 AND POINTS OF CONCERN FOR RESEARCH COMMUNITIES IN NIGERIA. 2021 , 15, 36-43	O
1361	Migration of households from New York City and the Second Peak in Covid-19 cases in New Jersey, Connecticut and New York Counties. 2021 ,	
1360	Possible Therapeutic Role of Cholinergic Agonists on COVID-19 related inflammatory response. 2021 , 5, 102-108	
1359	Bidirectional link between diabetes mellitus and coronavirus disease 2019 leading to cardiovascular disease: A narrative review. 2021 , 12, 215-237	13
1358	Different characteristics of critical COVID-19 and thinking of treatment strategies in non-elderly and elderly severe adult patients. 2021 , 92, 107343	5
1357	Kidney transplant dysfunction in a patient with COVID - 19 infection: role of concurrent Sars-Cov 2 nephropathy, chronic rejection and vitamin C-mediated hyperoxalosis: case report. 2021 , 22, 91	4
1356	Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. 2021 , 22,	16
1355	The spatial landscape of lung pathology during COVID-19 progression. 2021 , 593, 564-569	72
1354	The potential of herbal extracts to inhibit SARS-CoV-2: a pilot study. 2021 , 7,	4
1353	Perspectives on RNA Vaccine Candidates for COVID-19. 2021 , 8, 635245	21
1352	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. 2021 , 41,	6
1351	SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm. 2021 , 10,	6
1350	Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. 2021 , 92, 107336	4
1349	Using TikTok App for Therapy and Sharing Happiness in COVID-19 Outbreak. 2021 , Publish Ahead of Print,	3
1348	Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. 2021 , 11, 7052	45

1347	Interactions of SARS-CoV-2 with the Blood-Brain Barrier. 2021 , 22,	30
1346	Covid-19 and oral diseases: Crosstalk, synergy or association?. 2021 , 31, e2226	19
1345	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. 2021 , 13,	1
1344	Phytochemicals as Potential Therapeutics for SARS-CoV-2-Induced Cardiovascular Complications: Thrombosis and Platelet Perspective. 2021 , 12, 658273	О
1343	Circulating Adaptive Immune Cells Expressing the Gut Homing Marker 40 Integrin Are Decreased in COVID-19. 2021 , 12, 639329	3
1342	Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. 2021 , 118,	4
1341	Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property. 2021 , 35, 4246-4257	3
1340	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. 2021 , 12, 589095	32
1339	Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients. 2021 , 96, 875-886	27
1338	Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits. 2021 , 19, 1245-1258	4
1337	Vitamin D status of Arab Gulf residents screened for SARS-CoV-2 and its association with COVID-19 infection: a multi-centre case-control study. 2021 , 19, 166	12
1336	Interrogating the Impact of Intestinal Parasite-Microbiome on Pathogenesis of COVID-19 in Sub-Saharan Africa. 2021 , 12, 614522	5
1335	COVID-19-associated secondary hemophagocytic lymphohistiocytosis (cytokine storm syndrome). 2021 , 76, 51-66	6
1334	The Deadly Duo of COVID-19 and Cancer!. 2021 , 8, 643004	9
1333	Increased Hospitalization and Mortality from COVID-19 in Prostate Cancer Patients. 2021, 13,	6
1332	Disposable over Reusable Face Masks: Public Safety or Environmental Disaster?. 2021 , 8, 31	14
1331	Epigenetic Remodeling in Innate Immunity and Inflammation. 2021 , 39, 279-311	13
1330	COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns. 2021 , 9,	4

1329	An Integrated Approach of the Potential Underlying Molecular Mechanistic Paradigms of SARS-CoV-2-Mediated Coagulopathy. 2021 , 36, 1-17	3
1328	Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. 2021 , 82, 264-269	23
1327	SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. 2021 , 10,	49
1326	SARS-CoV-2 Spike Targets USP33-IRF9 Axis Exosomal miR-148a to Activate Human Microglia. 2021 , 12, 656700	13
1325	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. 2021 , 184, 1821-1835	.egk6
1324	COVID-19 in ocrelizumab-treated people with multiple sclerosis. 2021 , 49, 102725	35
1323	How to Understand Herd Immunity in the Context of COVID-19. 2021 , 34, 174-181	9
1322	Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation.	
1321	Increased Serum Levels of Soluble TNF-Receptor Is Associated With ICU Mortality in COVID-19 Patients. 2021 , 12, 592727	12
1320	Molecular Profiling of COVID-19 Autopsies Uncovers Novel Disease Mechanisms.	
1319	Bead-assisted SARS-CoV-2 multi-antigen serological test allows effective identification of patients.	
1318	Possibilities of conservative treatment for andrological conditions in men with history of COVID-19. 2021 , 22, 71-75	3
1317	Hypoxia and viral infectious diseases. 2021 , 6,	2
1316	Infecciñ por SARS-CoV-2. Anlisis descriptivo de una serie de casos seleccionada. 2021 , 69, 34-34	
1315	Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial. 2021 , 58,	13
1314	COVID-19 immunity and vaccines: what a pharmacist needs to know. 2021 , 15, 51-67	
1313	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. 2021 , 3, e481-e488	8
1312	Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection. 2021 , 12, 660087	14

1311	MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak. 2021 , 19, 164	7
1310	SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs. 2021 , 9,	13
1309	SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naWe-like and memory B cell responses.	1
1308	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2. 2021 , 13,	17
1307	Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. 2021 , 9,	10
1306	Animal Models of COVID-19 II. Comparative Immunology. 2021 ,	9
1305	Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients. 2021 , 51, 1449-1460	3
1304	Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. 2021 , 76, 1010-1019	16
1303	In-depth analysis of laboratory parameters reveals the interplay between sex, age, and systemic inflammation in individuals with COVID-19. 2021 , 105, 579-587	7
1302	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. 2021 , 6,	18
1301	Changes of Damage Associated Molecular Patterns in COVID-19 Patients. 2021 , 1, 20-27	2
1300	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. 2021 , 50, 743-779	8
1299	Animal Models of COVID-19. I. Comparative Virology and Disease Pathogenesis. 2021,	12
1298	Cancer as a prospective sequela of long COVID-19. 2021 , 43, e2000331	10
1297	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. 2021 , 184, 1804-1820.e16	149
1296	The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review. 2021 , 61, 987-1000	6
1295	SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. 2021 , 12, 638334	6
1294	SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopenia. 2021 ,	O

1293	Trends in Coronavirus Disease 2019 Hospitalization and Prognosis: Gender Effect. 2021 , 41, 312-317	2
1292	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). 2021 , 69, 213-224	9
1291	Co-infection of H9N2 Influenza A Virus and in a BALB/c Mouse Model Aggravates Lung Injury by Synergistic Effects. 2021 , 12, 670688	5
1290	Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?. 2021 , 215, 113294	12
1289	A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19. 2021 , 11, 8062	1
1288	IL-6 modulation for COVID-19: the right patients at the right time?. 2021 , 9,	12
1287	Adhatoda Vasica attenuates inflammatory and hypoxic responses in preclinical mouse models: potential for repurposing in COVID-19-like conditions. 2021 , 22, 99	7
1286	Thrombose und COVID-19. 2021 , 20, 92-97	1
1285	Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. 2021 , 12, 652688	52
1284	Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!. 2021 , 12, 668507	27
1283	Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. 2021 , 136, 111272	42
1282	SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. 2021 , 58, 1-15	28
1281	Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. 2021 , 184, 1836-1857.e2	264
1280	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 2021 , 21, 319-329	192
1279	Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. 2021 , 78, 380-386	128
1278	RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF- B hyper-activation and inflammation. 2021 , 6, 167	24
1277	Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp15 Endoribonuclease.	
1276	SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity.	

1275	Assessment of Pediatric Admissions for Kawasaki Disease or Infectious Disease During the COVID-19 State of Emergency in Japan. 2021 , 4, e214475	8
1274	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection.	4
1273	A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. 2021 , 21, 675-686	8
1272	Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19. 2021 , 12, 633769	3
1271	Genetics Insight for COVID-19 Susceptibility and Severity: A Review. 2021 , 12, 622176	34
1270	Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay. 2021 , 15, 8996-9004	30
1269	Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. 2021 , 14,	10
1268	Untargeted GC/MS-based approach for identification of anti-inflammatory alkaloids from Hippeastrum elegans (Amaryllidaceae) using a human neutrophil model. 2021 , 199, 114061	1
1267	Pre-existing conditions in Latin America and factors associated with adverse outcomes of COVID-19: A review. 2021 , 21, e8181	О
1266	Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. 2021 , 1-20	5
1265	[Role of the immune system in SARS-CoV-2 infection: immunopathology of COVID-19]. 2021 , 13, 1917-1931	1
1264	Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. 2021 , 8, 671923	
1263	Functional and tissue enrichment analyses suggest that SARS-CoV-2 infection affects host metabolism and catabolism mediated by interference on host proteins. 2021 , 52, 1151-1159	О
1262	COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis. 2021 , 12, 666067	7
1261	Spectrum of Immunopathogenesis in Coronavirus Disease 2019 (COVID-19): An Updated Review. 2021 , 17, 358-369	
1260	Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease. 2021 , 1-13	3
1259	COVID-19 Severity Potentially Modulated by Cardiovascular-Disease-Associated Immune Dysregulation. 2021 , 13,	2
1258	COVID-19 in Africa: an ovarian victory?. 2021 , 14, 70	1

Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-patients: a case series and review of the literature. 2021 ,	19
Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2. 2021 , 93, 5487-5504	4
1255 The role of IL-6 and IL-6 blockade in COVID-19. 2021 , 17, 601-618	10
Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-Co\ 2021, 16, 1165-1181	/-2. 21
1253 COVID-19 impact on nurses in Spain: a considered opinion survey. 2021 , 68, 248-255	5
BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. 2021 , 76, 2895-2998	16
Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. 2021 , 65, 515-525	34
Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives. 2021 , 272, 119251	14
1249 The Effect of Minnelide against SARS-CoV-2 in a Murine Model.	
Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats 2021 ,	4
	4
Community-Acquired Pneumonia of Bacterial Etiology and the Spectrum of Pathogen Sensitivity	y to 2
Community-Acquired Pneumonia of Bacterial Etiology and the Spectrum of Pathogen Sensitivity Antibiotics in Corona-Positive and Corona-Negative Patients in Rostov-on-Don. 2021 , 66, 26-32 Presentation and Outcome of Congenital Heart Disease During Covid-19 Pandemic: A Review. 2	y to 2
Community-Acquired Pneumonia of Bacterial Etiology and the Spectrum of Pathogen Sensitivity Antibiotics in Corona-Positive and Corona-Negative Patients in Rostov-on-Don. 2021, 66, 26-32 Presentation and Outcome of Congenital Heart Disease During Covid-19 Pandemic: A Review. 2 47, 100905	9 to 2 022, 1
Community-Acquired Pneumonia of Bacterial Etiology and the Spectrum of Pathogen Sensitivity Antibiotics in Corona-Positive and Corona-Negative Patients in Rostov-on-Don. 2021, 66, 26-32 Presentation and Outcome of Congenital Heart Disease During Covid-19 Pandemic: A Review. 2 47, 100905 COVID-19 exposure and obstructive sleep apnea: a therapeutic approach. 2021, 81, 123 Successful use of CytoSorb in a Covid-19 patient with secondary septic shock due to a sacral	4 y to 2 022, 1
Community-Acquired Pneumonia of Bacterial Etiology and the Spectrum of Pathogen Sensitivity Antibiotics in Corona-Positive and Corona-Negative Patients in Rostov-on-Don. 2021, 66, 26-32 Presentation and Outcome of Congenital Heart Disease During Covid-19 Pandemic: A Review. 2 47, 100905 COVID-19 exposure and obstructive sleep apnea: a therapeutic approach. 2021, 81, 123 Successful use of CytoSorb in a Covid-19 patient with secondary septic shock due to a sacral decubitus infection. 2021, 44, 1034-1038	4 y to 2 022, 1 0
2021, Community-Acquired Pneumonia of Bacterial Etiology and the Spectrum of Pathogen Sensitivity Antibiotics in Corona-Positive and Corona-Negative Patients in Rostov-on-Don. 2021, 66, 26-32 Presentation and Outcome of Congenital Heart Disease During Covid-19 Pandemic: A Review. 2 47, 100905 COVID-19 exposure and obstructive sleep apnea: a therapeutic approach. 2021, 81, 123 Successful use of CytoSorb in a Covid-19 patient with secondary septic shock due to a sacral decubitus infection. 2021, 44, 1034-1038 Future Biomarkers for Infection and Inflammation in Febrile Children. 2021, 12, 631308	4 y to 2 022, 1 0

1239	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. 2021 , 44, 499-513	4
1238	Lung histopathological findings in COVID-19 disease - a systematic review. 2021 , 16, 34	13
1237	Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. 2021 , 35, e22795	1
1236	Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. 2021 , 77, 777-785	17
1235	The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19. 2021 , 137, 111267	22
1234	Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. 2021 , 3, 774-785	78
1233	Testing at scale during the COVID-19 pandemic. 2021 , 22, 415-426	80
1232	Hypoxia induces expression of angiotensin-converting enzyme II in alveolar epithelial cells: Implications for the pathogenesis of acute lung injury in COVID-19. 2021 , 9, e14854	4
1231	The Immunological Role of the Placenta in SARS-CoV-2 Infection-Viral Transmission, Immune Regulation, and Lactoferrin Activity. 2021 , 22,	3
1230	The effects of increased pollution on COVID-19 cases and deaths. 2021 , 107, 102431	12
1229	Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital. 2021 , 1	3
1228	Mitochondrial cyclophilin D promotes disease tolerance by licensing NK cell development and IL-22 production against influenza virus.	
1227	Late thrombotic complications after SARS-CoV-2 infection in hemodialysis patients. 2021 , 25, 507-514	2
1226	Promising Immunotherapies against COVID-19. 2021 , 4, 2100044	3
1225	Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosis-Manifested Severe Disease. 2021 , 12, 670170	5
1224	Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. 2021 , 35, 109126	61
1223	Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance. 2021 , 43, 265-270	2
1222	Peripheral and lung resident memory T cell responses against SARS-CoV-2. 2021 , 12, 3010	29

Immune status determined as per quidelines of Ayurveda found associated with clinical outcomes 1221 of COVID-19 disease - Results of a cross-sectional pilot study. 2021, 13, 100425-100425 SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine 1220 development. 2021, 179, 45-60 Impact of Sleep Deprivation on Emotional Regulation and the Immune System of Healthcare Workers as a Risk Factor for COVID 19: Practical Recommendations From a Task Force of the Latin 1219 3 American Association of Sleep Psychology, 2021, 12, 564227 A method for the rational selection of drug repurposing candidates from multimodal knowledge 1218 harmonization. 2021, 11, 11049 Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases. 2021, 4, 1528-1554 6 Integrative omics provide biological and clinical insights into acute respiratory distress syndrome. 1216 2 **2021**, 47, 761-771 1215 COVID-19 enters the expanding network of apolipoprotein E4-related pathologies. 2021, 41, 101938 11 Elevated Blood Glucose Levels as a Primary Risk Factor for the Severity of COVID-19. \circ ORAL VIRAL LOAD OF SARS-COV-2 AND EXACERBATION OF CHRONIC PERIODONTAL DISEASE IN \circ 1213 PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19). 2021, 17, 70-75 1212 The interplay between the immune system and SARS-CoV-2 in COVID-19 patients. 2021, 166, 2109-2117 2 Simultaneous detection of the spike and nucleocapsid proteins from SARS-CoV-2 based on 1211 4 ultrasensitive single molecule assays. 2021, 413, 4645-4654 Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil. 2021, 1210 27, 1446-1453 Navigating in Deep Waters: How Tissue Damage and Inflammation Shape Effector and Memory CD8 1209 2 T Cell Responses. 2021, 5, 338-348 Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or 1208 ARBs. 2021, 17, 2841-2850 The Glasgow Prognostic Score and fibrinogen to albumin ratio as prognostic factors in hospitalized 1207 1 patients with COVID-19. 2021, 15, 1061-1068 The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. 1206 11 2021, 10, SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug 1205 70 discovery. 2021, 35, 109055 1204 Copper-impregnated three-layer mask efficiently inactivates SARS-CoV2. 2021, 196, 110947 21

1203	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. 2021 , 9,	3
1202	Acute Retinal Necrosis as a presenting ophthalmic manifestation in COVID 19 recovered patients. 2021 , 29, 722-725	7
1201	Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection. 2021 , 7, 121-131	
1200	Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions. 2021 , 28, 3173-3192	2
1199	COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus. 2021 , 27, 1553-1563	7
1198	In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives. 2021 , 40, e2100028	15
1197	Vitamin D Levels in COVID-19 Outpatients from Western Mexico: Clinical Correlation and Effect of Its Supplementation. 2021 , 10,	9
1196	Lactoferrin for Mental Health: Neuro-Redox Regulation and Neuroprotective Effects across the Blood-Brain Barrier with Special Reference to Neuro-COVID-19. 2021 , 1-35	Ο
1195	Variable Induction of Pro-inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo.	1
1194	Revealing the host antiviral protein ZAP-S as an inhibitor of SARS-CoV-2 programmed ribosomal frameshifting.	2
1193	Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality. 2021 , 12, 659339	11
1192	COVID-19 severity and obesity: are MAIT cells a factor?. 2021 , 9, 445-447	3
1191	SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. 2021 , 137, 111352	14
1190	Cardiac complications during the active phase of COVID-19: review of the current evidence. 2021 , 16, 2051-2061	4
1189	Divergent early antibody responses define COVID-19 disease trajectories. 2021 ,	3
1188	Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned. 2021 , 13,	5
1187	Long COVID: An overview. 2021 , 15, 869-875	97
1186	SARS CoV2 infection _The longevity study perspectives. 2021 , 67, 101299	11

1185	. 2021,	O
1184	Markers of brain and endothelial Injury and inflammation are acutely and sex specifically regulated in SARS-CoV-2 infection.	O
1183	High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. 2021 , 13,	54
1182	African Americans and European Americans exhibit distinct gene expression patterns across tissues and tumors associated with immunologic functions and environmental exposures. 2021 , 11, 9905	6
1181	Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure. 2021 , 12, 671013	2
1180	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. 2021 , 14,	10
1179	StackIL6: a stacking ensemble model for improving the prediction of IL-6 inducing peptides. 2021 , 22,	28
1178	Aging and Options to Halt Declining Immunity to Virus Infections. 2021 , 12, 681449	1
1177	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.	4
1176	A Case of Elsberg Syndrome in the Setting of Asymptomatic SARS-CoV-2 Infection. 2021 , 22, 228-231	4
1175	Broad antiviral and anti-inflammatory efficacy of nafamostat against SARS-CoV-2 and seasonal coronaviruses in primary human bronchiolar epithelia. 2021 ,	1
1174	Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals. 2021 , 11, 13164	6
1173	Cycling Therapy for Reducing Psychological Problems of Patients With COVID-19: As an Alternative Treatment After Recovery. 2021 , 29, e490	1
1172	Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. 2021 , 12, 684014	9
1171	COVID-19: individual and herd immunity. 2021 , 344, 7-18	O
1170	Advanced Applications of Fuel Cells during the COVID-19 Pandemic. 2021 , 2021, 1-9	2
1169	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. 2021 , 117, 2148-2160	8
1168	Altered amino acid profile in patients with SARS-CoV-2 infection. 2021 , 118,	21

1167	Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19-The Role of RAGE-RAS Crosstalk. 2021 , 11,	8
1166	Viral coinfections in COVID-19. 2021 , 93, 5310-5322	13
1165	LTB-Driven Inflammation and Increased Expression of / During Severe COVID-19 in Individuals With Diabetes. 2021 , 70, 2120-2130	4
1164	Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators. 2021 , 22,	13
1163	Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization. 2021 , 26,	35
1162	A reasoned approach towards administering COVID-19 vaccines to pregnant women. 2021 , 41, 1018-1035	3
1161	Physical phenotype of blood cells is altered in COVID-19. 2021 , 120, 2838-2847	38
1160	Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. 2021 , 19, 173	8
1159	Mathematical Model of Antiviral Immune Response against the COVID-19 Virus. 2021 , 9, 1356	3
1158	Unraveling the thread of uncontrolled immune response in COVID-19 and STEMI: an emerging need for knowledge sharing. 2021 , 320, H2240-H2254	O
1157	Implicating Gene and Cell Networks Responsible for Differential COVID-19 Host Responses via an Interactive Single Cell Web Portal. 2021 ,	2
1156	Glycolytic inhibitor 2-Deoxy-D-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.	Ο
1155	Expression of SARS-CoV-2 Host Cell Entry Factors in Immune System Components of Healthy Individuals and Its Relevance for COVID-19 Immunopathology. 2021 , 34, 352-357	3
1154	Uncoupling of macrophage inflammation from self-renewal modulates host recovery from respiratory viral infection. 2021 , 54, 1200-1218.e9	13
1153	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. 2021 , 8, e2100985	8
1152	The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications. 2021 , 70, 877-889	2
1151	Changes in amino acid profile of cord blood plasma and amniotic fluid of mothers with COVID-19. 2021 ,	О
1150	COVID-19-associated mucormycosis: an epidemic within a pandemic. 2021 , 114, 355-356	10

1149	Clinical-Pathological Correlation of the Pathophysiology and Mechanism of Action of COVID-19 - a Primer for Clinicians. 2021 , 21, 38	2
1148	Nucleic Acid Testing of SARS-CoV-2. 2021 , 22,	10
1147	The U-shaped association of serum iron level with disease severity in adult hospitalized patients with COVID-19. 2021 , 11, 13431	3
1146	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. 2021 , 9,	2
1145	Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants. 2021, 13,	14
1144	Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19. 2021 , 11,	40
1143	Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2. 2021 , 12, 698672	6
1142	An Immunoinformatics Approach for SARS-CoV-2 in Latam Populations and Multi-Epitope Vaccine Candidate Directed towards the World's Population. 2021 , 9,	1
1141	The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing. 2021 , 274, 119289	3
1140	Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients. 2021 , 12, 658896	2
1139	Immune dynamics in a time of covid.	
1138	COVID-19 Pathology on Various Organs and Regenerative Medicine and Stem Cell-Based Interventions. 2021 , 9, 675310	O
1137	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. 2021 , 6, 100123	5
1136	The Plausible Role of Indian Traditional Medicine in Combating Corona Virus (SARS-CoV 2): A Mini-Review. 2021 , 22, 906-919	9
1135	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. 2021 , 6,	8
1134	Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination. 2021 , 18, 1395-1414	3
1133	Lung-Centric Inflammation of COVID-19: Potential Modulation by Vitamin D. 2021 , 13,	8
1132	Association of CXCR6 with COVID-19 severity: delineating the host genetic factors in transcriptomic regulation. 2021 , 140, 1313-1328	4

1131	Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome-with a preliminary reference to SARS-CoV-2 pneumonia. 2021 , 22, 141-160	21
1130	Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. 2021 , 44, 408-421	12
1129	How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility. 2021 , 12, 646894	3
1128	COVID-19-associated diarrhea. 2021 , 27, 3208-3222	8
1127	The response of total testing process in clinical laboratory medicine to COVID-19?pandemic. 2021 , 31, 020713	2
1126	The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. 2021 , 1, 20-38	10
1125	Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. 2021 , 13, 110	32
1124	Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury. 2021 , 232, 37-48	12
1123	Does Covera-19 know 'when to hold 'em or 'when to fold 'em? A translational thought experiment. 2021 , 6, 12	O
1122	SARS-CoV-2: Unique Challenges of the Virus and Vaccines. 2021 , 50, 802-809	5
1121	Severe COVID-19 in Hospitalized Carriers of Single Pathogenic Variants. 2021 , 11,	5
1120	Three-Dimensional Cell Cultures as a Research Platform in Lung Diseases and COVID-19. 2021 , 18, 735-745	1
1119	The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis. 2021 , 119, 154753	65
1118	Brain Mechanisms of COVID-19-Sleep Disorders. 2021 , 22,	5
1117	Role of red blood cell distribution width, as a prognostic indicator in COVID-19: A systematic review and meta-analysis. 2021 , e2264	6
1116	Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients. 2021 , 12, e0122921	10
1115	An Overview About the Role of Adaptive Immunity in Keeping SARS-CoV-2 Reinfections at Bay. 2021 , 34, 588-596	1
1114	Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation. 2021 , 16, 1219-1235	13

A strong correlation exists between platelet consumption and platelet hyperactivation in C patients. Pilot study of the patient cohort from CCH RAS Hospital (Troitsk) 2021 , 1, 1-10	OVID-19 3
1112 Innate immune response analysis in COVID-19 and kawasaki disease reveals MIS-C predictor	rs. 2021 , 3
1111 COVID-19: Lung-Centric Immunothrombosis. 2021 , 11, 679878	11
Development and validation of a sensitive, fast and simple LC-MS / MS method for the quar of favipiravir in human serum. 2021 , 1176, 122768	ntitation 10
SARS-CoV-2 genomic surveillance identifies naturally occurring truncation of ORF7a that lin immune suppression. 2021 , 35, 109197	nits 26
1108 A sensitive indicator for the severity of COVID-19: thiol. 2021 , 51, 921-928	11
Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review 14, 2259-2268	v. 2021 ,
Efficacy of phytochemicals as immunomodulators in managing COVID-19: a comprehensive 2021 , 32, 1-11	view.
The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immu Responses in RNA-SARS-Cov-2 Vaccinated Individuals. 2021 , 9,	ine 1
Investigating the active compounds and mechanism of HuaShi XuanFei formula for prevent treatment of COVID-19 based on network pharmacology and molecular docking analysis. 20	
A Cross-sectional Study of Clinical COVID-19 Myocarditis: Differences in Biomarkers in Fulm and Non-fulminant Cases.	ninant
HIF-1Hs a negative regulator of interferon regulatory factors: Implications for interferon production by hypoxic monocytes. 2021 , 118,	12
Photobiomodulation Therapy as a Possible New Approach in COVID-19: A Systematic Review 1101 11,	w. 2021 ,
Elevated Procalcitonin Is Positively Associated with the Severity of COVID-19: A Meta-Analy Based on 10 Cohort Studies. 2021 , 57,	ysis 3
1099 Viral Nephropathies, Adding SARS-CoV-2 to the List. 2021 , 14, 157-164	3
The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects 13, e2021045	s. 2021 ,
1097 Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19. 2021 ,	39, 713-726 ₇
1096 Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. 2021 , 10,	6

1095	From Bulk to Nanoparticles: An Overview of Antiviral Materials, Its Mechanisms, and Applications. 2021 , 38, 2100044	1
1094	How and to What Extent Immunological Responses to SARS-CoV-2 Shape Pulmonary Function in COVID-19 Patients. 2021 , 12, 628288	2
1093	Role of vitamins and minerals as immunity boosters in COVID-19. 2021 , 29, 1001-1016	29
1092	The Role of Th17 Response in COVID-19. 2021 , 10,	17
1091	The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy. 2021 , 10,	9
1090	Impact of Aligning Saliency Maps on COVID-19 Disease Detection Using Chest X-Ray Images. 2021 ,	O
1089	Primary adrenal insufficiency due to bilateral adrenal infarction in COVID-19: a case report. 2021,	3
1088	Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage. 2021 , 14, 101095	9
1087	The Quality of SARS-CoV-2-Specific T Cell Functions Differs in Patients with Mild/Moderate versus Severe Disease, and T Cells Expressing Coinhibitory Receptors Are Highly Activated. 2021 , 207, 1099-1111	7
1086	Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. 2021 , 10,	9
1085	Proinflammatory and Hepatic Features Related to Morbidity and Fatal Outcomes in COVID-19 Patients. 2021 , 10,	3
1084	Pulmonary function, computerized tomography features and six-minute walk test at three months in severe COVID-19 patients treated with intravenous pulsed methylprednisolone: a preliminary report. 2021 ,	1
1083	SARS-CoV-2 receptor-binding mutations and antibody contact sites. 2021 , 4, 149-158	5
1082	Chitin and chitosan as tools to combat COVID-19: A triple approach. 2021 , 183, 235-244	24
1081	Antibodies Can Last for More Than 1 Year After SARS-CoV-2 Infection: A Follow-Up Study From Survivors of COVID-19. 2021 , 8, 684864	7
1080	Physical activity and exercise as an essential medical strategy for the COVID-19 pandemic and beyond. 2021 , 246, 2324-2331	O
1079	SARS-CoV-2 and pathological matrix remodeling mediators. 2021 , 70, 847-858	3
1078	Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. 2021 , 6, 13	1

1077	A Validated Mathematical Model of the Cytokine Release Syndrome in Severe COVID-19. 2021 , 8, 639423	2
1076	Analisi dei principali fattori di rischio preesistenti nei pazienti con diagnosi di COVID-19 ad Amap[] Amazfiia, Brasile. 56-72	
1075	Does chronic inflammation cause acute inflammation to spiral into hyper-inflammation in a manner modulated by diet and the gut microbiome, in severe Covid-19?. 2021 , 43, e2000211	1
1074	Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective. 2021 , 134, 104406	5
1073	Bacterial superinfection in adults with COVID-19 hospitalized in two clinics in Medell-Colombia, 2020. 2021 , 16, e0254671	15
1072	Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2. 2021 , 22,	2
1071	Advances in the computational landscape for repurposed drugs against COVID-19. 2021 , 26, 2800-2815	4
1070	Non-permissive SARS-CoV-2 infection in human neurospheres. 2021 , 54, 102436	6
1069	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. 2021 , 16, e0253977	11
1068	SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs. 2021 ,	13
	SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs. 2021 , Airway and Alveoli Organoids as Valuable Research Tools in COVID-19. 2021 , 7, 3487-3502	0
1067		
1067	Airway and Alveoli Organoids as Valuable Research Tools in COVID-19. 2021 , 7, 3487-3502	0
1067 1066 1065	Airway and Alveoli Organoids as Valuable Research Tools in COVID-19. 2021 , 7, 3487-3502 COVID-19 and lung pathologies. 2021 , The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and	0
1067 1066 1065	Airway and Alveoli Organoids as Valuable Research Tools in COVID-19. 2021, 7, 3487-3502 COVID-19 and lung pathologies. 2021, The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences. 2021, 2021, 7769516	O 2 5
1067 1066 1065	Airway and Alveoli Organoids as Valuable Research Tools in COVID-19. 2021, 7, 3487-3502 COVID-19 and lung pathologies. 2021, The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences. 2021, 2021, 7769516 Could Immunonutrition Help in the Fight against COVID-19 in Cancer Patient?. 2021, 1-10	o 2 5
1067 1066 1065 1064	Airway and Alveoli Organoids as Valuable Research Tools in COVID-19. 2021, 7, 3487-3502 COVID-19 and lung pathologies. 2021, The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences. 2021, 2021, 7769516 Could Immunonutrition Help in the Fight against COVID-19 in Cancer Patient?. 2021, 1-10 A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. 2021, 1 Single-cell analysis reveals cell communication triggered by macrophages associated with the	o 2 5 1 28

1059	Stability analysis and simulation of the novel Corornavirus mathematical model via the Caputo fractional-order derivative: A case study of Algeria. 2021 , 26, 104324	5
1058	Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. 2021 , 131,	35
1057	Mechanisms of immunothrombosis in COVID-19. 2021 , 28, 445-453	7
1056	Facial paralysis as the only symptom of COVID-19: A prospective study. 2021 , 42, 102956	13
1055	COVID-19 age-dependent immunology and clinical outcomes: implications for vaccines. 2021 , 1-7	0
1054	Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. 2021 , 10, 2791-2804	1
1053	Prognostic value of inflammatory markers in patients with COVID-19 in Indonesia. 2021 , 11, 100803	5
1052	Anlīsis de los principales factores de riesgo preexistentes en pacientes diagnosticados con COVID-19 en Amap[lAmazfiia, Brasil. 56-72	
1051	Asthma and COVID-19: a dangerous liaison?. 2021 , 7, 9	8
1050	The risk of severe COVID-19 and mortality from COVID-19 in people living with HIV compared to individuals without HIV - a systematic review and meta-analysis of 1 268 676 individuals.	
1049	Sensitive and Specific Immunohistochemistry Protocol for Nucleocapsid Protein from All Common SARS-CoV-2 Virus Strains in Formalin-Fixed, Paraffin Embedded Tissues. 2021 , 4,	1
1048	Effectiveness of low-dose radiation therapy to improve mortality of COVID-19. 2021 , 147, 2621-2624	1
1047	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. 2021 , 14,	11
1046	Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4. 2021 , 22,	3
1045	SSRIs: Applications in inflammatory lung disease and implications for COVID-19. 2021 , 41, 325-335	8
1044	Predictive Value of Neutrophil/Lymphocyte Ratio (NLR) on Cardiovascular Events in Patients with COVID-19. 2021 , 14, 3899-3907	3
1043	Testing for COVID-19 in dental offices: Mechanism of action, application, and interpretation of laboratory and point-of-care screening tests. 2021 , 152, 514-525.e8	4
1042	A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19. 2021 , 9, 695139	13

1041	Transcriptome Analysis of Peripheral Blood Mononuclear Cells Reveals Distinct Immune Response in Asymptomatic and Re-Detectable Positive COVID-19 Patients. 2021 , 12, 716075	2
1040	Omega-3 Index and Clinical Outcomes of Severe COVID-19: Preliminary Results of a Cross-Sectional Study. 2021 , 18,	7
1039	Analyse wichtiger vorbestehender Risikofaktoren bei Patienten mit COVID-19-Diagnose in Amap[] Amazfiia, Brasilien. 56-72	
1038	Peripheral blood natural killer cell depletion is associated with severe pneumonia in coronavirus disease-2019 (COVID-19). 2021, 1	1
1037	Impact of Chronic RAAS Use in Elderly COVID-19 Patients: A Retrospective Analysis. 2021 , 10,	2
1036	Analysis of the Main Preexisting Risk Factors In Patients Diagnosed With COVID-19 In Amap[] Amazfiia, Brazil. 56-72	
1035	Coronavirus, the King Who Wanted More Than a Crown: From Common to the Highly Pathogenic SARS-CoV-2, Is the Key in the Accessory Genes?. 2021 , 12, 682603	2
1034	Comprehensive Profiling of Inflammatory Factors Revealed That Growth Differentiation Factor-15 Is an Indicator of Disease Severity in COVID-19 Patients. 2021 , 12, 662465	4
1033	Modulation of Host Immune Response Is an Alternative Strategy to Combat SARS-CoV-2 Pathogenesis. 2021 , 12, 660632	1
1032	ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients. 2021 , 191, 1154-1164	9
1031	Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo. 2021 , 22,	2
1030	Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19?. 2021 , 38, 101	5
1029	Amazilia, II5 6-72	
1028	Inhibitory and complementary therapeutic effect of sweet lime (Citrus limetta) against RNA-viruses. 2021 , 7, 37-44	3
1027	Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. 2021 , 31, 49-60	11
1026	Analyse des principaux facteurs de risque prèxistants chez les patients diagnostiqus covid-19 ^ Amap[Amazfiia, Brŝil. 56-72	
1025	Infected Inflation and Symptoms Without the Impact of Covid 19 with Ahp Calculation Method. 2022 , 393-402	
1024	Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?. 2021 , 22, 1149-1157	

The Many Faces of JAKs and STATs Within the COVID-19 Storm. 2021 , 12, 690477	3
$_{1022}$ COVID-19 candidate genes and pathways potentially share the association with lung cancer. 2 00.000 $_{1022}$	021, 0
Promising role of curcumin against viral diseases emphasizing COVID-19 management: A revie the mechanistic insights with reference to host-pathogen interaction and immunomodulation, , 82, 104503	
Impact of COVID-19 Pandemic on Presentation and Outcome of Consecutive Patients Admitte Hospital Due to ST-Elevation Myocardial Infarction. 2021 , 151, 10-14	ed to
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. 138, 1481-1489	2021 , 26
1018 SARS-CoV-2: is there neuroinvasion?. 2021 , 18, 32	15
Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory j diseases and autoinflammatory disorders. 2021 , 61, 45	oint 1
1016 Quantitative Insight into Immunopathology of SARS-CoV-2 Infection. 2021 , 41, 244-257	
SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity 2021 , 13,	·. 8
An untargeted metabolomic approach to identify antiviral defense mechanisms in memory leukocytes secreting in vitro IgG anti-SARS-Cov-2.	
Differential Association of Viral Dynamics With Disease Severity Depending on Patients' Age C in COVID-19. 2021 , 12, 712260	Group 3
1012 Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection. 2021 , 13,	13
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. 20 11,	021 , 44
1010 Happy hypoxia in COVID-19: pathophysiology and pulse oximetry accuracy. 2021 , 13, 288-296	
Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells. 2021 , 13,	15
$_{1008}$ An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. 202 1	I, 45, 123 1
Acceleration of Biological Aging and Underestimation of Subjective Age Are Risk Factors for S COVID-19. 2021 , 9,	evere 4
Changes in the presentation of newly diagnosed type 1 diabetes in children during the COVID-pandemic in a tertiary center in Southern Turkey. 2021 , 34, 1303-1309	-19 2

1005	Triangle of cytokine storm, central nervous system involvement, and viral infection in COVID-19: the role of sFasL and neuropilin-1. 2021 ,	4
1004	Anlise Dos Principais Fatores De Risco Preexistentes Em Pacientes Diagnosticados Com A COVID-19 No Amap‡Amazilia, Brasil. 56-72	7
1003	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease. 2021 , 478, 2465-2479	11
1002	Socio-demographic and health factors drive the epidemic progression and should guide vaccination strategies for best COVID-19 containment. 2021 , 26, 104433	23
1001	Do inflammasome impact COVID-19 severity?. 2021 , 32, 1-11	4
1000	Immediate Pre-Partum SARS-CoV-2 Status and Immune Profiling of Breastmilk: A Case-Control Study. 2021 , 12, 720716	2
999	Incidence and risk factors for early readmission after hospitalization for SARS-CoV-2 infection: results from a retrospective cohort study. 2021 , 1	5
998	Individual risk management strategy for SARS-CoV-2 infection: A step toward personalized healthcare. 2021 , 96, 107629	
997	The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications. 2021 , 13,	3
996	Blood cell morphology and COVID-19 clinical course, severity, and outcome. 2021 , 14, 1-8	2
995	SARS-CoV-2-specific immune response in COVID-19 convalescent individuals. 2021 , 6, 256	13
994	Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components. 2021 , 9,	3
993	The Ichikado CT score as a prognostic tool for coronavirus disease 2019 pneumonia: a retrospective cohort study. 2021 , 9, 51	1
992	Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection. 2021 , 10, 2431-2446	2
991	SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. 2021 ,	12
990	IIcanII cope with multiple inputsIIQualitative study of the lived experience of Brain foglafter Covid-19.	2
989	Bioinspiration as a method of problem-based STEM education: A case study with a class structured around the COVID-19 crisis 2021 ,	3
988	Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19: biological and clinical plausibility. 2021 ,	4

A look at the C3 and C5 proteins in the Covid-19. 2021, 43, 1-9 987 Troponin I biomarker as a strong prognostic factor for predicting COVID-19 mortality: A systematic 986 review. 2021, 9, 342-352 Liposomal Dexamethasone Reduces A/H1N1 Influenza-Associated Morbidity in Mice. 985 Successful Chemotherapy of an Acute Myeloid Leukemia Case Infected with SARS-CoV-2. 2021, 14, 984 Thrombotic and Hypercoagulability Complications of COVID-19: An Update. 2021, 12, 785-793 6 983 Vitamin D deficiency and COVID-19: A case-control study at a tertiary care hospital in India. 2021, 982 11 68, 102661 Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19. 2021, 981 1 278, 119510 Clinical laboratory evaluation of COVID-19. 2021, 519, 172-182 980 Early Reduction of SARS-CoV-2 Replication in Bronchial Epithelium by Kinin B2 Receptor 979 Antagonism. The relationship between Dietary Inflammatory Index and disease severity and inflammatory 978 7 status: a case-control study of COVID-19 patients. 2021, 1-9 Two-Step In Vitro Model to Evaluate the Cellular Immune Response to SARS-CoV-2. 2021, 10, 977 1 COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of 976 9 JAK1/2 inhibitors in combination with interferon. 2021, 60, 28-45 Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host 975 1 therapeutic targets and SARS-CoV-2 oncogenesis mechanism. 2021, 301, 198464 Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor 974 interplay: interventions to trigger vaccine development. Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting 973 Infection, Inflammation, and Immunity in COVID-19. 2021, 1, 285-304 ACE2, the Counter-Regulatory Renin-Angiotensin System Axis and COVID-19 Severity. 2021, 10, 972 The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, 971 1 and its application as potential therapeutic target. 2021, 43, 177-196 Single-reaction multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients

by flow cytometry. **2021**, 51, 2633-2640

969	SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. 2021 , 12, e0141521	8
968	Autoimmunity and COVID-19 - The microbiotal connection. 2021 , 20, 102865	5
967	Role of potential COVID-19 immune system associated genes and the potential pathways linkage with type-2 diabetes. 2021 ,	3
966	Tailoring glucocorticoids in patients with severe COVID-19: a narrative review. 2021 , 9, 1261	O
965	Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. 2021 , 1	7
964	Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2.	
963	A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome. 2021 , 12, 5120	10
962	Disparities in COVID-19 severities and casualties across ethnic groups around the globe and patterns of ACE2 and PIR variants. 2021 , 92, 104888	5
961	Biochemical composition, transmission and diagnosis of SARS-CoV-2. 2021 , 41,	8
960	YouTube as a source of information during the Covid-19 pandemic: a content analysis of YouTube videos published during January to March 2020. 2021 , 21, 255	1
959	Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. 2021 , 97, 107828	7
958	Assessment of fetal growth and anomalies in the era of COVID-19 pandemic: an Egyptian pilot study. 2021 , 26, 32	O
957	Microbiota-Gut-Brain Communication in the SARS-CoV-2 Infection. 2021 , 10,	6
956	Low-Dose Lung Radiation Therapy for COVID-19 Lung Disease: A Preclinical Efficacy Study in a Bleomycin Model of Pneumonitis. 2021 ,	3
955	No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study. 2021 , 1	1
954	Severe Lymphopenia as a Predictor of COVID-19 Mortality in Immunosuppressed Patients. 2021 , 10,	O
953	Asthma and COVID-19: Emphasis on Adequate Asthma Control. 2021, 2021, 9621572	3
952	Immunity and security using holism, ambient intelligence, triangulation, and stigmergy: Sensitivity analysis confronts fake news and COVID-19 using open set transduction. 2021 , 1-18	

951	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. 2021 , 6, 317	17
950	Prevalence and effect of bacterial co-infections on clinical outcomes in hospitalized COVID-19 patients at a tertiary care centre of India.	
949	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. 2021 , 12, 637554	4
948	Thromboprophylaxis in COVID-19 - Rationale and considerations. 2021 , 81, 100819	2
947	A time-resolved proteomic and prognostic map of COVID-19. 2021 , 12, 780-794.e7	32
946	Inflammasome activation at the crux of severe COVID-19. <i>Nature Reviews Immunology</i> , 2021 , 21, 694-703,6.5	50
945	SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. 2021 , 12, 4664	73
944	Is diabetes mellitus a wrongdoer to COVID-19 severity?. 2021 , 178, 108936	3
943	HIF-1‡promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. 2021 , 6, 308	19
942	Early use of cytokine adsorption in treatment of COVID-19 associated respiratory distress syndrome. 2021 , 71-75	
941	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. 2021 , 10,	10
940	Susceptibility of lung cancer patients to COVID-19: A review of the pandemic data from multiple nationalities. 2021 , 12, 2637-2647	3
939	Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19. 2021 , 6, 316	4
938	Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis. 2022 , 94, 211-221	11
937	SARS-CoV-2 Impairs Dendritic Cells and Regulates DC-SIGN Gene Expression in Tissues. 2021 , 22,	4
936	The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance. 2021 , 59, 807-818	11
935	Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. 2021 , 17, e1009758	8
934	The obstetric patient in the Covid pandemic: anaesthesia and perioperative care. 2021 , 33, 361-369	O

933	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. 2021 , 13,	2
932	Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. 2021 , 6, 304	7
931	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. 2021 , 20, 817-838	106
930	The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data. 2021 , 7, e07665	2
929	Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains. 2021 , 9,	4
928	Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19 2021 , 1, 277-293	O
927	Providing Comfort through Music to People Amidst the COVID-19 Pandemic as a Humanitarian Disaster. 2021 , 1542305021992000	О
926	Reprogramming of the intestinal epithelial-immune cell interactome during SARS-CoV-2 infection.	
925	Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network. 2021 , 16, e0255644	3
924	May mesenchymal stem cell transplantation be a solution for COVID-19 induced cytokine storm?. 2021 , 11, 344-355	O
923	Astaxanthin protective barrier and its ability to improve the health in patients with COVID-19. 2021 , 13, 434-441	1
922	The microbiota-related coinfections in COVID-19 patients: a real challenge. 2021 , 10, 47	1
921	Faculty readiness for online teaching at Imam Abdulrahman Bin Faisal University during the COVID-19 crisis: a cross-sectional study. 10, 840	
920	One Year on: An Overview of Singapore's Response to COVID-19-What We Did, How We Fared, How We Can Move Forward. 2021 , 18,	1
919	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. 2021 , 12, 719023	7
918	Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?. 2021 , 45, 570-587	2
917	Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan ECoronaviruses. 2021 , 11, 729622	1
916	Effect of BCG vaccination on proinflammatory responses in elderly individuals. 2021 , 7,	5

(2021-2021)

915	The food choice determinants and adherence to Mediterranean diet in Iranian adults before and during COVID-19 lockdown: population-based study. 2021 , ahead-of-print,	1
914	Pathophysiology of pulmonary function anomalies in COVID-19 survivors 2021 , 17, 210065	7
913	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. 2021 , 29, 951-962.e3	13
912	Major cardiac concerns in therapy and vaccinations for COVID-19. 2021 , 11, 100102	5
911	TIM-3 as a potential exhaustion marker in CD4 T cells of COVID-19 patients. 2021, 9, 1707-1715	6
910	Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients. 2021 , 10,	7
909	Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy. 2021 , 21, e731-e735	4
908	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. 2021 , 9, 3237-3248	1
907	Characterisation of the blood RNA host response underpinning severity in COVID-19 patients.	1
906	. 2021 , 103115	1
906	. 2021 , 103115 COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two case reports. 2021 , 14, 1567-1570	1
	COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two	
905	COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two case reports. 2021 , 14, 1567-1570	1
905	COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two case reports. 2021 , 14, 1567-1570 COVID-19 and low-dose radiation therapy. 2021 , 2, 139-145 Peripheral granular lymphocytopenia and dysmorphic leukocytosis as simple prognostic markers in	3
905 904 903	COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two case reports. 2021 , 14, 1567-1570 COVID-19 and low-dose radiation therapy. 2021 , 2, 139-145 Peripheral granular lymphocytopenia and dysmorphic leukocytosis as simple prognostic markers in COVID-19. 2021 , 43, 1309-1318 [Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19	1 3 2
905 904 903 902	COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two case reports. 2021, 14, 1567-1570 COVID-19 and low-dose radiation therapy. 2021, 2, 139-145 Peripheral granular lymphocytopenia and dysmorphic leukocytosis as simple prognostic markers in COVID-19. 2021, 43, 1309-1318 [Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic]. 2021, 66, 299-309 Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in	1 3 2 2
905 904 903 902 901	COVID-19 with underdiagnosed influenza B and parainfluenza-2 co-infections in Saudi Arabia: Two case reports. 2021, 14, 1567-1570 COVID-19 and low-dose radiation therapy. 2021, 2, 139-145 Peripheral granular lymphocytopenia and dysmorphic leukocytosis as simple prognostic markers in COVID-19. 2021, 43, 1309-1318 [Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic]. 2021, 66, 299-309 Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in children: A pilot study. 2021, 15353702211046835	1 3 2 2 3

897	Interleukin-1RA Mitigates SARS-CoV-2-Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice. 2021 , 41, 2773-2785	6
896	Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. 2021 , 40, 101125	16
895	Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes. 2021 , 37, 109793	2
894	Identification of oligopeptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non structural protein 8 (NSP8) and their similarities with type 1 angiotensin II receptor key sites. 2021 , 141, 111722	O
893	Molecular mimicry between SARS-CoV-2 and the female reproductive system. 2021 , 86, e13494	10
892	Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection. 2021 , 83, 339-346	O
891	Evolution of cytokine production capacity in ancient and modern European populations. 2021, 10,	7
890	Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. 2021 , 23, 1916-1926	24
889	Experimental Technologies in the Diagnosis and Treatment of COVID-19 in Patients with Comorbidities. 2021 , 1-24	
888	Dysregulated immune responses in COVID-19 patients correlating with disease severity and invasive oxygen requirements.	
887	Incidence of Fungal Aerosols from Selected Crowded Places in Port Harcourt, Nigeria. 2021 , 15, 56-64	
886	Bio-inspired Ag nanovilli-based sandwich-type SERS aptasensor for ultrasensitive and selective detection of 25-hydroxy vitamin D. 2021 , 188, 113341	3
885	Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. 2021 , 11, 499	9
884	Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?. 2021 , 8, 663708	3
883	Evaluation of Admission Chest X-Ray Findings in Patients With Respiratory Infection During the COVID-19 Pandemic. 2021 , 13, e18114	
882	Patterns of Comorbidity and In-Hospital Mortality in Older Patients With COVID-19 Infection. 2021 , 8, 726837	1
881	Bibliometric Analysis of the 103 Most-Cited Articles about COVID-19 in the Intensive Care Field.	O
880	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. 2021 , 16, e0257376	2

879	Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. 2021 , 186, 490-500	11
878	Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. 2021 , 27, 5502-5519	
877	An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19. 2021 , 367, 104398	1
876	Current therapeutic strategies for respiratory diseases using mesenchymal stem cells. 2021 , 2, 351-380	4
875	SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. 2021 , 16, 1105-1133	3
874	Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. 2021 , 12, 742941	15
873	Altered Lipid Profile Is a Risk Factor for the Poor Progression of COVID-19: From Two Retrospective Cohorts. 2021 , 11, 712530	О
872	Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases. 2021 , 28, 3403-3407	O
871	The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. 2021 , 27, 423-437	26
870	[Mucociliary clearance in COVID-19 - an underestimated danger area in early phase of disease?]. 2021 , 163, 21-27	1
869	F-FDG-PET/CT in SARS-CoV-2 infection and its sequelae. 2021 , 40, 299-309	5
868	Predictors of Mortality in COVID-19 Patients in Southern California - Retrospective Multicenter Study. 2021 , 13, e18137	1
867	Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?. 2021 , 101, 108200	5
866	Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms. 2021 , 41, 1723-1732	1
865	SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism. 2021 , 6, 345	7
864	An Efficient Approach to Predict Fear of Human® Mind During COVID-19 Outbreaks Utilizing Data Mining Technique. 2022 , 41-51	
863	Pro-inflammatory microenvironment and systemic accumulation of CXCR3+ cell exacerbate lung pathology of old rhesus macaques infected with SARS-CoV-2. 2021 , 6, 328	3
862	Implicit, Intrinsic, Extrinsic, and Host Factors Attributing the Covid-19 Pandemic. Part 1- Intrinsic Factor Nitrous Oxide Emissions: A Systematic Analysis.	

861	SARS-CoV-2 triggers DNA damage response in Vero E6 cells.	O
860	Nanotechnology-empowered vaccine delivery for enhancing CD8 T cells-mediated cellular immunity. 2021 , 176, 113889	6
859	Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment.	1
858	Endothelial Cell Activation by SARS-CoV-2 Spike S1 Protein: A Crosstalk between Endothelium and Innate Immune Cells. 2021 , 9,	4
857	Molecular Profiling of Coronavirus Disease 2019 (COVID-19) Autopsies Uncovers Novel Disease Mechanisms. 2021 , 191, 2064-2071	1
856	Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients: a retrospective cohort study in a Mediterranean area.	
855	Biomarkers of severe COVID-19 pneumonia on admission using data-mining powered by common laboratory blood tests-datasets. 2021 , 136, 104738	3
854	The Effects of COVID-19 on the Placenta During Pregnancy. 2021 , 12, 743022	4
853	. 2021 , 7, 121-141	3
852	Effects of COVID-19 on the Musculoskeletal System: Clinician's Guide. 2021 , 13, 141-150	5
851	Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy to COVID-19 Patients With Different Background Risks. 2021 , 111, 233-239	5
850	Pathophysiologie von COVID-19 und deren m\u00dfliche Bedeutung f\u00e4.Long-COVID. 2021 , 37, 205-205	
849	18F-FDG-PET/TC ante la infeccifi por SARS-CoV-2 y sus secuelas. 2021 , 40, 299-309	78
848	The Extrapulmonary Manifestations of SARS-CoV-2. 2021 , 1, 80-92	
847	Mood and Changes in Alcohol Consumption in Young Adults during COVID-19 Lockdown: A Model Explaining Associations with Perceived Immune Fitness and Experiencing COVID-19 Symptoms. 2021 , 18,	2
846	Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir. 2021 , 71, 462-472	1
845	Neuropsychiatric Disorders and COVID-19: What We Know So Far. 2021 , 14,	2
844	Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection. 2021 , 9,	2

(2021-2021)

843	COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF- B Pathway. 2021 , 13,	2
842	Inflammatory cytokine storms severity may be fueled by interactions of micronuclei and RNA viruses such as COVID-19 virus SARS-CoV-2. A hypothesis. 2021 , 788, 108395	1
841	Emergency drug use in a pandemic: Harsh lessons from COVID-19. 2021 , 184, 5497-5500	2
840	Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples. 2021 , 11,	10
839	Carotenoids: Therapeutic Strategy in the Battle against Viral Emerging Diseases, COVID-19: An Overview. 2021 , 26, 241-261	5
838	Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?. 2021 , 9, 725606	2
837	SARS-CoV-2, COVID-19 and the Ageing Immune System. 2021 , 1, 769-782	34
836	Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice infected with SARS-CoV-2. 2021 , e12772	6
835	Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19). 2021 , 137, 104188	19
834	A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. 2021 ,	9
833	Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. 2021 , 18, e1003773	98
832	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. 2021 , 17, e1009878	19
831	Exposing Structural Variations in SARS-CoV-2 Evolution. 2021 ,	
830	Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns.	1
829	Shorter leukocyte telomere length is associated with severity of COVID-19 infection. 2021 , 27, 101056	1
828	The Vitamin D, IL-6 and the eGFR Markers a Possible Way to Elucidate the Lung-Heart-Kidney Cross-Talk in COVID-19 Disease: A Foregone Conclusion. 2021 , 9,	5
827	SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs.	
826	Comparative Study of Government Response Measures and Epidemic Trends for COVID-19 Global Pandemic. 2021 ,	1

825	From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry. 2021 , 10,	7
824	Context-aware deconvolution of cell-cell communication with Tensor-cell2cell.	3
823	Computational simulations to dissect the cell immune response dynamics for severe and critical cases of SARS-CoV-2 infection. 2021 , 211, 106412	2
822	COVID-19 Associated Mucormycosis: A Systematic Review from Diagnostic Challenges to Management. 2021 , 9,	11
821	Comparative analysis of machine learning-based approaches for identifying therapeutic peptides targeting SARS-CoV-2. 2021 ,	1
820	Network-Based Identification and Experimental Validation of Drug Candidates Toward SARS-CoV-2 Targeting Virus-Host Interactome. 2021 , 12, 728960	2
819	Systemic antiviral immunization by virus-mimicking nanoparticles-decorated erythrocytes. 2021 , 40, 101280	9
818	Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. 2021 , 111, 211-218	7
817	Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. 2022 , 283, 114701	1
816	COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee). 2021 , 11, 569-580	5
815	Melatonin interferes with COVID-19 at several distinct ROS-related steps. 2021 , 223, 111546	11
814	The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. 2021 , 72, 103595	29
813	CD38 in the age of COVID-19: a medical perspective. 2021 , 101, 1457-1486	9
812	Urinary cytokines correlate with acute kidney injury in critically ill COVID-19 patients. 2021 , 146, 155589	4
811	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. 2021 , 100, 915-927	2
810	Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells. 2021 , 46, 102099	6
809	Immunomodulation and immunotherapeutics of COVID-19. 2021 , 231, 108842	2
808	High intelligence may exacerbate paediatric inflammatory response to SARS-CoV-2 infection. 2021 , 155, 110677	

(2021-2021)

807	Severe acute respiratory syndrome coronavirus 2 and respiratory syncytial virus coinfection in children. 2021 , 12, 286-292	1
806	Handheld plasmonic biosensor for virus detection in field-settings. 2021 , 344, 130301	2
805	Effect of Biomodulina-T ^[] and VA-MENGOC-BC ^[] on lymphocyte subpopulations in older adults. 2021 , 153, 111497	Ο
804	Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. 2021 , 12, 738697	2
803	Pathophysiology of the Acute Respiratory Distress Syndrome: Insights from Clinical Studies. 2021 , 37, 795-815	7
802	Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. 2021 , 41, 101139	6
801	Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review. 2021 , 45, 101752	3
800	Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. 2021 , 116, 105363	3
799	Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue. 2021 , 100, 108150	3
798	Pathogenesis of taste impairment and salivary dysfunction in COVID-19 patients. 2021 , 57, 111-122	11
798 797	Pathogenesis of taste impairment and salivary dysfunction in COVID-19 patients. 2021 , 57, 111-122 SARS-CoV-2 triggers DNA damage response in Vero E6 cells. 2021 , 579, 141-145	11 7
797	SARS-CoV-2 triggers DNA damage response in Vero E6 cells. 2021 , 579, 141-145	7
797 796	SARS-CoV-2 triggers DNA damage response in Vero E6 cells. 2021 , 579, 141-145 Impact of maternal nutrition in viral infections during pregnancy. 2021 , 1867, 166231 Association between ABO blood groups and rhesus antigen and susceptibility to COVID-19 in the	7
797 796 795	SARS-CoV-2 triggers DNA damage response in Vero E6 cells. 2021 , 579, 141-145 Impact of maternal nutrition in viral infections during pregnancy. 2021 , 1867, 166231 Association between ABO blood groups and rhesus antigen and susceptibility to COVID-19 in the Yazd hospital. 2021 , 44, 100934 Systems level insights into the impact of airborne exposure on SARS-CoV-2 pathogenesis and	7 1 2
797 796 795 794	SARS-CoV-2 triggers DNA damage response in Vero E6 cells. 2021, 579, 141-145 Impact of maternal nutrition in viral infections during pregnancy. 2021, 1867, 166231 Association between ABO blood groups and rhesus antigen and susceptibility to COVID-19 in the Yazd hospital. 2021, 44, 100934 Systems level insights into the impact of airborne exposure on SARS-CoV-2 pathogenesis and COVID-19 outcome - A multi-omics big data study. 2021, 25, 101312 SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed	7 1 2
797 796 795 794 793	SARS-CoV-2 triggers DNA damage response in Vero E6 cells. 2021, 579, 141-145 Impact of maternal nutrition in viral infections during pregnancy. 2021, 1867, 166231 Association between ABO blood groups and rhesus antigen and susceptibility to COVID-19 in the Yazd hospital. 2021, 44, 100934 Systems level insights into the impact of airborne exposure on SARS-CoV-2 pathogenesis and COVID-19 outcome - A multi-omics big data study. 2021, 25, 101312 SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling. 2021, 1867, 166260	7 1 2 1

789	A novel G-quadruplex aptamer-based spike trimeric antigen test for the detection of SARS-CoV-2. 2021 , 26, 321-332	8
788	Analysis of the ternary antiretroviral therapy dolutegravir, lamivudine and abacavir using UV spectrophotometry and chemometric tools. 2022 , 264, 120334	O
787	Pathogen Recognition Receptors and the Lung. 2022 , 264-270	
786	Frequency and Significance of Coinfection in Patients with COVID-19 at Hospital Admission. 2021 , 60, 3709-3719	2
7 ⁸ 5	Dynamic change and clinical relevance of post-infectious SARS-CoV-2 antibody responses.	
7 ⁸ 4	The up-to-date pathophysiology of Kawasaki disease. 2021 , 10, e1284	8
783	New coronavirus infection in the aspect of psoriasis. 2021 , 20, 77	
782	C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19. 2021 , 41, 729-732	5
781	Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm". 2021 , 146, 110473	3
780	Risk of in-hospital death associated with Covid-19 lung consolidations on chest computed tomography - A novel translational approach using a radiation oncology contour software. 2021 , 8, 100322	3
779	Holistic Ayurveda approach to face the post-COVID challenges ahead. 2021 , 4, 37	
778	COVID-19 Mortality in Europe, by Latitude and Obesity Status: A Geo-Spatial Analysis in 40 Countries.	
777	Coronavirus Disease 2019: Quick Diet and Nutrition Guide for Patients With Chronic Kidney Disease. 2021 , 31, 39-42	1
776	Does the Global Outbreak of COVID-19 or Other Viral Diseases Threaten the Stem Cell Reservoir Inside the Body?. 2021 , 17, 214-230	7
776 775		7
	Inside the Body?. 2021 , 17, 214-230	
775	Inside the Body?. 2021 , 17, 214-230 Dynamic Changes of Lymphocyte Subsets in the Course of COVID-19. 2021 , 182, 254-262 Structural assessment of SARS-CoV2 accessory protein ORF7a predicts LFA-1 and Mac-1 binding	13

Cardiac Involvement in COVID-19 Infection. 2021, 87-89 771 Genomic Evidence Provides the Understanding of SARS-CoV-2 Composition, Divergence, and Diagnosis. **2021**, 63-79 769 State-of-the-art equipment for rapid and accurate diagnosis of COVID-19. 2021, 19-40 Neuropathophysiology of COVID-19. 2021, 11, 116-123 768 Sedating Mechanically Ventilated COVID-19 Patients with Volatile Anesthetics: Insights on the 767 4 Last-Minute Potential Weapons. 2021, 89, 6 Recurrence of COVID-19 related symptoms and viral detection in a patient discharged after 766 complete recovery and test negativization. 2021, 15, Lower values of a novel index of Vagal-Neuroimmunomodulation are associated to higher all-cause 765 3 mortality in two large general population samples with 18 year follow up. 2021, 11, 2554 764 COVID-19 and the Microbiome: The Gut-Lung Connection. **2021**, 442-442 Salivary markers and coronavirus disease 2019: insights from cross-talk between the oral microbiome and pulmonary and systemic low-grade inflammation and implications for vascular 763 1 complications. 2021, 10, 162-167 The effect of coincidental SARS-CoV-2 infection on pre-operative cardiopulmonary exercise testing. 762 2021, 9, 122-126 Two different patterns of lymphocyte alterations in critically ill COVID-19 patients. 2021, 16, 1411-1414 761 1 Novel Coronavirus Disease (COVID-19) in Italian Patients: Gender Differences in Presentation and 760 Severity. **2021**, 9, 59-62 Chemokines and chemokine receptors during COVID-19 infection. 2021, 19, 976-988 759 50 Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility. 2021, 43, 37-50 758 Evolutionarily Conserved Long Non-coding RNA Regulates Gene Expression in Cytokine Storm 12 757 During COVID-19. **2020**, 8, 582953 The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases. 756 **2021**, 31, 927-932 SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory 65 755 pathways (NLRP12 and TAB1): implications for disease presentation across species. 2021, 10, 178-195 Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody 21 754 testing. 2021, 61, 1181-1190

753	Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. 2021,	41
752	Relationship Between ABO Blood Types and Coronavirus Disease 2019 Severity 2022 , 56, 1-20	
75 ¹	SARS-CoV-2 Infection of Airway Epithelial Cells. 2021 , 21, e3	18
75°	TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target. 2020 , 11, 601685	15
749	Potential Antiviral Immune Response Against COVID-19: Lessons Learned from SARS-CoV. 2021 , 1318, 149-167	2
748	Rituximab for the treatment of multiple sclerosis: a review. 2021 , 1	26
747	Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys. 2021 , 13,	68
746	Ratios between circulating myeloid cells and lymphocytes are associated with mortality in severe COVID-19 patients. 2021 , 16, 351-360	
745	A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. 2020 , 6,	1
744	Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19. 2020 , 8, e00653	16
743	Phytotherapics in COVID19: Why palmitoylethanolamide?. 2020 , 35, 2514	6
742	Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. 2021 , 35, 3013-3031	28
74 ¹	Classical and alternative receptors for SARS-CoV-2 therapeutic strategy. 2021 , 31, 1-9	18
740	Correlation between immune response and self-reported depression during convalescence from COVID-19. 2020 , 88, 39-43	39
739	Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak?. 2020 , 164, 108219	21
738	Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. 2020 , 328, 112-126	22
737	Peptides to combat viral infectious diseases. 2020 , 134, 170402	13
736	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. 2020 , 196, 382-394	43

735	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. 2021 , 7, 1742-1764	7
734	Effective treatment of SARS-CoV-2-infected rhesus macaques by attenuating inflammation. 2021 , 31, 229-232	7
733	Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs. 2020 , 10, 22375	27
732	How SARS-CoV-2 (COVID-19) spreads within infected hosts - what we know so far. 2020 , 4, 371-378	8
731	Hypercoagulopathy in Severe COVID-19: Implications for Acute Care. 2020 , 120, 1654-1667	16
730	SARS-CoV-2 reinfection and implications for vaccine development. 2020 , 16, 3061-3073	23
729	Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls. 2021 , 5, pkaa103	6
728	The emerging potential of Aptamers as therapeutic agents in infection and inflammation 2022, 108173	1
7 ² 7	Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia 2021, 10,	Ο
726	Activation of mucosal immunity and novel prophylactic and therapeutic strategy in combating COVID-19.	
725	Synopsis of symptoms of COVID-19 during second wave of the pandemic in India. 2021 ,	2
724	Machine Learning Approaches for COVID-19 Pandemic. 2022 , 133-143	1
723	Prospects for assessing the biological and immunological age of a person by blood factors. 2021 , 6, 19-39	
722	Acute respiratory syndrome-2 (SARS-CoV-2): A solution of hydrogen peroxide and sodium bicarbonate as an expectorant for recanalization of the respiratory tract and blood oxygenation in respiratory obstruction (review). 2021 , 19, 383-393	
721	COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management 2021 , 11,	1
720	Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic 2021 , 12, 789317	O
719	Underlying co morbidity reveals unique immune signatures in Type II diabetes patients infected with SARS-CoV2.	
718	An integrative bioinformatics analysis for identifying hub genes associated with infection of lung samples in patients infected with SARS-CoV-2 2021 , 26, 146	1

717	Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19. 2021 , 1-9	2
716	Severe and long-lasting neuropsychiatric symptoms after mild respiratory symptoms caused by COVID-19: A case report. 2021 ,	2
715	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19 2021 , 10,	0
714	SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer's Disease Patients 2021 , 22,	5
713	Assessment of serological tests for antibodies to different antigens of the SARS-CoV-2 virus: comparison of six immunoassays. 2021 , 23, 1395-1404	О
712	Editorial: A Compendium of Recent Research on Stem Cell-Based Therapy for Covid-19 2021 , 9, 813384	
711	Macrophage Polarity and Disease Control 2021 , 23,	7
710	Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses 2021 , 9,	1
709	Use of Micro-Computed Tomography to Visualize and Quantify COVID-19 Vaccine Efficiency in Free-Breathing Hamsters 2022 , 2410, 177-192	1
708	Analysis of Clinical Characteristics and Virus Strains Variation of Patients Infected With SARS-CoV-2 in Jiangsu Province-A Retrospective Study 2021 , 9, 791600	1
707	Predicting the Molecular Mechanism of Sini Jia Renshen Decoction in Treating Severe COVID-19 Patients Based on Network Pharmacology and Molecular Docking. 2021 , 16, 1934578X2110592	1
706	Acute Cerebellitis and Myeloradiculitis Associated With SARS-CoV-2 Infection in Common Variable Immunodeficiency-A Case Report 2022 , 12, 361-365	1
705	A 1-minute blood test detects decreased immune function and increased clinical risk in COVID-19 patients. 2021 , 11, 23491	
704	A Prospective Observational Study of 42 Patients with COVID-19 infection and a History of Hepatitis C Virus Infection and Thyroid Disease with Follow-Up Thyroid Function and Autoantibody Testing 2021 , 27, e935075	O
703	How Does COVID-19 Pandemic Impact on Incidence of Infection and Exacerbation of Its Gastrointestinal Symptoms?. 2021 , 8, 775063	1
702	Exploration of Human Lung-Resident Immunity and Response to Respiratory Viral Immunization in a Humanized Mouse Model 2021 ,	O
701	Can the immune system be targeted to treat COVID-19?. 2021 , 69-85	0
700	Sex-Related Factors in Cardiovascular Complications Associated to COVID-19 2021 , 12,	2

699	High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients 2021 , 10,	0
698	IMMUNE AGING AND SERIOUS CLINICAL IMPLICATIONS IN THE ELDERLY IN COVID-19. 2021 , 1, e1553	
697	COVID-19 Generated Personal Protective Equipment: Sources of Microplastics and Pathogen Vectors in Marine Environments?. 2021 , 8,	0
696	NF-B signaling in inflammation and cancer 2021 , 2, 618-653	8
695	Impairment of T cells' antiviral and anti-inflammation immunities may be critical to death from COVID-19 2021 , 8, 211606	2
694	Modern possibilities and prospects of using computed tomography in the diagnosis of a new coronavirus infection (COVID-19). 2021 , 12, 7-15	
693	Gout and the COVID-19 pandemic 2021 , 34,	O
692	Complement inhibition: A possible therapeutic approach in the fight against Covid-19. 2021 , e2316	2
691	Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients-Is It Related to Immunosuppression Only?. 2021 , 9,	2
690	Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic. 2021 , 13, 79-89	О
689	Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients 2021 , 23,	O
688	Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients. 2021 , 2,	3
687	Prognostic Significance of Some Hematological Syndromes in SARS-CoV-2 Infection. 2020 , 161-171	3
686	Coronavirus Infections of Animals and Humans: Ideological Use in Media vs Evidence-Based Scientific Approach. 2021 , 3, 020130318	1
685	Putative autoimmune mechanisms for Acute Disseminated Encephalomyelitis (ADEM) and Guillain-Barr'Syndrome (GBS) associated with SARS-CoV-2 infection.	
684	Cytokine profile in hospitalized patients with COVID-19 of different severity. 2022 , 27, 4846	
683	Molekler doking metoduyla SARS-CoV-2 Mpro enziminin aktif blgesinin incelenmesi ve borlu ilali gelilirme imkan ñ aralifimas.	
682	OUP accepted manuscript.	O

681	The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection 2022, 13, 813924	6
680	Social Communication of Maternal Immune Activation-Affected Offspring Is Improved by Si-Based Hydrogen-Producing Agent 2022 , 13, 872302	1
679	Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives 2022 , 32, 020901	1
678	Disrupting ACE2 Dimerization Mitigates the Infection by SARS-COV-2.	
677	USE OF IMMUNOBIOLOGICAL DRUGS IN THERAPY OF COVID-19. 2022 , 3, 37-43	
676	COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response. 2022 , 2, 115-144	
675	Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease 2022 ,	О
674	The role of Hyaluronan synthesis and degradation in the critical respiratory illness COVID-19 2022 ,	О
673	Liposomal Dexamethasone Reduces A/H1N1 Influenza-Associated Morbidity in Mice 2022, 13, 845795	О
672	Preinfection Anticoagulation/Antiplatelet Therapy Does Not Influence the Outcome of COVID-19 Disease in Hospitalized Patients 2022 ,	
671	Potential of Omega 3 Supplementation for Coronavirus Disease 2019 (COVID-19): A Scoping Review 2022 , 15, 3915-3922	3
670	Muscle dysfunction in the long coronavirus disease 2019 syndrome: Pathogenesis and clinical approach 2022 , e2355	2
669	A factor not to be ignored in post-COVID-19 erectile dysfunction; psychological effect, a prospective study 2022 ,	1
668	Global Gene Expression and Docking Profiling of COVID-19 Infection 2022 , 13, 870836	O
667	Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality 2022 ,	2
666	Classic mechanisms and experimental models for the anti-inflammatory effect of traditional Chinese medicine 2022 ,	O
665	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials 2022 , 109, 108786	0
664	Role of the inflammatory activity in haemodialysis patients with COVID-19. 2022 , 9, 237-242	

(2020-2022)

663	Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model 2022 , 13, 2028	3
662	Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction 2022 , 10,	O
661	Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern 2022 ,	1
660	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment 2022,	O
659	The effectiveness of dexamethasone as a combination therapy for COVID-19. 2022 , 72, 345-358	1
658	Effect of the COVID-19 Pandemic on Kidney Transplant and on Chronic Dialysis Patients 2022,	
657	Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells 2022 ,	3
656	DataSheet_1.xlsx. 2020 ,	
655	DataSheet_2.zip. 2020 ,	
654	DataSheet_3.zip. 2020 ,	
653	DataSheet_4.xlsx. 2020 ,	
652	DataSheet_5.zip. 2020 ,	
651	Presentation_1.pdf. 2020 ,	
650	Data_Sheet_1.PDF. 2020 ,	
649	DataSheet_1.pdf. 2020 ,	
648	DataSheet_1.pdf. 2020 ,	
647	Table_1.csv. 2020 ,	
646	Table_2.csv. 2020 ,	



627	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets 2022, 1	О
626	Design of therapeutic biomaterials to control inflammation 2022 , 1-18	16
625	Human endogenous retrovirus K in the respiratory tract is associated with COVID-19 physiopathology 2022 , 10, 65	2
624	Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria 2022 , 46, 115	1
623	Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients 2022 , 17, e0267102	O
622	A case of xenon inhalation therapy for respiratory failure and neuropsychiatric disorders associated with COVID-19 2021 , 20, 1517-1525	O
621	Measurement of SARS-CoV-2-Specific Humoral and Cellular Immunity in Coronavirus Disease 2019 Convalescent Health Care Workers in Iraq 2021 , 76, 1255-2127	
620	Perioperative melatonin in COVID-19 patients: benefits beyond sedation and analgesia. 2022 , 12, 41-43	Ο
619	Hormone Therapy in the Era of the COVID-19 Pandemic: A Review 2022 , 28, 1-8	1
618	Characteristics and immunobiology of COVID-19. 2022 , 7-22	
617	A tentative tracking of the SARS-Cov2 pandemic in France, based on a corrected SIR model including vaccination effects. 2022 , 263, 01002	
616	COVID-19, Immunity and Pre-Diabetes: Are We Missing Another Target Area to Be Explored?. 2022 , 22, 154-157	
615	Changes of LipoxinA4 Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study.	
614	Role of Dendritic Cells in Viral Brain Infections 2022 , 13, 862053	1
613	Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson Disease: A Narrative Review. 2022 , 12, 536	1
612	Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels 2022 , 23,	O
611	The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. 2022 , 2, 540-552	0
610	COMPARISON OF INFECTED LUNG VOLUME OF COVID-19 PATIENTS AND THEIR CLINIC AND LABORATORY DATA. 63-72	

609 Clinical features associated with Severe Acute Respiratory Syndrome (SARS-COV2). 5679-5688

608	Polarization of Microglia and Its Therapeutic Potential in Sepsis 2022 , 23,	О
607	Assessment and Monitoring of Coagulation in Patients with COVID-19: A Review of Current Literature 2022 ,	О
606	Development of a rapid neutralizing antibody test for SARS-CoV-2 and its application for neutralizing antibody screening and vaccinated serum testing. 2022 ,	O
605	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. 2022 , 10, 712	
604	Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2 2022 , 13, 848335	O
603	Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19. 2022, 6, 13	0
602	RESISTANCE FACTORS OF KLEBSIELLA PNEUMONIAE BACTERIA DURING COVID-19 PANDEMIC.	
601	The importance of nutritional status on clinical outcomes among both ICU and Non-ICU patients with COVID-19. 2022 ,	1
600	Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens 2022 ,	O
599	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. 2022 , 2, 344-371	1
598	Major bat-borne zoonotic viral epidemics in Asia and Africa: A systematic review and meta-analysis 2022 ,	O
597	Mapping the epithelial-immune cell interactome upon infection in the gut and the upper airways 2022 , 8, 15	О
596	COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO CoCARE). 2022 , 100499	1
595	Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis. 2022	1
594	Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development. 2022 , 13,	O
593	Unraveling T Cell Responses for Long Term Protection of SARS-CoV-2 Infection. 2022 , 13,	0
592	The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses. 2022 , 13,	О

591	COVID-19 and the role of cytokines in this disease 2022 , 1	4
590	Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C. 2022 , 10,	O
589	Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 2022 ,	3
588	Exploring the Association Between Latent Toxoplasma gondii Infection and COVID-19 in Hospitalized Patients: First Registry-Based Study 2022 ,	Ο
587	Th1/Th2/Th17 Cytokine Profile among Different Stages of COVID-19 Infection 2022, 1-7	1
586	Correlation of the Imbalance in the Circulating Lymphocyte Subsets With C-Reactive Protein and Cardio-Metabolic Conditions in Patients With COVID-19. 2022 , 13,	Ο
585	Impact Of Metabolic Risk Factors On Covid-19 Clinical Outcomes: An Extensive Review 2022,	O
584	Long COVID'-Frequency and Pattern of Persistent Symptoms in COVID Patients-A Follow-up Study from a Single Centre. 2021 , 16, 42-47	
583	Green Transformation of Anti-Epidemic Supplies in the Post-Pandemic Era: An Evolutionary Approach. 2022 , 19, 6011	O
582	The Role of Zinc and Copper in Platelet Activation and Pathophysiological Thrombus Formation in Patients with Pulmonary Embolism in the Course of SARS-CoV-2 Infection. 2022 , 11, 752	1
581	COVID-19 Impact on Small and Medium Scale Agro-Allied Manufacturing Enterprises in Southwest Nigeria. 2022 , 219-232	
580	Organ-specific immune response in lethal SARS-CoV-2 infection by deep spatial phenotyping. 2022 , 11,	
579	Multimorbilidad y resultados clíticos de una poblacifi pedifirica con sospecha de COVID-19 atendida en un hospital mexicano. 2022 , 54,	
578	SARS-CoV-2: overview of immune response, insights into vaccine platforms and their challenges. 245-263	
577	COVID-19 in G6PD-deficient patients, oxidative stress, and neuropathology 2022,	1
576	Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells. 2022 ,	4
575	The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients 2022 ,	2
574	The anti-atherosclerotic effects of natural polysaccharides: from phenomena to the main mechanisms of action 2022 ,	

573	Respuesta inmune e inmunosupresiß en pacientes con ventilaciß mecßica por infecciß por SARS-CoV-2. 2022 , 36, 148-154	
572	MiR-29a-3p Improves Acute Lung Injury by Reducing Alveolar Epithelial Cell PANoptosis. 2022 , 13, 899	1
571	Incidence and association of ocular manifestations with the disease severity in COVID-19 patients of northern region of India. 2022 ,	
570	THE VIEW OF THE CLINICIAN ON THE PROBLEM OF COVID-19: review. 2022 , 8, 217-225	
569	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?.	
568	A REVIEW ON LACTOFERRIN PRINCIPLE CONSTITUENT OF BOVINE COLOSTRUM: IN COVID19. 1-8	
567	Assessment of oxidative stress markers in elderly patients with SARS-CoV-2 infection and potential prognostic implications. An observational study.	
566	Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor. 2022 , 14, 1080	1
565	Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients. 2022 , 4, e0694	0
564	Exploring the Spike-hACE 2 Residue Residue Interaction in Human Coronaviruses SARS-CoV-2, SARS-CoV, and HCoV-NL63.	O
563	?Factors associated with coronavirus disease 2019 infection severity among a sample of Lebanese adults: Data from a cross-sectional study. 2022 , 5,	0
562	The Relationship between the Serotonergic System and COVID-19 Disease: A Review. 2022 , e09544	O
561	Inflammatory Markers and Auto-Abs to Type I IFNs in COVID-19 Convalescent Plasma.	
560	Therapeutic applications of low-molecular-weight thiols and selenocompounds. 2022 , 643-677	1
559	Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial. 2022 ,	
558	Nanomedicine to deliver biological macromolecules for treating COVID-19. 2022 ,	O
557	Development of a Novel SARS-CoV-2 Immune Complex Vaccine Candidate (CRCx) with Broad Immune Responses: A Preclinical Trial in Animal Model.	
556	Impairment of the Cardiovascular System during SARS-CoV-2 Infection.	

555	PERFIL EPIDEMIOLŒICO DAS COINFECES FNGICAS E BACTERIANAS EM PACIENTES COM COVID-19. 2022 , 2, 184-201	
554	Safety of COVID-19 vaccines in patients with non-communicable diseases: a protocol for systematic review and meta-analysis of randomised controlled trials. 2022 , 12, e057233	
553	SARS-CoV-2 Infection Dysregulates Host Iron (Fe)-Redox Homeostasis (Fe-R-H): Role of Fe-Redox Regulators, Ferroptosis Inhibitors, Anticoagulants, and Iron-Chelators in COVID-19 Control. 1-60	0
552	Nature and mechanism of immune boosting by Ayurvedic medicine: A systematic review of randomized controlled trials. 2022 , 12, 132-147	
551	Isolation and Characterization of Werneria Chromene and Dihydroxyacidissimol from Burkillanthus malaccensis (Ridl.) Swingle. 2022 , 11, 1388	0
550	Hemin shows antiviral activity in vitro, possibly through suppression of viral entry mediators.	Ο
549	BARICITINIB ATTENUATES THE PROINFLAMMATORY PHASE OF COVID-19 DRIVEN BY LUNG-INFILTRATING MONOCYTES. 2022 , 110945	1
548	Altered amino acid profiles of the Bhotherfletus Bystem in COVID-19. 2022,	
547	Could a Lower Toll-like Receptor (TLR) and NF-B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. 2022 , 23, 5966	2
546	Activatable Fluorescent-Photoacoustic Integrated Probes with Deep Tissue Penetration for Pathological Diagnosis and Therapeutic Evaluation of Acute Inflammation in Mice.	1
545	Cryptococcosis among hospitalized patients with COVID -19: a multicenter research network study.	3
544	Drugging the efferocytosis process: concepts and opportunities.	1
543	Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment. 2022 , 13,	
542	Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19. 2022 , 13,	1
541	Molecular signaling pathways, pathophysiological features in various organs, and treatment strategies in SARS-CoV2 infection. 2022 , 124, 151908	
540	Metabolites and growth factors produced by airway epithelial cells induce tolerance in macrophages. 2022 , 302, 120659	
539	Natural compounds may contribute in preventing SARS-CoV-2 infection: a narrative review. 2022 , 11, 1134-1142	O
538	The Impacts of Anti-Inflammatory Agents on COVID-19 Cytokine Storm.	

537	Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection. 2022 , 145-189	1
536	Relacifi de la presifi de distensifi pulmonar con la mortalidad en pacientes bajo ventilacifi mecfiica con COVID-19. 2022 , 36, 223-227	
535	Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis.	
534	Mitochondrial cyclophilin D promotes disease tolerance by licensing NK cell development and IL-22 production against influenza virus. 2022 , 39, 110974	1
533	Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity. 2022 , 14, 1099-1110	0
532	Communication and visiting policies in Italian intensive care units during the first COVID-19 pandemic wave and lockdown: a nationwide survey. 2022 , 22,	1
531	Synergistic Anti-Inflammatory Activity of Ginger and Turmeric Extracts in Inhibiting Lipopolysaccharide and Interferon-Enduced Proinflammatory Mediators. 2022 , 27, 3877	1
530	Clinical and Gene Features of SARS-CoV-2-Positive Recurrence in Patients Recovered From COVID-19. 9,	O
529	Significant association between HIV infection and increased risk of COVID-19 mortality: a meta-analysis based on adjusted effect estimates.	
528	Natural killer cell exhaustion in SARS-CoV-2 infection. 175342592210777	
527	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. 2022 , 2, 275-308	О
526	Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review. 12,	1
525	SARS-CoV-2 productively infects human brain microvascular endothelial cells. 2022, 19,	4
524	Prevalence, Features and Degree of Association of Oral Lesions in COVID-19: A Systematic Review of Systematic Reviews. 2022 , 19, 7486	8
523	Hematological- and Immunological-Related Biomarkers to Characterize Patients with COVID-19 from Other Viral Respiratory Diseases. 2022 , 11, 3578	О
522	Biologics in COVID-19 So Far: Systematic Review. 2022 , 15, 783	О
521	Characteristics and Prognosis of Antibody Non-responders With Coronavirus Disease 2019. 9,	
520	Unraveling protein dynamics to understand the brain Ithe next molecular frontier. 2022, 17,	O

519	Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia. 2022 , 22,	Ο
518	Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review.	1
517	Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology. 2022 , 9, e200010	
516	Vitamin D deficiency predicts 30-day hospital mortality of adults with COVID-19. 2022 ,	O
515	Association between chronic kidney disease and mortality in patients with a confirmed COVID-19 diagnosis. 10, e13437	О
514	Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications. 2022 , 2, 230-241	
513	A narrative review on the role of temperature and humidity in COVID-19: transmission, persistence, and epidemiological evidence. 2022 ,	1
512	Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients.	
511	A Pilot Study on COVID-19 Positive Subjects: An Excerpt of Post-Infection-Pro-Diabetic Disposition & Related Consequences in Correlation to Hepato-Pancreatic Bio-Markers, Pro-Inflammatory Cytokines and Other Risk Factors.	
510	A diminished immune response underlies age-related SARS-CoV-2 pathologies. 2022 , 111002	О
509	Uncovering the genetic links of SARS-CoV-2 infections on heart failure co-morbidity by a systems biology approach.	O
508	Relation of spice consumption with COVID-19 first wave statistics (infection, recovery and mortality) across India.	
507	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. 2022 , 15, 739	2
506	Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2. 13,	Ο
505	Absorption, distribution, metabolism, excretion and toxicity of microplastics in the human body and health implications. 2022 , 437, 129361	2
504	Experimental Models of SARS-COV-2 Infection in the Central Nervous System. 2022 , 14, 117957352211022	
503	Spontaneous remission of chronic lymphocytic leucemia in a patient with SARS-CoV2. 2022 , 18, 100336	
502	COVID-19 and anemia in children with nephrotic syndrome. 2022 , 5, 21	

501	General overview on SARS-CoV-2 and potential role of natural compounds as antiviral drugs targeting SARS-CoV-2 proteins. 2022 , 15-36	
500	General overview on SARS-CoV-2 and potential role of natural compounds as antiviral drugs targeting SARS-CoV-2 proteins. 2022 , 1-13	
499	The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19.	2
498	Gene Networks of Hyperglycemia, Diabetic Complications, and Human Proteins Targeted by SARS-CoV-2: What Is the Molecular Basis for Comorbidity?. 2022 , 23, 7247	1
497	The impact of infection with COVID-19 on the respiratory microbiome: A narrative review. 2022 , 13, 1076-1087	7
496	A virusEarget host proteins recognition method based on integrated complexes data and seed extension. 2022 , 23,	
495	Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition. 2022 , 23, 7248	
494	Implementation of immuno-chemoinformatics approaches to construct multi-epitope for vaccine development against Omicron and Delta SARS-CoV-2 variants. 2022 ,	
493	Mediators of Obesity Do Not Influence SARS-CoV-2 Infection or Activation of Primary Human Lung Microvascular Endothelial Cells In Vitro. 13,	0
492	Inhibitory effects of GT0918 on acute lung injury and the molecular mechanisms of anti-inflammatory response.	
491	Genomic surveillance of SARS-CoV-2 in patients presenting neurological manifestations. 2022 , 17, e0270024	
490	Extracorporeal therapy in critically ill patients with COVID-19: a single-center experience. 2022 , 11, 72-83	
489	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. 13,	1
488	Effect of Chemokine Gene Variants on Covid-19 Disease Severity. 1-10	O
487	Exenterate or Not: A Simple Proposed Management Algorithm for Mucormycosis During the Era of COVID-19 in a Tertiary Eye Care Center in Egypt. Volume 16, 1933-1940	0
486	The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2. 13,	Ο
485	Prediabetes Induces More Severe Acute COVID-19 Associated With IL-6 Production Without Worsening Long-Term Symptoms. 13,	1
484	Network Embedding Across Multiple Tissues and Data Modalities Elucidates the Context of Host Factors Important for COVID-19 Infection. 13,	

483	COVID-19 disease and autoimmune disorders: A mutual pathway. 2022 , 12, 200-223	0
482	Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients. 13,	O
481	Morphofunctional characteristics of blood cells in reconvalescents after suffering COVID-19. 2022 , 24, 741-750	
480	Biobehavioral Implications of Covid-19 for Transplantation and Cellular Therapy Recipients. 13,	O
479	The adverse inflammatory response of tobacco smoking in COVID-19 patients: biomarkers from proteomics and metabolomics. 2022 , 16, 046002	
478	Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. 2022 , 5,	1
477	Severe COVID-19 Is Characterised by Perturbations in Plasma Amines Correlated with Immune Response Markers, and Linked to Inflammation and Oxidative Stress. 2022 , 12, 618	1
476	COVID-19 and Tuberculosis: Two Knives in a Sheath. 2022 , 03,	
475	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.	1
474	The Dynamic Role of FOXP3+ Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection. 13,	3
473	The potential of pathogenetic therapy in the treatment of new coronavirus infection COVID-19. 2022 , 100, 46-52	1
472	Animal models for COVID-19: advances, gaps and perspectives. 2022 , 7,	4
471	RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease. 2022 , 11, 800	1
470	Functional Laryngeal Assessment in Patients with Tracheostomy Following COVID-19 a Prospective Cohort Study.	
469	Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid. 2022 , 11, 228-235	
468	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. 2022 , 11, 269-297	O
467	Pros and Cons of Skeletal Medications in the COVID-19 Era.	O
466	Effects of bioactive compounds from Pleurotus mushrooms on COVID-19 risk factors associated with the cardiovascular system. 2022 ,	1

465	Disrupting ACE2 Dimerization Mitigates the Infection by SARS-CoV-2 Pseudovirus. 2,	О
464	Percutaneous Auricular Vagus Nerve Stimulation Reduces Inflammation in Critical Covid-19 Patients. 13,	O
463	Characterisation of the blood RNA host response underpinning severity in COVID-19 patients. 2022 , 12,	1
462	The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.	1
461	Nasopharyngeal Bacterial Microbiota Composition and SARS-CoV-2 IgG Antibody Maintenance in Asymptomatic/Paucisymptomatic Subjects. 12,	O
460	Colostrum ingredients, its nutritional and health benefits - an overview. 2022 , 44, 126-143	1
459	JAK inhibition as a new treatment strategy for patients with COVID-19. 2022 , 202, 115162	O
458	Exploring the management approaches of cytokines including viral infection and neuroinflammation for neurological disorders. 2022 , 157, 155962	3
457	Association between pregnancy and severe COVID-19 symptoms in Qatar: a cross-sectional study.	
456	SARS-CoV-2, COVID-19, and Reproduction: Effects on Fertility, Pregnancy, and Neonatal Life. 2022 , 10, 1775	О
455	Parthenolide reveals an allosteric mode to inhibit the delSGylation activity of SARS-CoV-2 papain-like protease. 2022 ,	О
454	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. 2022 , 14, 3598	2
453	Association between COVID-19 and telomere length: a bidirectional Mendelian randomization study.	0
452	SARS-CoV -2 Infection Impacts Carbon Metabolism and Depends on Glutamine for Replication in Syrian Hamster Astrocytes.	1
451	Combining L-Arginine with Vitamin C Improves Long-COVID Symptoms: The Nationwide Multicenter LINCOLN Study. 2022 , 106360	3
450	Optical biometric measurements in patients with previous COVID-19 treatment.	
449	Application of emetine in SARS-CoV-2 treatment: regulation of p38 MAPK signaling pathway for preventing emetine-induced cardiac complications. 1-8	0
448	Association between periodontitis and COVID-19 severity in a Tertiary Hospital: A retrospective cohort study. 2022 ,	O

447	Post-COVID-19-Invasive Pulmonary Mycosis. 2022 , 07, 007-011	2
446	An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. 2022 , 21, 123-129	
445	Covid-19 Tedavisinde Sitokin Filtresi Deneyimi;Tek Merkezli Bir 🖫 🖺 a.	
444	Immune B athogen Dynamics. 2022 , 32,	
443	Polyphenolic Phytochemicals Exhibit Promising SARS-COV-2 Papain Like Protease (PLpro) Inhibition Validated through a Computational Approach. 1-22	
442	Complement activation in COVID-19 and targeted therapeutic options: A scoping review. 2022 , 100995	1
441	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. 2022 , 23, 8485	1
440	SARS-CoV-2 infection threatening intestinal health: A review of potential mechanisms and treatment strategies. 1-19	1
439	Immunomodulatory mechanisms of abatacept: A therapeutic strategy for COVID-19. 9,	0
438	Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.	1
437	BACTEREMIA: THE CULPRIT FOR THE MORBIDITY & MORTALITY IN POST COVID PATIENTS. 2022 , 74-76	
436	Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8+ T Cell Response in HLA-A Transgenic Mice. Volume 17, 3325-3341	1
435	Features of antibody responses after SARS-COV-2 infection in healthcare workers in the first wave of COVID-19 pandemic in Mexico City. 2022 , 50, 030006052210994	
434	Co-Infection and Ventilator-Associated Pneumonia in Critically Ill COVID-19 Patients Requiring Mechanical Ventilation: A Retrospective Cohort Study. 2022 , 10, 1952	O
433	Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant.	
432	Prognostic Value of Catestatin in Severe COVID-19: An ICU-Based Study. 2022 , 11, 4496	O
431	Comparison of mucormycosis infection between patients with and without a history of COVID-19 infection: a retrospective cohort study.	
430	Cognitive impairment in patients with coronavirus infection. 2022 , 14, 96-102	

429	The Role of Inflammasomes in COVID-19: Potential Therapeutic Targets. 2022 , 42, 406-420	
428	Efficacy of tadalafil on improvement of men with erectile dysfunction caused by COVID-19: A randomized placebo-controlled trial. 2022 ,	
427	Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. 2022 , 14,	3
426	The role of platelets, neutrophils and endothelium in COVID-19 infection. 1-19	Ο
425	T cell perturbations persist for at least 6 months following hospitalization for COVID-19. 13,	О
424	Defying convention in the time of COVID-19: Insights into the role of Γ cells. 13,	
423	Determining SARS-CoV-2 non-infectivity state brief overview. 10,	
422	B.1.1.7 (Alpha) variant is the most antigenic compared to Wuhan strain, B.1.351, B.1.1.28/triple mutant and B.1.429 variants. 13,	
421	Neurological manifestations of SARS-CoV-2 infections: towards quantum dots based management approaches. 1-14	
420	The BioFire RP2.1 Panel Did Not Identify Concurrent Respiratory Virus Infection in Adults with Variable SARS-CoV-2 Disease Severity and Infection Duration. 2022 , 2022, 1-6	
419	Promising use of immune cell-derived exosomes in the treatment of SARS-CoV-2 infections. 2022 , 12,	1
418	Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review. Publish Ahead of Print,	Ο
417	Vulvar Aphthous Ulcers in an Adolescent After Coronavirus Disease 2019 (COVID-19) Vaccination. 2022 , 140, 514-517	О
416	Self-assembled flagella protein nanofibers induce enhanced mucosal immunity. 2022 , 121733	2
415	Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. 2022 , 2022, 1-13	1
414	Prevalence and clinical disease severity of respiratory co-infections during the COVID-19 pandemic. 2022 ,	Ο
413	Challenges in Diagnosing COVID-19-Associated Pulmonary Aspergillosis in Critically Ill Patients: The Relationship between Case Definitions and Autoptic Data. 2022 , 8, 894	
412	USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING. 2022 , 13,	О

411	Cascading failure of complex networks based on load redistribution and epidemic process. 2022 , 128041	О
410	SARS-CoV-2 Spike Does Not Possess Intrinsic Superantigen-like Inflammatory Activity. 2022 , 11, 2526	2
409	Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion.	0
408	COVID-19 Mortality and Related Comorbidities in Hospitalized Patients in Bulgaria. 2022 , 10, 1535	
407	Where do T cell subsets stand in SARS-CoV-2 infection: an update. 12,	O
406	SARS-CoV-2 seroprevalence in hospital healthcare workers in Western Switzerland at the end of the second pandemic wave. 2022 , 71,	
405	Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19.	O
404	Impact of Microbiota Depletion by Antibiotics on SARS-CoV-2 Infection of K18-hACE2 Mice. 2022 , 11, 2572	O
403	The effects of hypertension on the prognosis of coronavirus disease 2019: a systematic review and meta-analysis on the interactions with age and antihypertensive treatment. Publish Ahead of Print,	0
402	ANALYSIS OF INITIAL DENTAL CARE ENCOUNTERS OF PATIENTS RECOVERED FROM NEW CORONAVIRUS INFECTION COVID-19. 2022 , 18, 55-60	
402 401		1
	CORONAVIRUS INFECTION COVID-19. 2022 , 18, 55-60 Online Yoga and Ayurveda Intervention as Tertiary Prevention of Psychological Comorbidities in	1
401	CORONAVIRUS INFECTION COVID-19. 2022, 18, 55-60 Online Yoga and Ayurveda Intervention as Tertiary Prevention of Psychological Comorbidities in COVID-19 Survivors: A Randomized Controlled Trial. 097275312211176 Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2	
401	Online Yoga and Ayurveda Intervention as Tertiary Prevention of Psychological Comorbidities in COVID-19 Survivors: A Randomized Controlled Trial. 097275312211176 Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. 2022, 13, A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and	1
400	Online Yoga and Ayurveda Intervention as Tertiary Prevention of Psychological Comorbidities in COVID-19 Survivors: A Randomized Controlled Trial. 097275312211176 Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. 2022, 13, A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. 2022, 40, 111276 Small molecules targeting endolysosomal acidification and signaling in sepsis and severe	1
401 400 399 398	Online Yoga and Ayurveda Intervention as Tertiary Prevention of Psychological Comorbidities in COVID-19 Survivors: A Randomized Controlled Trial. 097275312211176 Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. 2022, 13, A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. 2022, 40, 111276 Small molecules targeting endolysosomal acidification and signaling in sepsis and severe SARS-CoV-2 infection/COVID-19. 484-509 Integrated microbiome and metabolome analysis reveals the potential therapeutic mechanism of	1
401 400 399 398 397	Online Yoga and Ayurveda Intervention as Tertiary Prevention of Psychological Comorbidities in COVID-19 Survivors: A Randomized Controlled Trial. 097275312211176 Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. 2022, 13, A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. 2022, 40, 111276 Small molecules targeting endolysosomal acidification and signaling in sepsis and severe SARS-CoV-2 infection/COVID-19. 484-509 Integrated microbiome and metabolome analysis reveals the potential therapeutic mechanism of Qing-Fei-Pai-Du decoction in mice with coronavirus-induced pneumonia. 12, Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in	1 0

Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels. 10,

392	Pathogenic role of cytokines in COVID-19, its association with contributing co-morbidities and possible therapeutic regimens.	2
391	IL-6 drives T cell death to participate in lymphopenia in COVID-19. 2022 , 111, 109132	1
390	Endoplasmic reticulum secretory pathway: Potential target against SARS-CoV-2. 2022 , 320, 198897	
389	Association of trace element status in COVID-19 patients with disease severity. 2022 , 74, 127055	1
388	Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic control. 2022 , 1868, 166527	O
387	Pregnant Women Infected with Coronavirus Disease 2019 Pneumonia: A Case Series in Medan, Indonesia. 2022 , 10, 246-251	0
386	Effect of SARS-CoV-2 infection in neonates or in pregnancy on developmental outcomes at 21 2 4 months (SINEPOST): study protocol for a prospective cohort study. 2022 , 6, e001571	O
385	Association of nitrogen balance trajectories with clinical outcomes in critically ill COVID-19 patients: A retrospective cohort study. 2022 ,	О
384	Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy. 2022 , 3,	O
383	Therapeutic Plants with Immunoregulatory Activity and Their Applications: A Scientific Vision of Traditional Medicine in Times of COVID-19.	О
382	Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients. 2022 , 23, 10344	1
381	Changes in lactate dehydrogenase on admission throughout the COVID-19 pandemic and possible impacts on prognostic capability.	1
380	Targeting ATP2B1 impairs PI3K/Akt/Fox-O3 signaling and reduces SARS-COV-2 replication in vivo.	O
379	Post-acute COVID syndrome (long COVID): What should radiographers know and the potential impact for imaging services. 2022 ,	О
378	Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host. 2022 , 149, 106049	O
377	Long COVID: a narrative review of the clinical aftermaths of COVID-19 with a focus on the putative pathophysiology and aspects of physical activity. 2022 , 3,	1
376	COVID-19 and the Human Gut Microbiome: An Under-Recognized Association. 2022 , 58, 96	O

375	Pulmonary Phospholipid Components as Promising Natural Inhibitors against COVID-19 Mpro; Molecular Docking Analysis Based Study. 2022 , 34, 2191-2197	О
374	Vascular access thrombosis among end-stage renal disease patients with acute COVID19 infection (a retrospective cohort study). 2022 , 22, 168	O
373	Antibiotics, Antiretroviral, Corticosteroids, Other Therapies Against SARS-CoV-2. 2022 , 281-293	Ο
372	The air[]quid interface model. 2022 , 51-72	O
371	Dynamic Single-Cell RNA Sequencing Reveals that Intravenous BCG Vaccination Curtails SARS-CoV-2 Induced Disease Severity and Lung Inflammation.	O
370	COVID-19 in Blood Donors at Laquintinie Hospital in Douala during the Third Wave: A Cross Sectional Study. 2022 , 12, 367-379	O
369	Perforaciñ intestinal causada por COVID-19. 2022 , 36, 393-396	О
368	A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19. 2022 , 6, 11-27	O
367	Features Of Immune Status In COVID-19 Convalescents. 2022 , 11,	O
366	Dual Inhibition of HIV-1 and Cathepsin L Proteases by Sarcandra glabra. 2022 , 27, 5552	O
365	COVID-19 in Children and Newborn. 2022 , 305-342	O
364	Anti-inflammatory and Immunostimulant Therapy with Lactobacillus fermentum and Lactobacillus plantarum in COVID-19: A Literature Review. 2022 , 5, 255-267	O
363	COVID-19 and Cardiovascular Manifestations. 2022 , 102-136	O
362	Coronavirus Infection COVID-19 and Pregnancy. 2022 , 92, 445-451	O
361	After the virus has clearedtan preclinical models be employed for Long COVID research?. 2022 , 18, e1010741	1
3 60	COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity. 13,	1
359	Impact of immunosuppression regimen on COVID-19 mortality in kidney transplant recipients: Analysis from a Colombian transplantation centers registry. 2022 ,	0
358	Long COVID-19 and the heart: is cardiac mitochondria the missing link?.	O

357	The Impact of Chest Computed Tomography in A Covid-19 Reference Hospital - First Wave - Distrito Federal - Brazil. 2022 , 4, 28-42	O
356	Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic. 13,	o
355	The Role of Macrophages and Alveolar Epithelial Cells in the Development of ARDS.	0
354	Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above. 1-7	1
353	Transcriptomic clustering of critically ill COVID-19 patients. 2200592	О
352	The Effects of COVID-19 on Skeletal Muscles, Muscle Fatigue and Rehabilitation Programs Outcomes. 2022 , 58, 1199	О
351	Formation and activity of NLRP3 inflammasome and histopathological changes in the lung of corpses with COVID-19.	1
350	Neurological changes post-covid-19 infection. 2022 , 10, 336-350	О
349	Associations of habitual glucosamine use with SARS-CoV-2 infection and hospital admission and death with COVID-19: Evidence from a large population based cohort study.	О
348	Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating NaWe CD4+ T Cell Counts Correspond with Delayed Viral Clearance. 2022 , 11, 2743	2
347	Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis. 2022 , 10, 2194	О
346	Serum biomarkers associated with SARS-CoV-2 severity. 2022 , 12,	1
345	Leukocyte glucose index as a novel biomarker for COVID-19 severity. 2022 , 12,	О
344	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2.	1
343	Low skeletal muscle radiodensity and neutrophil-to-lymphocyte ratio as predictors of poor outcome in patients with COVID-19. 2022 , 12,	0
342	A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.	О
341	COVID-19 as a Potential Cause of Muscle Injuries in Professional Italian Serie A Soccer Players: A Retrospective Observational Study. 2022 , 19, 11117	1
340	Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19).	2

339	What molecular imaging of cancer patients can teach us about COVID-19. 2022, 137,	O
338	Scaling rules for pandemics: Estimating infected fraction from identified cases for the SARS-CoV-2 Pandemic.	O
337	Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19. 2022 , 7,	Ο
336	In vitro Screening of Herbal Medicinal Products for Their Supportive Curing Potential in the Context of SARS-CoV-2. 2022 , 2022, 1-9	O
335	Isquemia arterial bilateral espontfiea de extremidades inferiores por COVID-19 leve. 31, 81-86	О
334	Aportes de la biotecnologë en el diagnëtico de COVID-19. 2022 , 42, 143-151	O
333	Emerging and re-emerging fungal threats in Africa.	O
332	A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progression and mortality. 1-16	1
331	Is mucormycosis the end? A comprehensive management of orbit in COVID associated rhino-orbitalDerebral mucormycosis: preserving the salvageable.	О
330	SARS-CoV-2 vaccines: A double-edged sword throughout rapid evolution of COVID-19.	O
329	Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. 2022 , 13,	2
328	Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. 13,	Ο
327	Difference in mortality rates in hospitalized COVID-19 patients identified by cytokine profile clustering using a machine learning approach: An outcome prediction alternative. 9,	0
326	Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions.	O
325	Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection. 2022 , 8,	1
324	Therapeutic plasma exchange: A potential therapeutic modality for critically ill adults with severe acute respiratory syndrome coronavirus 2 infection.	O
323	Impact of COVID-19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study.	О
322	Biomedical and Antioxidant Potentialities in Chilli: Perspectives and Way Forward. 2022 , 27, 6380	2

321	Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development. 2022 , 79,	О
320	Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases. 2022 , 30, 783-794	О
319	IL-6 and cfDNA monitoring throughout COVID-19 hospitalisation are accurate markers of its outcomes.	0
318	BNT162b2 coronavirus disease-2019 vaccination accelerated rheumatoid arthritis disease activity in chronic eosinophilic pneumonia: A case report. 2022 , 101, e30806	O
317	Inflammasome Genetic Variants Are Associated with Protection to Clinical Severity of COVID-19 among Patients from Rio de Janeiro, Brazil. 2022 , 2022, 1-15	O
316	Development and validation of chest CT-based imaging biomarkers for early stage COVID-19 screening. 10,	O
315	Current understanding on long non-coding RNAs in immune response to COVID-19. 2022, 198956	0
314	Emerging technologies of 3D printing and mHealth in COVID-19 immunity and regenerative dentistry.	О
313	The Lancet Commission on lessons for the future from the COVID-19 pandemic. 2022 , 400, 1224-1280	19
312	Integrated System for On-Site Rapid and Safe Screening of COVID-19.	O
312	Integrated System for On-Site Rapid and Safe Screening of COVID-19. A case of acute respiratory distress syndrome: An unusual presentation of post-COVID-19. 2022, 19, em417	0
311	A case of acute respiratory distress syndrome: An unusual presentation of post-COVID-19. 2022 , 19, em417 Testosterone protects mice against Zika virus infection and suppresses the inflammatory response	0
311	A case of acute respiratory distress syndrome: An unusual presentation of post-COVID-19. 2022 , 19, em417 Testosterone protects mice against Zika virus infection and suppresses the inflammatory response in brain. 2022 , 105300 Assessment of oxidative stress markers in elderly patients with SARS-CoV-2 infection and potential	0
311 310 309	A case of acute respiratory distress syndrome: An unusual presentation of post-COVID-19. 2022 , 19, em417 Testosterone protects mice against Zika virus infection and suppresses the inflammatory response in brain. 2022 , 105300 Assessment of oxidative stress markers in elderly patients with SARS-CoV-2 infection and potential prognostic implications in the medium and long term. 2022 , 17, e0268871 Analysis and identification of potential type II helper T cell (Th2)-Related key genes and therapeutic	0 0
311 310 309 308	A case of acute respiratory distress syndrome: An unusual presentation of post-COVID-19. 2022, 19, em417 Testosterone protects mice against Zika virus infection and suppresses the inflammatory response in brain. 2022, 105300 Assessment of oxidative stress markers in elderly patients with SARS-CoV-2 infection and potential prognostic implications in the medium and long term. 2022, 17, e0268871 Analysis and identification of potential type II helper T cell (Th2)-Related key genes and therapeutic agents for COVID-19. 2022, 150, 106134 Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. 2022,	o o o
311 310 309 308 307	A case of acute respiratory distress syndrome: An unusual presentation of post-COVID-19. 2022, 19, em417 Testosterone protects mice against Zika virus infection and suppresses the inflammatory response in brain. 2022, 105300 Assessment of oxidative stress markers in elderly patients with SARS-CoV-2 infection and potential prognostic implications in the medium and long term. 2022, 17, e0268871 Analysis and identification of potential type II helper T cell (Th2)-Related key genes and therapeutic agents for COVID-19. 2022, 150, 106134 Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. 2022, 1868, 166559	o o o

303	Glucocorticoid therapy in respiratory illness: bench to bedside. jim-2021-002161	O
302	Clinical Features Related to Severity and Mortality among COVID-19 Patients in a Pre-Vaccine Period in Luanda, Angola. 2022 , 7, 338	1
301	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. 2022 , 10, 1751	О
300	Neurolimmune Interactions in Severe COVID-19 Infection. 2022 , 11, 1256	1
299	Work performance among healthcare workers with post COVID-19 syndrome and its relation to antibody response.	О
298	Quantum tunnelling in the context of SARS-CoV-2 infection. 2022 , 12,	O
297	Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome.	0
296	Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data. 9,	O
295	Cellular Landscaping of COVID-19 and Gynaecological Cancers: An Infrequent Correlation. 2022 , 2022, 1-15	О
294	HIV and SARS-CoV-2 Coinfection in Pregnancy: Case Report. 2022 , 4, 41-43	О
294 293	HIV and SARS-CoV-2 Coinfection in Pregnancy: Case Report. 2022 , 4, 41-43 Cytolytic syndrome in patients with COVID-19. 2022 , 115-122	0
293	Cytolytic syndrome in patients with COVID-19. 2022 , 115-122 Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects	o
293	Cytolytic syndrome in patients with COVID-19. 2022 , 115-122 Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines. Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation	0
293 292 291	Cytolytic syndrome in patients with COVID-19. 2022, 115-122 Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines. Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer. 2022, 14, 48464-48475 Reconstructed Genome-Scale Metabolic Model Characterizes Adaptive Metabolic Flux Changes in	0 0
293 292 291 290	Cytolytic syndrome in patients with COVID-19. 2022, 115-122 Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines. Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer. 2022, 14, 48464-48475 Reconstructed Genome-Scale Metabolic Model Characterizes Adaptive Metabolic Flux Changes in Peripheral Blood Mononuclear Cells in Severe COVID-19 Patients. 2022, 23, 12400 CD169+ macrophages orchestrate plasmacytoid dendritic cell arrest and retention for optimal	o o o
293 292 291 290 289	Cytolytic syndrome in patients with COVID-19. 2022, 115-122 Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines. Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer. 2022, 14, 48464-48475 Reconstructed Genome-Scale Metabolic Model Characterizes Adaptive Metabolic Flux Changes in Peripheral Blood Mononuclear Cells in Severe COVID-19 Patients. 2022, 23, 12400 CD169+ macrophages orchestrate plasmacytoid dendritic cell arrest and retention for optimal priming in the bone marrow of malaria-infected mice. 11, Exploring NFkB pathway as a potent strategy to mitigate COVID-19 severe morbidity and mortality.	0 0 0

285	Rethinking of value of early-stage infectious disease modelling to public health: a real-world data validation of SIR models.	О
284	An expanded lexicon for the ubiquitin code.	5
283	Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance.	1
282	Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more. 1-19	2
281	Immune cells-derived exosomes: A promising strategy for COVID-19 treatment. 2022 , 2,	О
280	The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir). 2022 ,	1
279	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.	3
278	Glucocorticoids and COVID-19. 2022 , 185, 106511	1
277	Numerical study of a nonlinear COVID-19 pandemic model by finite difference and meshless methods. 2022 , 100460	О
276	IMMUNOADSORPTION AND COVID 19 PANDEMIC. 2022 , 103599	O
275	Consolidating food safety measures against COVID-19. 2022 , 97,	0
274	Exploration of bloodderived coding and non-coding RNA diagnostic immunological panels for COVID-19 through a co-expressed-based machine learning procedure. 13,	O
273	Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. 2022 , 25, 105316	2
272	Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure. 2022 , 13,	3
271	Concomitant aortic, inferior mesenteric artery thrombosis and sigmoid colon perforation in severe COVID-19 disease. 2022 , 100, 736-738	0
270	Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table. 2022 , 113, 109325	1
269	Phages and SARS-CoV-2. 2023 , 273-292	1
268	Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC). 2022 , 15, 175628642211353	1

267	Mucormicosis asociada a pacientes con COVID-19: un primer informe en Venezuela. 2022 , 2, 128-133	О
266	Phase separation and infectious diseases. 2023 , 681-698	O
265	Angiotensin Converting Enzyme 2 (ACE2) - A macromolecule and its impact on human reproduction during COVID-19 pandemic. 2022 , 10, 960-977	O
264	A Prospective Study of Using Chaihu Shugan Powder Combined with Zu San Li Acupoint Stimulation to Improve the Prognosis of Liver Stagnation and Qi Stagnation Syndrome in Acute Pancreatitis. 2022 , 2022, 1-6	O
263	Elevated Plasma D-Dimer Concentrations in Adults after an Outpatient-Treated COVID-19 Infection. 2022 , 14, 2441	О
262	COVID-19: From Pathophysiology to Treatment.	O
261	Dynamic inflammatory response among routine laboratory biomarkers and their predictive ability for mortality in patients with severe COVID-19. 9,	1
260	AUTCD-Net: An Automated Framework for Efficient Covid-19 Diagnosis on Computed Tomography Scans. 2023 , 109-116	O
259	Multi-kingdom gut microbiota analyses define COVID-19 severity and post-acute COVID-19 syndrome. 2022 , 13,	2
258	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. 2022 , 100126	O
257	Characteristics of COVID-19 (Delta Variant)/HIV Co-infection: A Cross-sectional Study in Henan Province, China.	0
256	Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD). 2022 , 27,	1
255	A country-based review in COVID-19 related research developments.	О
254	H7N9 avian influenza virus infection in men is associated with testosterone depletion. 2022 , 13,	O
253	Immune-profiling of SARS-CoV-2 viremic patients reveals dysregulated innate immune responses. 13,	O
252	Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung. 13,	O
251	Assessment of inflammatory markers and their association with disease mortality in severe COVID-19 patients of tertiary care hospital in South India. 2022 , 16,	0
250	Altered Serum Uric Acid Levels in Kidney Disorders. 2022 , 12, 1891	O

249	Phase separation drives the formation of biomolecular condensates in the immune system. 13,	1
248	Molecular and cellular mechanisms involved in tissue-specific metabolic modulation by SARS-CoV-2.	O
247	Dysfunctional phenotype of systemic and pulmonary regulatory T cells associates with lethal COVID -19 cases.	0
246	Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. 2022 , 245, 109177	1
245	Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity. 2022 , 105643	0
244	Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms. 2022 , 13, 2147	O
243	Combined Use of ECMO, Prone Positioning, and APRV in the Management of Severe COVID-19 Patients. 2022 , 16, 117954842211344	0
242	Coronary artery calcification: Effects on severity and survival in patients with COVID-19. 2022 , 27, 89	O
241	A virological view of tenascin-C in infection. 2023 , 324, C1-C9	0
240	Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. 2023 , 87, 104414	0
239	Immunosenescence and inflamm-ageing in COVID-19. 2023 , 84, 101818	1
238	Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning. 2023 , 17, 100148	2
237	Structural patterns of SARS-CoV-2 variants of concern (alpha, beta, gamma, delta) spike protein are influenced by variant-specific amino acid mutations: A computational study with implications on viral evolution. 2023 , 558, 111376	0
236	Network analysis of the autophagy biochemical network in relation to various autophagy-targeted proteins found among SARS-CoV-2 variants of concern. 2023 , 119, 108396	O
235	Photocatalytic ozonation inactivation of bioaerosols by NiFeOOH nanosheets in situ grown on nickel foam. 2023 , 324, 122273	0
234	Dose kelofan syrup effective for clinical symptoms and biochemical factorsin COVID-19 patients? A double-blind clinical trials. 2022 , 11, 204	O
233	Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy. Publish Ahead of Print,	0
232	Implementation of immuno-chemoinformatics approaches to construct multi-epitope for vaccine development against Omicron and Delta SARS-CoV-2 variants. 2022 , 23, S18-S31	O

231	Antimicrobial, Antioxidant, Anti-Inflammatory Activities of Eight Essential Oils Obtained from Traditional Chinese Medicines Using Supercritical Fluid Extraction Coupled Molecular Distillation. 2022 , 25, 1145-1158	O
230	POST-GAM-COVID-VAC COMBINED VECTOR VACCINE CELLULAR AND HUMORAL IMMUNE RESPONSE.	O
229	Molecular Mechanisms of Non-coding RNAs in Modulating the Pathogenesis of SARS-CoV-2 Infection. 2022 , 2,	O
228	IL-33 and the Cytokine Storm in COVID-19: From a Potential Immunological Relationship towards Precision Medicine. 2022 , 23, 14532	2
227	Characteristics and Outcomes of Cryptococcosis among Patients with and without COVID-19. 2022 , 8, 1234	1
226	An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. 13,	O
225	Identification of herbal teas and their compounds eliciting antiviral activity against SARS-CoV-2 in vitro. 2022 , 20,	O
224	The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. 2022 , 23, 14914	1
223	Host genetics impact on SARS-CoV-2 vaccine-induced immunoglobulin levels and dynamics: The role of TP53, ABO, APOE, ACE2, HLA-A, and CRP genes. 13,	1
222	In-depth characterization of the Syrian hamster as translational model for COVID-19 in humans.	O
221	COVID-19-induced liver injury in adult patients: A brief overview. 11, 443-452	0
220	Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines. 2022 , 14,	O
219	A novel sensor for antiviral drug Favipiravir in the treatment of COVID-19 designed by G/In 2 O 3 nanomaterial.	О
218	N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro. 2022 , 23, 14518	O
217	SARS-CoV-2 in brief: from virus to prevention.	1
216	Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19. 13,	O
215	The Connection between Gut and Lung Microbiota, Mast Cells, Platelets and SARS-CoV-2 in the Elderly Patient. 2022 , 23, 14898	О
214	New-onset type 1 diabetes and SARS-CoV -2 infection.	O

213	Regulation of the alveolar regenerative niche by amphiregulin-producing regulatory T cells. 2023 , 220,	O
212	The Role of HMGB1 in COVID-19-Induced Cytokine Storm and Its Potential Therapeutic Targets: A Review.	O
211	Evaluation of 34 Cytokines and Vitamin D Status Reveal A Sexually-Dimorphic Active Immune Response to SARS-CoV-2. 2022 , 10, 2571	1
2 10	Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention. 2022 ,	O
209	Polyoxygenated Terpenoids and Polyketides from the Roots of Flueggea virosa and Their Inhibitory Effect against SARS-CoV-2-Induced Inflammation. 2022 , 27, 8548	O
208	Eckmaxol Isolated from Ecklonia maxima Attenuates Particulate-Matter-Induced Inflammation in MH-S Lung Macrophage. 2022 , 20, 766	1
207	A new framework for host-pathogen interaction research. 13,	0
206	Glycogen Synthase Kinase-3 Interaction Domain Enhances Phosphorylation of SARS-CoV-2 Nucleocapsid Protein. 2022 , 45, 911-922	O
205	Outcomes in Severe COVID-19 Patients Following Percutaneous Versus Open Surgical Tracheostomy: An Analysis of Clinical and Prognostic Indicators. 2022 ,	0
204	Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19. 2023 , 45, 33-50	1
203	Spectral Domain Optical Coherence Tomography Findings in Vision-Threatening Rhino-Orbital Cerebral Mucor Mycosis Prospective Analysis. 2022 , 12, 3098	0
202	Performance of D-dimer to lymphocyte ratio in predicting the mortality of COVID-19 patients. 12,	O
201	Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19.	0
200	The immunogenetics of COVID-19.	1
199	Age and Comorbidities Predict COVID-19 Outcome, Regardless of Innate Immune Response Severity: A Single Institutional Cohort Study. 2022 , 4, e0799	1
198	Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. 2022 , 10, 2167	O
197	Peripheral blood cell anomalies in COVID-19 patients in the United Arab Emirates: A single-centered study. 9,	О
196	Emerging toolset of three-dimensional pulmonary cell culture models for simulating lung pathophysiology towards mechanistic elucidation and therapeutic treatment of SARS-COV-2 infection. 13,	O

195	Hyperactive immature state and differential CXCR2 expression of neutrophils in severe COVID-19. 2023 , 6, e202201658	O
194	Integrated bioinformatics to identify potential key biomarkers for COVID-19-related chronic urticaria. 13,	O
193	Studying C-reactive protein and D-dimer levels in blood may prevent severe complications: A study in Bangladeshi COVID-19 patients. 13,	О
192	Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis. 2022 , 159, 575-583	O
191	Multi-objective optimization identifies a specific and interpretable COVID-19 host response signature. 2022 , 13, 989-1001.e8	О
190	SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far. 2022 , 12, 2087	O
189	Factors associated with critical care requirements in diabetic patients treated with dexamethasone for COVID-19 infection in the first wave of the pandemia. 13,	О
188	Impact of plasmapheresis on severe COVID-19. 2023 , 13,	1
187	Can Baseline IL-6 Levels Predict Long COVID in Subjects Hospitalized for SARS-CoV-2 Disease?. 2023 , 24, 1731	0
186	Proinflammatory and Thrombotic Manifestations and the Therapeutic Options of COVID-19. 2023, 49-78	0
185	Serum biomarker panel for disease severity and prognosis in patients with COVID -19.	O
184	COVID-19 and Autoimmunity. 2022, 57-84	0
183	Cardiovascular Complications in Coronavirus Disease 2019 Pathogenesis and Management. 2023 , 44, 021-034	0
182	Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. 2023 , 24, 1701	1
181	Association between COVID-19 and chronic liver disease: Mechanism, diagnosis, damage, and treatment. 12, 22-29	О
181		0
	Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies. 2023 ,	

177	Antiviral Potential of Melissa officinalis L.: A Literature Review. 2023, 16, 117863882211466	0
176	Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients.	O
175	Quantification of Vitamin D at Different Levels of Clinical Worsening of COVID-19. 2023, 24,	O
174	Guillain B arr'syndrome associated with COVID-19: A systematic review. 2023 , 100578	O
173	One of the possibilities of optimizing the therapy of a new coronavirus infection in children with the inclusion of an extract from marshmallow root, chamomile flowers, horsetail grass, walnut leaves, yarrow grass, oak bark and dandelion grass: prospective open comparative cohort study.	O
172	2023 , 322-330 Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact.	1
171	Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: a multicenter double-blind randomized controlled trial.	0
170	Immune regulatory functions of biologically active proteins from edible fungi. 13,	O
169	Characteristics of patients with COVID-19 who have deteriorating chest X-ray findings within 48 hours: a retrospective cohort study.	O
168	The nasopharyngeal microbiome in COVID-19.	1
167	COVID-19∄ immuno-pathology and cardiovascular diseases. 108155892211418	1
166	Modelling of the Innate and Adaptive Immune Response to SARS Viral Infection, Cytokine Storm and Vaccination. 2023 , 11, 127	1
165	Sex Differences in D-Dimer and Critical Illness in COVID-19 Patients: A Systematic Review and Meta-analysis. 2023 , 100042	0
164	Human Coronavirus Cell Receptors Provide Challenging Therapeutic Targets. 2023, 11, 174	O
163	SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-induced inflammatory responses.	O
162	6-Shogaol Exhibits Anti-viral and Anti-inflammatory Activity in COVID-19-Associated Inflammation by Regulating NLRP3 Inflammasomes. 2023 , 8, 2618-2628	1
161	Pediatric Systemic Lupus Erythematous in COVID-19 Era. 2023 , 15, 272	О
	Utility of hematological and biochemical parameters as a screening tool for assessing coronavirus	

159	Severity of Illness Scores and Biomarkers for Prognosis of Patients with Coronavirus Disease 2019. 2023 , 44, 075-090	О
158	Effects of Dexamethasone Use on Viral Clearance Among Patients with COVID-19: A Multicenter Cohort Study. 2023 ,	O
157	A simple in-host model for COVID-19 with treatments: model prediction and calibration. 2023, 86,	О
156	The use of prognostic nutritional index (PNI) and selected inflammatory indicators for predicting malnutrition in COVID-19 patients: A retrospective study. 2023 , 16, 280-285	O
155	Health in the Time Of Covid-19. 2021 , 1, 17-22	О
154	Global Properties of a Diffusive SARS-CoV-2 Infection Model with Antibody and Cytotoxic T-Lymphocyte Immune Responses. 2023 , 11, 190	O
153	Pharmacologic Therapeutics for COVID-19. 2023 , 290-318	О
152	Bioinformatics and systems biology approaches to identify the effects of COVID-19 on neurodegenerative diseases: A review. 2022 , 101, e32100	O
151	Manifestations of Mucormycosis and Its Complications in COVID-19 Patients: A Case Series Study. 0145561	32211438
150	Association between Vitamin D Status and Secondary Infections in Patients with Severe COVID-19 Admitted in the Intensive Care Unit of a Tertiary-Level Hospital in Turkey. 2023 , 13, 59	O
149	Effect of physical activity on COVID-19 and underlying mechanisms. 2,	О
148	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. 2023 , 12, 177	Ο
147	Network pharmacology- and molecular simulation-based exploration of therapeutic targets and mechanisms of heparin for the treatment of sepsis/COVID-19. 1-13	О
146	Innate immune responses in COVID-19. 2023 , 63-128	О
145	The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies among staff and students in a Cameroon University. 2023 , 14,	O
144	Immune responses in mildly versus critically ill COVID-19 patients. 14,	1
143	Blood pH and COVID-19.	О
142	Sleep as a likely immunomodulation agent: novel approach in the treatment of COVID-19. 2023 , 16,	O

141	Bioinformatics Approaches to Determine the Effect of SARS-CoV-2 Infection on Patients with Intrahepatic Cholangiocarcinoma.	О
140	Interaction between vitamin D deficiency and COVID-19. 2023 , 685-709	1
139	Impact of immunosuppression regimen on COVID-19 mortality in kidney transplant recipients: Analysis from a Colombian transplantation centers registry. 2023 ,	0
138	COVID-19: Diabetes PerspectivePathophysiology and Management. 2023, 12, 184	1
137	Cortical-blood vessel assembloids exhibit Alzheimer disease phenotypes by activating glia after SARS-CoV-2 infection. 2023 , 9,	0
136	COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections. 2023 , 11, 232	О
135	Targeting TLR-4 Signaling to Treat COVID-19-induced Acute Kidney Injury. 0976500X2211477	O
134	COVID-19 and autoimmune diseases: is there a connection?. Publish Ahead of Print,	2
133	Prognosis prediction of the mean tracheal air column area in COVID-19 patients. 2023 , 5, 24-28	O
132	Com probe implemented STexS II greatly enhances specificity in SARS-CoV-2 variant detection. 2023 , 13,	О
131	Innate immune recognition against SARS-CoV-2. 2023 , 43,	1
130	Linfopenia como predictor de severidad en pacientes con infecciñ por SARS-CoV-2. 51,	О
129	Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia. 14,	0
128	Persistent SARS-CoV -2 infection in patients seemingly recovered from COVID -19. 2023 , 259, 254-263	2
127	Revealing the Impact of COVID-19 on Urban Residential Travel Structure Based on Floating Car Trajectory Data: A Case Study of Nantong, China. 2023 , 12, 55	О
126	The Pathogenetic Role of DAMPs in Severe Infectious Diseases. 2023 , 285-380	О
125	Detecting the behaviors of single viruses by atomic force microscopy. 2023 , 135-160	0
124	Natural killer´cells in COVID-19: from infection, to vaccination and therapy. 2023 , 18, 177-191	О

123	Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection. 10,	О
122	Patients with SARS-CoV-2-Induced Viral Sepsis Simultaneously Show Immune Activation, Impaired Immune Function and a Procoagulatory Disease State. 2023 , 11, 435	O
121	Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.	О
120	Association of lymphopenia and RDW elevation with risk of mortality in acute aortic dissection. 2023 , 18, e0283008	О
119	Redefying the therapeutic strategies against cardiorenal morbidity and mortality: Patient phenotypes. 15, 76-83	0
118	Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. 2023 , 31, 517-525	O
117	The SARS-CoV-2 UTRE Intrudes Host RBPE and Modulates Cellular Splicing. 2023 , 2023, 1-11	О
116	The Role of Diet and Specific Nutrients during the COVID-19 Pandemic: What Have We Learned over the Last Three Years?. 2023 , 20, 5400	Ο
115	Effect of colchicine and aspirin given together in patients with moderate COVID-19. 2023 , 32, 101070	0
114	Inflammasome genes polymorphisms are associated with progression to mechanical ventilation and death in a cohort of hospitalized COVID-19 patients in a reference hospital in Rio de Janeiro, Brazil. 2023 , 865, 147325	0
113	Dendrobium officinale aqueous extract influences the immune response following vaccination against SARS-CoV-2. 2023 , 162, 114702	О
112	Decoding the bidirectional relationship between gut microbiota and COVID-19. 2023 , 9, e13801	O
111	Immunomodulatory effect of sulfated galactofucan from marine macroalga Turbinaria conoides. 2023 , 238, 124021	О
110	A Comprehensive Mini-review on COVID-19 Pathogenesis on Perspectives of Cytokine Storm and Recent Developments in Anti-Covid Nucleotide Analogues. 2023 , 17, 1-11	O
109	Development of indolealkylamine derivatives as potential multi-target agents for COVID-19 treatment. 2023 , 249, 115152	О
108	Global Dynamics of an HTLV-I and SARS-CoV-2 Co-Infection Model with Diffusion. 2023 , 11, 688	O
107	Association of clinically significant obstructive sleep apnoea with risks of contracting COVID-19 and serious COVID-19 complications: a retrospective population-based study of health administrative data. thorax-2022-219574	0
106	Evaluation of Physical Adsorption Properties of the Activated Carbon Layers Used in the Commercial Face Mask Inserts. 2023 , 4, 434-443	Ο

105	Cutaneous exanthema revealing Multisystem-Inflammatory Syndrome in adults (MIS-A) in the course of SARS-CoV-2 infection. 2023 ,	0
104	Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics. 2023 , 861, 147232	O
103	Real-world performance of SARS-Cov-2 serology tests in the United States, 2020. 2023 , 18, e0279956	O
102	Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes. 2023 , 15, 428	О
101	Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review. 14,	0
100	Hyaluronan in the pathogenesis of acute and post-acute COVID-19 infection. 2023 , 116, 49-66	O
99	The Landscape of Expressed Chimeric Transcripts in the Blood of Severe COVID-19 Infected Patients. 2023 , 15, 433	0
98	Holistic View on the Structure of Immune Response: Petri Net Model. 2023 , 11, 452	O
97	T Cell Responses to SARS-CoV-2. 2023 , 41,	1
96	Research Progress of Near-Infrared Fluorescent Probes Based on 1,3-Dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone (DDAO). 2023 , 43, 94	O
95	Relationship between severe acute respiratory syndrome coronavirus 2 and diabetes mellitus (review). 2023 , 26, 66-74	0
94	Sepsis in the Pediatric Cardiac Intensive Care Unit: An Updated Review. 2023,	O
93	Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab. 2023 , 24, 3591	O
92	Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies. 2023 , 15, 525	o
91	Synthesis of conjugates of (aR,7S)-colchicine with monoterpenoids and investigation of their biological activity. 2023 , 72, 248-262	O
90	Endotoxin tolerance and low activation of TLR-4/NF-B axis in monocytes of COVID-19 patients. 2023 , 101, 183-195	o
89	Endogenous Catecholamine Release in COVID-19 Related Acute Respiratory Distress Syndrome: Link between Enhanced Sympathetic Stimulation, Cardiac Dysfunction and Outcome. 2023 , 12, 1557	О
88	Effect of High-Dose Vitamin D on Inflammatory Status of ICU Patients with COVID-19; a Double-Blind, Parallel Randomized Clinical Trial.	O

87	Editorial: Neuromodulation in COVID-19: From basic research to clinical applications. 14,	0
86	Association of the Interleukin 1B-31*C Proinflammatory Allele with the Severity of COVID-19 Patients: A Preliminary Report.	О
85	The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy. 14,	O
84	Optimal control strategies of cell infections in a covid-19 model with inflammatory response. 2023 , 69, 747-757	О
83	Can we predict critical care mortality with non-conventional inflammatory markers in SARS-CoV-2 infected patients?. 2023 , 1-12	0
82	Serum chemokine CC -motif ligand 17 is a predictive marker of severe COVID -19 in haemodialysis patients: A retrospective observational study. 2023 , 28, 240-248	О
81	Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. 2023 , 117, 109929	O
80	Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19. 2023 , 8,	О
79	Current status in cellular-based therapies for prevention and treatment of COVID-19. 1-25	0
78	Peripheral Blood Smear Atypical Lymphocytes Association With Covid-19 Mortality. 2022 , 18, 21-26	O
77	COVID-19 aus Sicht der Gastroenterologie. 2023 , 18, 84-92	0
76	Angina Bullosa Haemorrhagica in COVID 19: A Diagnostic Conundrum. Case Report and Review of Literature.	O
75	Inducible generalized activation of hSTING-N154S expression in mice leads to lethal hypercytokinemia: a model for Bytokine stormD2023, 113, 326-333	О
74	The Journey of Clinical Manifestation Covid-19 After Favipiravir Treatment. 2023, 767-773	О
73	High Plasma tPAPAI-1C Levels May Be Related to a Poor Prognosis in Patients with Severe or Critical COVID-19: A Single-Center Retrospective Study. 2023 , 12, 2019	O
72	Cerebrovascular Manifestations of SARS-CoV-2: A Comprehensive Review. 2023 , 25, 71-92	О
71	The association of dietary approach to stop hypertension (DASH) diet with hospitalization risk in patients with COVID-19. 2023 , 48, 55-63	0
70	Autophagy in Inflammatory Response against SARS-CoV-2. 2023 , 24, 4928	O

69	Phase I Clinical Trial. Safety of Baricitinib to prevent respiratory insufficiency in oncohematological patients affected by Coronavirus Disease-19: BARCOVID19 study.	O
68	Understanding COVID-19 in children: immune determinants and post-infection conditions.	O
67	SARS-CoV-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe COVID-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequalae.	O
66	Severe COVID-19versusmultisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection. 2023 , 32, 220197	O
65	Cardamonin as a p38 MAPK Signaling Pathway Activator Inhibits Human Coronavirus OC43 Infection in Human Lung Cells. 2023 , 15, 1335	О
64	The genesis of the unequal burden of pain: a selective review examining social inequities and unheard voices. 2023 , Publish Ahead of Print,	O
63	Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.	О
62	Clinical, Biochemical, and ATR-FTIR Spectroscopic Parameters Associated with Death or Survival in Patients with Severe COVID-19. 2023 , 2023, 1-13	O
61	Impact of In-hospital Statin Use on Mortality in COVID-19 Patients from a Majority African American Population. 2023 ,	O
60	Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections. 2023 , 18, e0281981	O
59	Novel evidence of Thymosin is immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model. 2023 , 117, 109996	О
58	Nanomedicine Applied to Inflammatory and Infectious Pulmonary Diseases. 2023 , 241-269	O
57	Macrophage-Targeted Nanomedicines. 2023 , 193-240	O
56	Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis. 19,	O
55	SARS-CoV-2 E protein-induced THP-1 pyroptosis is reversed by Ruscogenin.	O
54	Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. 14,	O
53	Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities. 2023 , 132, 751-774	O
52	Immune Dynamics Involved in Acute and Convalescent COVID-19 Patients. 2023 , 3, 86-111	O

51	Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial. 2023 , 18,	O
50	Insights Into Targeting the SARS-CoV-2: Design, Synthesis, In Silico Studies and Antiviral Evaluation of New Dimethylxanthine Derivatives.	O
49	Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). 12,	O
48	Cerebral Cryptococcosis Associated with CD4+ T-lymphocytopenia in Non-HIV Patients after SARS-CoV-2 Infection: Case Series in a Specialized Institute in Lima, Peru. 2023 , 8, 182	O
47	Design, Synthesis and In Vitro Biological Activity of Novel C-7 Methylene Congeners of Furanoallocolchicinoids. 2023 , 15, 1034	0
46	Low CD4 Counts and History of Sore Throat Predict High SARS-CoV-2 Seropositivity among Human Immunodeficiency Virus-Infected Patients in Mwanza, Tanzania. 2023 , 3, 418-427	O
45	Anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors in COVID-19.	О
44	QSPR Analysis of Some Drug Candidates Investigated for COVID-19 via New Topological Coindices. 1-18	O
43	Role of gut microbiota in infectious and inflammatory diseases. 14,	O
42	Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients. 14,	O
41	A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. 2023 , 24, 6369	О
40	Cell-Based Biomaterials for Coronavirus Disease 2019 Prevention and Therapy.	O
39	Anti-HERV-K Drugs and Vaccines, Possible Therapies against Tumors. 2023 , 11, 751	O
38	Risk Perception, Perceived Government Coping Validity, and Individual Sleep Problems in the Early Stage of the COVID-19 Pandemic in China: Mediation Analysis Based on Negative Emotions. 2023 , 11, 986	O
37	Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). 2023, 205,	О
36	Human thymopoiesis produces polyspecific CD8+ 如 cells responding to multiple viral antigens. 12,	O
35	HLA Variation and SARS-CoV-2 Specific Antibody Response. 2023 , 15, 906	О
34	Direct and indirect impact of SARS-CoV-2 on the brain.	O

33	Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma. 2023 , 3,	0
32	Lymphocytes regulate expression of the SARS-CoV -2 cell entry factor ACE2 in the pancreas of T2DM patients.	O
31	An Approach to Acute SARS-CoV-2 Management with Complementary Neuraltherapeutic Medicine: A Case Report. 2023 , 16, 117954762311595	0
30	Host Defenses to Viruses. 2023, 320-330	O
29	Transmission dynamics and baseline epidemiological parameter estimates of Coronavirus disease 2019 pre-vaccination: Davao City, Philippines. 2023 , 18, e0283068	O
28	Relationship between Vitamin D and Immunity in Older People with COVID-19. 2023 , 20, 5432	О
27	Mycobacterium tuberculosis and SARS-CoV-2 co-infections: The knowns and unknowns. 2023 , 26, 106629	0
26	Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network. 13,	O
25	Associations of habitual glucosamine use with SARS-CoV-2 infection and hospital admission and death with COVID-19: Evidence from a large population based cohort study. 2023 , 95,	0
24	Rhythm Disturbances in Post-Acute COVID-19 Syndrome in Young Men without Pre-Existing Known Cardiovascular Disease Case Series. 2023 , 11, 1146	О
23	The effect of Pickering emulsion adjuvants on the immune efficacy of the COVID-19 polypeptide vaccine. 2023 ,	0
22	Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients. 2023 , 16,	О
21	A new coronavirus infection in pregnant women: risks for the mother and the newborn. 2023, 23, 34	0
20	UHPLC/TOFHRMS analysis and anti-inflammatory effect of leaf extracts from Zizyphus jujuba in LPS-stimulated RAW264.7 cells. 50, 27-33	О
19	Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. 14,	0
18	Severe COVID-19: Drugs and Clinical Trials. 2023 , 12, 2893	О
17	SARS CoV-2 infection as a risk factor of preeclampsia and pre-term birth. An interplay between viral infection, pregnancy-specific immune shift and endothelial dysfunction may lead to negative pregnancy outcomes. 2023 , 55,	0
16	REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT.	О

CITATION REPORT

15	Therapeutic strategies for COVID-19: progress and lessons learned.	O
14	Nonlinear interdependence of the results of measuring anti-SARS-CoV-2 IgG levels using Abbott and Euroimmun test systems. 2023 , 105448	O
13	Advancing COVID-19 Understanding: Simulating Omicron Variant Spread Using Fractional-Order Models and Haar Wavelet Collocation. 2023 , 11, 1925	O
12	Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients Busceptibility to COVID-19 to the possible caution of future global diabetes tsunami.	O
11	Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19. 2023, 24, 7593	О
10	Specific Activation of T Cells by an ACE2-Based CAR-Like Receptor upon Recognition of SARS-CoV-2 Spike Protein. 2023 , 24, 7641	О
9	The pursuit of natural medicine current perspective. 2023 , 173-192	0
8	Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment. 2023 , 21,	O
7	Blood brain barrier disruption following COVID-19 infection and neurological manifestations. 2023, 171-201	O
6	Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial. 2023 , 16, 631	O
5	Dynamics of changes in immunological parameters in adults with COVID-19. 2023, 15, 78-85	0
4	Computational modeling of fractional COVID-19 model by Haar wavelet collocation Methods with real data. 2023 , 20, 11281-11312	O
3	Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation. 2023 , 358, 128-141	O
2	Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations mini review. 10,	O
1	Prognostic Value of C-Reactive Protein in SARS-CoV-2 Infection: A Simplified Biomarker of COVID-19 Severity in Northern Ethiopia. Volume 16, 3019-3028	O